

AUTHOR INDEX

Arthritis and Rheumatism, Volume 52, Numbers 1-12, 2005

A

- Abbas S, 2719
 Abbate R, 3618
 Abdollahi-Roodsaz S, 2313
 Abe R, 2954
 Abitbol V, 2882
 Abraham DJ, 3772
 Abu-Amer Y, 2719
 Abu-Helu RF, 1517
 Acampa M, 677
 Accardo-Palumbo A, 2179
 Adachi K, 2530
 Adachi M, 1670
 Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT) Study Group, 3279
 Adam A, 2549
 Adema GJ, 1381
 Adlam M, 3192
 Aeschlimann A, 1402
 af Klint E, 61, 3439, 3880
 Afif H, 94
 Aganna E, 2906
 Agelan A, 2549
 Agle LMA, 225
 Aguilar F, 354
 Aguilar L, 2331
 Aguilera S, 2751
 Ahearn JM, 3087
 Ahmad N, 3433
 Aho K, 247
 Ahonen J, 36
 Aicher WK, 2010
 Aigner T, 136, 468, 1100
 Ainiala H, 674
 Akikusa JD, 990, 2953
 Akkoc N, 4048
 Aksentijevich I, 1287
 Akyerli CB, 1564, 3679
 Alarcón GS, 1473, 1481, 1655, 2060
 Alarcón-Riquelme ME, 363, 1058, 1138
 Alarcón-Segovia D, 1138
 Alard J-É, 4028
 Albertsson K, 3360
 Alcamí J, 354
 Alcaraz MJ, 3230
 Alessio M, 563
 Aletaha D, 2625, 2975, 3333
 Alexander D, 2010
 Alfredsson L, 3676
 Aliabadi P, 1418
 Alizadeh BZ, 1437
 Allaart CF, 3381
 Allamore Y, 2882, 3792
 Allen NB, 2168
 Alliende C, 2751
 Allison JJ, 2485
 Alm GV, 1185
 Almahrezi A, 3685
 Alt KW, 3318
 Altman RD, 2284
 Amano E, 2790
 Amano H, 2790
 Amara A, 1504
 Amara I, 1031
 Amasaki Y, 2697
 Ambrose CM, 2080
 Ambrose K, 296, 3660
 American College of Rheumatology Audiovisual Aids Subcommittee, 679
 Amin MA, 1907
 Amin S, 3152
 Amirahmadi SF, 1897
 Amos CI, 425, 1993, 3433
 Amos N, 1287
 Amoura Z, 608, 676, 2583
 Amselem S, 1848, 3603
 Anders S, 1711
 Anderson-MacKenzie JM, 3100
 Andersson U, 3880
 Andrade F, 1160
 Andréu J-L, 612, 2578
 Andriacchi TP, 2835
 Anelli MG, 2519
 Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy (ASSERT) Study Group, 582
 Annovazzi A, 1224
 Anract P, 171
 Anthony KK, 1196
 Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy (ATTRACT) Study Group, 1020
 Antoni C, 3403
 Antoni CE, 1227
 Antoniou J, 128
 Apaz MT, 2873
 Apparailly F, 1595
 Appel H, 892, 2582
 Appel LJ, 1843
 Appenzeller S, 2783
 Apte SS, 1451
 Arabshahi B, 3563
 Aranda R, 2263
 Aranow C, 1481
 Ardid D, 3470
 Arend WP, 239
 Argyle DA, 3079
 Aries P, 4039
 Arinuma Y, 847
 Arita N, 959
 Årlestig L, 1665
 Armstrong D, 2159
 Arnett FC, 257, 865, 2433, 3305
 Arning L, 4039
 Arntz OJ, 2202
 Artamonova V, 563
 Asano Y, 1237, 2897
 Asanuma Y, 1349, 3651
 Ashany D, 225
 Ashton BA, 2331
 Askanase AD, 1341
 Askling J, 1986
 Asselah T, 2917
 Atagunduz P, 892, 2582
 Athreya BH, 2873
 Atsumi T, 212, 2697
 Attia N, 3718
 Auger I, 3424
 Aune T, 1047
 Aurich M, 112
 Avalos I, 3045, 3651
 Avidor B, 3611
 Aviv RI, 2159
 B
 Bachmann LM, 304
 Back D, 670
 Backhaus M, 733
 Bacon PA, 2461
 Badell IR, 2708
 Bae SC, 1481
 Baecklund E, 1986
 Baeten D, 2146, 2192, 2323, 3898
 Baethge BA, 1473
 Baggott JE, 356, 1339
 Bağışlar S, 1564, 3679
 Bahram S, 608
 Baildam E, 563
 Bailey AJ, 3100
 Bajnok É, 3269
 Bako E, 2950
 Bala M, 1020
 Balandraud N, 3424
 Balboni A, 1623
 Baldissera E, 539
 Ballman KV, 402, 412, 722, 3039
 Balsa A, 219
 Baltus B, 430
 Bandeira M, 563, 3554
 Baraf HSB, 1205
 Baraliakos X, 1216, 2447
 Bardin T, 1063
 Barizzzone N, 539
 Baron G, 1858
 Barone F, 1773
 Barr S, 1481
 Barrow KD, 1623
 Bartoli M, 2092
 Barton A, 752, 1694, 2579, 3596
 Base de Datos de Productos Biológicos de la Sociedad Española de Reumatología (BIOBADASER) Group, 1766
 Baskin KM, 3563
 Baslund B, 2686
 Bastacky S, 3975
 Bastian HM, 1473, 1655, 2060
 Bateman JF, 1461
 Batliwalla F, 1952, 3813
 Bau B, 136
 Båve U, 1185
 Becker A, 2485
 Becker J-C, 2263
 Becker MA, 916
 Becker MD, 269
 Beckley V, 744
 Begovich AB, 2948
 Béhier J-M, 1756
 Bejarano V, 42
 Belluoccio D, 1461
 Bengoufa D, 1555
 Bengtsson C, 3676
 Bennink MB, 2202
 Benoist C, 1866
 Benseler SM, 2159
 Berlin AA, 296
 Bernatsky S, 1481
 Bernit E, 1949
 Bertilsson L, 1986
 Bertolaccini ML, 3868
 Better Anti-Rheumatic Pharmacotherapy (BARFOT) Study Group, 3360
 Beurskens FJM, 2686
 Beuthien W, 1334
 Bhattacharyya S, 1248
 Bheekha-Escura R, 3202
 Bianchi A, 759
 Bica B, 2854
 Bickels J, 3611
 Bidwell JL, 675
 Bieche I, 2917
 Bierma-Zeinstra SMA, 787, 3137, 3520
 Biesiadka J, 2581
 Bigliardi B, 539
 Bijkerk C, 1437
 Bijlsma J, 16, 1700, 3391
 Billingham MEJ, 3100
 Bingham SJ, 42, 365
 Birlik AM, 1564, 3679
 Birmingham DJ, 2396
 Biswas P, 3660
 Bixler SA, 2080
 Black CM, 3772
 Blades MC, 1773
 Blair A, 290
 Blanco P, 201
 Blanco R, 2226
 Blanco-Gelaz MA, 275
 Bley TA, 2470
 Blinn CM, 2808
 Blobel CP, 1100
 Blum A, 3492
 Boatright MD, 1336
 Bocci EB, 3890

AUTHOR INDEX

Arthritis and Rheumatism, Volume 52, Numbers 1-12, 2005

A

- Abbas S, 2719
 Abbate R, 3618
 Abdollahi-Roodsaz S, 2313
 Abe R, 2954
 Abitbol V, 2882
 Abraham DJ, 3772
 Abu-Amer Y, 2719
 Abu-Helu RF, 1517
 Acampa M, 677
 Accardo-Palumbo A, 2179
 Adachi K, 2530
 Adachi M, 1670
 Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT) Study Group, 3279
 Adam A, 2549
 Adema GJ, 1381
 Adlam M, 3192
 Aeschlimann A, 1402
 af Klint E, 61, 3439, 3880
 Afif H, 94
 Aganna E, 2906
 Agelan A, 2549
 Agle LMA, 225
 Aguilar F, 354
 Aguilar L, 2331
 Aguilera S, 2751
 Ahearn JM, 3087
 Ahmad N, 3433
 Aho K, 247
 Ahonen J, 36
 Aicher WK, 2010
 Aigner T, 136, 468, 1100
 Ainiala H, 674
 Akikusa JD, 990, 2953
 Akkoc N, 4048
 Aksentijevich I, 1287
 Akyerli CB, 1564, 3679
 Alarcón GS, 1473, 1481, 1655, 2060
 Alarcón-Riquelme ME, 363, 1058, 1138
 Alarcón-Segovia D, 1138
 Alard J-É, 4028
 Albertsson K, 3360
 Alcamí J, 354
 Alcaraz MJ, 3230
 Alessio M, 563
 Aletaha D, 2625, 2975, 3333
 Alexander D, 2010
 Alfredsson L, 3676
 Aliabadi P, 1418
 Alizadeh BZ, 1437
 Allaart CF, 3381
 Allamore Y, 2882, 3792
 Allen NB, 2168
 Alliende C, 2751
 Allison JJ, 2485
 Alm GV, 1185
 Almahrezi A, 3685
 Alt KW, 3318
 Altman RD, 2284
 Amano E, 2790
 Amano H, 2790
 Amara A, 1504
 Amara I, 1031
 Amasaki Y, 2697
 Ambrose CM, 2080
 Ambrose K, 296, 3660
 American College of Rheumatology Audiovisual Aids Subcommittee, 679
 Amin MA, 1907
 Amin S, 3152
 Amirahmadi SF, 1897
 Amos CI, 425, 1993, 3433
 Amos N, 1287
 Amoura Z, 608, 676, 2583
 Amselem S, 1848, 3603
 Anders S, 1711
 Anderson-MacKenzie JM, 3100
 Andersson U, 3880
 Andrade F, 1160
 Andréu J-L, 612, 2578
 Andriacchi TP, 2835
 Anelli MG, 2519
 Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy (ASSERT) Study Group, 582
 Annovazzi A, 1224
 Anract P, 171
 Anthony KK, 1196
 Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy (ATTRACT) Study Group, 1020
 Antoni C, 3403
 Antoni CE, 1227
 Antoniou J, 128
 Apaz MT, 2873
 Apparailly F, 1595
 Appel H, 892, 2582
 Appel LJ, 1843
 Appenzeller S, 2783
 Apte SS, 1451
 Arabshahi B, 3563
 Aranda R, 2263
 Aranow C, 1481
 Ardid D, 3470
 Arend WP, 239
 Argyle DA, 3079
 Aries P, 4039
 Arinuma Y, 847
 Arita N, 959
 Årlestig L, 1665
 Armstrong D, 2159
 Arnett FC, 257, 865, 2433, 3305
 Arning L, 4039
 Arntz OJ, 2202
 Artamonova V, 563
 Asano Y, 1237, 2897
 Asanuma Y, 1349, 3651
 Ashany D, 225
 Ashton BA, 2331
 Askanase AD, 1341
 Askling J, 1986
 Asselah T, 2917
 Atagunduz P, 892, 2582
 Athreya BH, 2873
 Atsumi T, 212, 2697
 Attia N, 3718
 Auger I, 3424
 Aune T, 1047
 Aurich M, 112
 Avalos I, 3045, 3651
 Avidor B, 3611
 Aviv RI, 2159
 Bachmann LM, 304
 Back D, 670
 Backhaus M, 733
 Bacon PA, 2461
 Badell IR, 2708
 Bae SC, 1481
 Baecklund E, 1986
 Baeten D, 2146, 2192, 2323, 3898
 Baethge BA, 1473
 Baggott JE, 356, 1339
 Bağışlar S, 1564, 3679
 Bahram S, 608
 Baildam E, 563
 Bailey AJ, 3100
 Bajnok É, 3269
 Bako E, 2950
 Bala M, 1020
 Balandraud N, 3424
 Balboni A, 1623
 Baldissera E, 539
 Ballman KV, 402, 412, 722, 3039
 Balsa A, 219
 Baltus B, 430
 Bandeira M, 563, 3554
 Baraf HSB, 1205
 Baraliakos X, 1216, 2447
 Bardin T, 1063
 Barizzzone N, 539
 Baron G, 1858
 Barone F, 1773
 Barr S, 1481
 Barrow KD, 1623
 Bartoli M, 2092
 Barton A, 752, 1694, 2579, 3596
 Base de Datos de Productos Biológicos de la Sociedad Española de Reumatología (BIOBADASER) Group, 1766
 Baskin KM, 3563
 Baslund B, 2686
 Bastacky S, 3975
 Bastian HM, 1473, 1655, 2060
 Bateman JF, 1461
 Batliwalla F, 1952, 3813
 Bau B, 136
 Båve U, 1185
 Becker A, 2485
 Becker J-C, 2263
 Becker MA, 916
 Becker MD, 269
 Beckley V, 744
 Begovich AB, 2948
 Béhier J-M, 1756
 Bejarano V, 42
 Belluoccio D, 1461
 Bengoufa D, 1555
 Bengtsson C, 3676
 Bennink MB, 2202
 Benoist C, 1866
 Benseler SM, 2159
 Berlin AA, 296
 Bernatsky S, 1481
 Bernit E, 1949
 Bertilsson L, 1986
 Bertolaccini ML, 3868
 Better Anti-Rheumatic Pharmacotherapy (BARFOT) Study Group, 3360
 Beurskens FJM, 2686
 Beuthien W, 1334
 Bhattacharyya S, 1248
 Bheekha-Escura R, 3202
 Bianchi A, 759
 Bica B, 2854
 Bickels J, 3611
 Bidwell JL, 675
 Bieche I, 2917
 Bierma-Zeinstra SMA, 787, 3137, 3520
 Biesiadka J, 2581
 Bigliardo B, 539
 Bijkerk C, 1437
 Bijlsma J, 16, 1700, 3391
 Bill J, 1885
 Billingham MEJ, 3100
 Bingham SJ, 42, 365
 Birlik AM, 1564, 3679
 Birmingham DJ, 2396
 Biswas P, 3660
 Bixler SA, 2080
 Black CM, 3772
 Blades MC, 1773
 Blair A, 290
 Blanco P, 201
 Blanco R, 2226
 Blanco-Gelaz MA, 275
 Bley TA, 2470
 Blinn CM, 2808
 Blobel CP, 1100
 Blum A, 3492
 Boatright MD, 1336
 Bocci EB, 3890

Bodzenta-Lukasz A, 3783
 Boers M, 1642, 2865
 Bohgaki T, 2697
 Böhm BB, 1100
 Boileau C, 488
 Boily M, 488
 Boivin JF, 1481
 Boletis JN, 501, 4051
 Bolon B, 1604, 3192
 Bolstad AI, 1534
 Bombardier C, 3813
 Bombardieri M, 1773
 Bommer J, 290
 Bongartz T, 280
 Böni T, 3318
 Bony C, 1595
 Boon C, 3918
 Boonen A, 3360
 Booth G, 3202
 Boots AM, 770
 Bootsma H, 2740
 Borenstein D, 6
 Boross P, 967
 Böttcher J, 3850
 Bottero P, 2926
 Bottini N, 2396
 Botto M, 1180
 Boulukos KE, 2708
 Bours V, 84, 3801
 Boutron I, 1858
 Bove KE, 3175
 Bowes J, 752
 Bowler R, 3479
 Bowness P, 3586
 Bowyer SL, 382, 1283, 3175
 Boyault S, 759
 Boyce BF, 2708
 Boyle DL, 1876, 2693
 Bozzola E, 826
 Bradley JD, 2015
 Brain SD, 3248
 Brandt KD, 1343, 2015, 3160, 3349
 Brandt L, 1986
 Braun J, 386, 582, 1216, 2447, 4049
 Breedveld FC, 1020, 1443, 1999, 2003, 2272, 2637, 3058, 3333, 3381, 3433
 Brennan P, 1287, 2952
 Brenner M, 322
 Brentano F, 2656
 Bridges SL Jr., 356
 Brindle KA, 3682, 3712
 British Society of Paediatric and Adolescent Rheumatology, 3548
 Britti D, 940
 Brodie TA, 1100
 Brogan PA, 3168
 Bronner F, 3110
 Brooks M, 3220
 Brown A, 27
 Brown C, 27
 Brown H, 1604, 3192
 Brown MA, 1110
 Brown-Bryan TA, 2133

Brucato A, 1623
 Bruce B, 2645
 Bruce IN, 670, 1694, 3596
 Bruckel J, 386
 Brucker PU, 3181
 Bruchmann P, 779
 Brunet J, 488
 Brunner E, 733
 Brunner HI, 2607, 3175
 Bruyn GAW, 3391
 Bryer D, 42
 Bryl E, 2996
 Buch MH, 42, 365
 Buchanan TS, 1418
 Buck RJ, 3132
 Buckley CD, 3460
 Buckwalter KA, 2015
 Bugatti S, 3448
 Bultink IEM, 1334, 2044
 Bünemann E, 1504
 Bunn D, 2293
 Buoncompagni A, 563, 2092
 Burger J, 3318
 Burgos-Vargas R, 2103
 Burkhardt H, 1100
 Burmester GR, 733, 1227
 Bursch LS, 2376
 Burstein D, 3528
 Buyon JP, 1341, 1625, 3079, 3934
 Buzio C, 2926

C

Cabane J, 1555, 3792
 Cacoub P, 911, 2917
 Caeiro F, 1138
 Cahill AM, 3563
 Cahue S, 2343, 3515
 Caillat-Zucman S, 608
 Cajander S, 1185
 Calandra T, 3020
 Çalgüneri M, 1564, 3679
 Calin A, 1205, 1756
 Cáliz R, 219
 Calvo-Alén J, 1655, 2060
 Cameron B, 3570
 Camoin L, 1949
 Camonis J, 1848
 Campbell IK, 1461, 3220, 3749
 Campbell PL, 3718
 Campbell-Webster N, 3570
 Cantaert T, 2323
 Cantagrel A, 3424
 Cantor RM, 2396
 Canvin J, 1360
 Cao Y, 1612
 Caporali R, 3448
 Cappelli M, 539
 Caputi AP, 940, 1929, 3755
 Carbone BD, 3479
 Carbone LD, 1623
 Cardiel MH, 1138
 Carlsen H, 2202
 Carlson CS, 2376
 Carlton VEH, 2948
 Carmagnat M, 1555
 Carmona L, 1766

Carpentier P, 3792
 Carr AJ, 1110, 3502
 Carr DJJ, 1305
 Carreira PE, 3015
 Carreño L, 1766
 Carson D, 3300
 Carter RH, 3943
 Carulli MT, 3772
 Casciola-Rosen LA, 1160, 1824
 Casebeer L, 2485
 Casiano CA, 2133
 Casper K, 1545
 Castaneda JL, 2549
 Castelli L, 539
 Catrina AI, 61, 3880
 Cauli A, 3319
 Cavuto S, 2854
 Cazeneuve C, 1848, 3603
 Cecil DL, 144
 Çelebi-Paul L, 627
 Celeste C, 181
 Cendes F, 2783
 Chaitow J, 2873
 Challacombe SJ, 1773
 Champigneulle J, 3492
 Chan AT, 3586
 Chan EKL, 3079
 Chan T-M, 1058
 Chandrasekhar P, 2584
 Chang A, 2343, 3515
 Chang J, 1824, 2366
 Chang RW, 1274, 2343
 Chang S, 659
 Chao J, 1319
 Chao L, 1319
 Chapin JL, 2125
 Chapman K, 3502
 Chapman PT, 2222
 Chariot A, 84
 Charles HC, 3132
 Charleston J, 1843
 Charni N, 1081
 Charron D, 1555
 Chary-Valckenaere I, 3492
 Chasan-Taber S, 290
 Chatham W, 3943
 Chatterjee S, 2415
 Chaussade S, 2882
 Chen C-J, 363
 Chen C-Y, 1950
 Chen G, 1248
 Chen H, 2376
 Chen M, 877
 Chen PP, 4018
 Chen S-Y, 339, 1319
 Chen W, 3433
 Chen Y, 1585
 Chen Y-W, 1824
 Cheng S, 94
 Chernajovsky Y, 2906, 3829
 Chertow GM, 290
 Cheung KSC, 3110
 Chiang B-L, 1626
 Chiba A, 1941
 Chichester CO, 1746
 Chilla M, 856
 Chimenti MS, 1224

Chiocchetti A, 539
 Chiu B, 1297
 Choi HK, 283
 Choi MJ, 1843
 Chokkalingam AP, 2948
 Chomel A, 171
 Chon Y, 592
 Chou C-C, 627
 Chouinard L, 1118
 Chowdhry IA, 2403
 Choy EHS, 3279
 Christman GM, 2761
 Chu CR, 3181
 Chu JL, 225
 Chubinskaya S, 468, 3910
 Chung CP, 3045, 3651
 Chung J, 592
 Cicuttini FM, 461, 1069, 2033, 2830, 3918
 Ciesielski CJ, 3300
 Cimaz R, 2854, 2873
 Cinelli M, 3618
 Ciruelo E, 3015
 Clancy M, 3152
 Clancy RM, 1625, 3079, 3934
 Clarke A, 1481
 Clarke NMP, 3110
 Clauw DJ, 296, 1577, 3660, 3670
 Clave E, 1555
 Clements PJ, 592
 Clerget-Darpoux F, 1063
 Clerson P, 3792
 Clowse MEB, 514
 Coari G, 1224
 Coffman JE, 269
 Cohen Tervaert JW, 2461
 Cohen P, 3143
 Cohen SB, 3030
 Cohen Tervaert JW, 2461
 Colbert RA, 382
 Colby TV, 73
 Cole AA, 112, 2376
 Colman RW, 2549
 Colmegna I, 4052
 Colson F, 1411
 Comaneshter D, 3611
 Conaghan PG, 27, 672
 Connolly MK, 592
 Conrads TP, 902
 Conrozier S, 1411
 Conrozier T, 1411
 Constantinescu F, 1622
 Conti F, 1224
 Cooley H, 1069
 Cooper GS, 1148
 Copel JA, 1341
 Corace C, 2926
 Corbin AE, 1264
 Cornelis F, 1063
 Corona F, 2873
 Corr M, 1876, 2233, 2693, 3300
 Corrigall V, 3829
 Costallat LTL, 2783
 Costedoat-Chalumeau N, 676, 1785
 Costenbader K, 1628
 Costenbader KH, 1341

Cöster L, 1986
Coto C, 2854
Covelli M, 2519
Cozzi F, 1623
Crabbe J, 744
Crapo J, 3479
Crawford F, 1885
Criswell LA, 3433, 3813
Crofford LJ, 1264, 1627, 3660
Croft P, 2350
Crombie DE, 1897
Cron RQ, 2229, 3563
Cronin M, 3928
Cronstein BN, 1338, 2567
Crow MK, 694, 1491
Crowson CS, 402, 412, 722, 3039
Csernok E, 4039
Csipo I, 2950
Cummings SR, 2594
Curhan G, 283
Curiel RV, 3712
Curtis B, 3248
Curtis JR, 2485
Cutolo M, 16
Cuttica R, 2854
Cutting S, 1824
Cuzzocrea S, 940, 1929, 3755

D

da Trindade Neto PB, 3073
Dahaghin S, 3520
Dahlberg L, 120, 3507
Dai S, 2719
Dalbeth N, 3678
Dale K, 833
D'Alfonso S, 539
Daneshpouy M, 1555
Dang D, 2133
Danieli MG, 539
Daniels T, 2133
Dannecker GE, 3606
Danneskiold-Samsøe B, 2686
Daoussis D, 1337
d'Arbonneau F, 2411
Datta SK, 659
David G, 2331
Davidson A, 522
Davies MJ, 2069
Davis C, 2026
Davis JC, 386, 902, 1216, 2168
Davis S, 461, 2033
Dawson L, 2984
Dayal N, 2343
D'Cruz DP, 841
de Benedetti F, 687
de Blas G, 612
de Craen AJM, 1443
de Groot K, 2461
de Groot PG, 1949
de Groote P, 3792
De Jager PL, 2396
De Keyser F, 2146, 2192, 2323, 3898
De La Cadena RA, 2549
de Majo M, 940
De Marco BM, 3682
de Maria R, 2179

de Nanteuil G, 171
de Pablo R, 219
De Rycke L, 2146, 2323, 3898
De Seny D, 3801
De Silva S, 333, 620
De Vathaire F, 779
de Vries RRP, 2212, 2637, 3058, 3433
de Vries-Bouwstra JK, 3381
De Wildt SC, 1437
Deane KD, 239
DeBusk LM, 1585
Del Papa N, 3890
del Rincón I, 3413
Del Rosso A, 3618
Del Rosso M, 3618
Delahaye A, 3603
Delano DL, 2567
Delle Monache F, 3890
Delpech M, 608
DeMarco PJ, 1622
Demircan K, 1451
Denton CP, 3772
Deocharan B, 2080
Derksen RHHM, 1949
Desai A, 2567
Desiati F, 548
D'Eustachio P, 2567
Deutsch R, 2693
Devauchelle-Pensec V, 2411
deVeber G, 2159
Devesa I, 3230
DeVita P, 2026
Dewitt EM, 3563
DeWoody K, 582
Dhabhar FS, 16
Diamond B, 2403
Dianzani U, 539
Dibbs ER, 2808
Dieppe PA, 1956, 3536
Dieu-Nosjean M-C, 1504
di Gaudio F, 2179
di Meglio P, 951
di Paola R, 940, 1929, 3755
Dijkmans B, 582
Dijkmans BAC, 1334, 2044, 2865, 3381
DiMicco MA, 2386
Dinarello CA, 1794, 1960
Ding C, 1069, 2033, 2830, 3918
Diot E, 3792
Direskeneli H, 2583
Distler JHW, 856, 3337
Distler O, 856, 1346, 3337, 3783
Dittmann A, 877
Djouad F, 1595
Dodé C, 608, 2583
Doherty M, 2040
Dombi GW, 2415
Dominick KL, 1424
Dong L, 651
Donn R, 1694, 3020, 3548
Donnelly E, 1585
Dooley MA, 1148, 1481
Dörner T, 2109
Dorrier C, 3030
Douay C, 1555

Dougados M, 386, 1205, 1756, 2263
Dowling B, 3502
Doyle TM, 269
Dragomir AD, 105
Drewe E, 2952
Drijfhout JW, 2645
Drynda S, 2010
Du Clos TW, 642
Duffy C, 554
Duffy CM, 382
Dugué C, 4028
Dulos J, 770
Dunlop DD, 1274, 2343, 3515
Duquesnoy P, 1848
Durez P, 2263
Dutch Juvenile Idiopathic Arthritis Study Group, 2865
Dwivedi S, 1824
Dworkin RH, 1264
Dyrby CO, 2835

E

Ebeling PR, 461, 2033
Echols JD, 2323
Eckstein F, 3132
Edworthy S, 1481
Egawa H, 1371
Egeland T, 833
Ejbjerg BJ, 2300, 3860
Ek M, 3639
El-Gabalawy H, 1481
El-Kattan A, 488
Elashoff D, 2284, 3030
Elashoff R, 592
Elchahal U, 366
Elezoglou A, 2513
Elkon KB, 225, 378
Elliott AL, 105
Eloranta M-L, 1185
Elsaid KA, 1746
Elson CJ, 675
Emery P, 27, 42, 365, 672, 2263, 2355, 3030
Emminger W, 563
Endou H, 2576
Englert C, 1091
Engström M, 61, 3880
Ensworth S, 1481
Ephros M, 3611
Epplen JT, 4039
Escalante A, 3413
Eschaler A, 3470
Esdaile JM, 1360
Espada G, 2854, 2873
Espinola RG, 2120
Espinosa A, 3639
Espinoza LR, 4052
Etienne M, 3470
European Vasculitis Study Group, 2461
Eustace D, 916
Evelhoch JL, 3132
Eyre S, 752
Fahmi H, 94
Falcini F, 563, 2854
Fall N, 3175
Falta MT, 1885
Fan Z, 136
Fantini F, 548
Farge D, 1555
Farrajota K, 94
Farwell L, 2396
Fatah R, 3829
Fatenejad S, 49
Favaro M, 1623
Favret H, 1411
Feghali-Bostwick CA, 3305
Feige U, 128, 1604, 3192
Feighery C, 2461
Feldman BM, 2607, 3570
Felici E, 826, 2092
Felson DT, 794, 1259, 1418, 2594, 2814, 3152, 3542
Feltelius N, 1986
Feng X, 3257
Fernández M, 1655, 2060
Fernandez P, 2567
Fernández-Luna JL, 2226
Fero M, 430
Ferrándiz ML, 3230
Ferrara D, 1545
Fertig N, 2425, 2439
Ferucci ED, 239
Fessler BJ, 592, 1473, 1655, 2060
Fibbi G, 3618
Fielding CA, 1287
Figdor CG, 1381
Figueroa M, 1766
Filer A, 3460
Fillet M, 3801
Fine MJ, 3143
Finnegan A, 1612
Finnish Rheumatoid Arthritis Combination Therapy (FIN-RACo) Trial Group, 36
Fiorillo MT, 3319
Firestein GS, 430, 1876
Fiselier TJW, 2865
Fisher SA, 358
Fitzcharles M-A, 3685
Fitzgerald AA, 1360, 1794
Fitzgerald JB, 2386
FitzGerald JD, 592, 2284, 4018
Flannely J, 3479
Flatø B, 833, 2051
Flierman R, 2212
Flores-Borja F, 3955
Flory C, 488
Foeldvari I, 563
Fontalba A, 2226
Fontenot AP, 1885
Fored CM, 1986
Førre Ø, 833, 2051
Forsberg S, 36
Fortin PR, 1481
Fosang AJ, 1325, 1461
Fossati-Jimack L, 2790
Fraenkel L, 1259

Fragiadaki KG, 501
 Frances C, 1785, 3792
 Franchimont N, 84
 Francois M, 759
 Franke B, 3020
 Franken-Kunkel P, 1504
 Fransen J, 2616
 Franssen MJAM, 2865
 Fraser A, 27
 Frasnelli M, 2227
 Frassi M, 2926
 Frauendorf E, 3318
 Frederiks WM, 2003
 Freeman A, 2485
 Freeman GL, 3413
 Frenkel B, 929
 Frey D, 779
 Friedman AW, 1473
 Friedman DM, 1341, 3079
 Friedrich S, 280
 Fries JF, 2645
 Fritz J, 733
 Fritz V, 1595
 Frøslie KF, 2051
 Frostegård J, 192
 Fu Y-X, 3202
 Fuchs S, 810
 Fujisawa A, 3579
 Fujita S, 1522
 Fukae J, 2697
 Funck-Brentano C, 676
 Furst DE, 592, 1020, 1227, 2284, 3030, 3873
 Futani H, 2530

G

Gabel CA, 362
 Gabriel SE, 402, 412, 722, 3039
 Gál I, 3269
 Gale DR, 794, 3152, 3542
 Gale ME, 794
 Galeazzi M, 539, 677
 Galindo M, 354
 Gamir ML, 2854
 Garden OA, 1180
 Gardner GC, 2225
 Gardner L, 2331
 Garg JP, 290
 Garner P, 1081, 2822
 Gattinara M, 548
 Gay RE, 856, 1402, 2010, 2248, 2656, 3315, 3783
 Gay S, 856, 1402, 2010, 2248, 2656, 2960, 3315, 3337, 3783
 Geborek P, 1986
 Gebretsadik T, 3045
 Geisser ME, 1577, 3660
 Gelber AC, 1843
 Genant HK, 2814
 Gendreau RM, 3670
 Genovese MC, 2645
 Genovese T, 940, 1929, 3755
 Genth E, 2433
 George S, 1491
 Georgiev M, 225
 Gerards AH, 3381
 Gerl M, 531

Gerl V, 531
 Gerli R, 3890
 Gerloni V, 548, 563, 2873
 Gershwin ME, 1804
 Geurts P, 3801
 Geurts-Moespot A, 3020
 Geusens P, 582
 Geyeregger R, 2730
 Gheorghe KR, 3439
 Ghillani P, 676
 Ghosh AK, 1248
 Ghosh S, 951
 Giacomelli F, 539
 Giali S, 1337
 Giannini EH, 2607, 3554
 Giesecke T, 1577
 Gil KM, 1196
 Giladi M, 3611
 Gilkeson GS, 1148
 Gillet P, 3492
 Gilliam AC, 1248
 Gilliet M, 1504
 Gimenez CR, 4052
 Ginzler E, 1481
 Giordano M, 539
 Girard C, 1118
 Girardi G, 2120
 Giraudeau B, 1858
 Girschick H, 2854
 Giurea A, 1091
 Giusti B, 3618
 Gladman DD, 1227, 1481, 3279
 Glant TT, 2452, 3269
 Glass DN, 239
 Glogauer M, 1297
 Gluckman E, 1555
 Glueck D, 3479
 Goebel JC, 3492
 Goekoop-Ruiterman YPM, 3381
 Goggins J, 3542
 Gogos H, 1337
 Gold RH, 2284
 Goldring MB, 1736
 Goldsmith D, 554
 Gombert M, 1504
 Gomez-Camara A, 3015
 Gómez-Reino JJ, 1766, 3015
 Gomoll AH, 3681
 González M-J, 2751
 González N, 354
 González S, 275
 Gonzalez-Crespo MR, 3015
 González-Escribano MF, 219
 González-Gay MA, 219
 Goodson NJ, 2293
 Gordon C, 1481
 Gordon TP, 2984, 3934
 Goronzy JJ, 1392, 2996, 3839
 Gosemann M, 2109
 Gould DJ, 2906
 Gow PJ, 2222
 Gracely RH, 296, 1577, 3660, 3670
 Gracie JA, 2686
 Graham DSC, 2396
 Graham KL, 1684
 Graham TB, 3175

Grainger AJ, 2355
 Grant E, 1360
 Grasselli C, 2926
 Grateau G, 608, 3603
 Grava C, 1623
 Green DR, 1876
 Greene D, 1431
 Greene RR, 3314
 Greenstein A, 27
 Greer W, 1993
 Gregersen PK, 1952, 3433, 3813
 Gregg P, 3536
 Gregorini G, 2461, 2926
 Gressin V, 3792
 Griep EN, 3391
 Griffiths CEM, 1694, 3596
 Griffiths MM, 322
 Grigoryan M, 3152
 Grinblat B, 1333
 Grinnell S, 80
 Grodzinsky AJ, 2386
 Grom AA, 3175
 Gromnica-Ihle E, 3403
 Groner KH, 3660
 Gross WL, 2461, 4039
 Grossman JM, 2396
 Gruber P, 3318
 Grumley JA, 358
 Grundtman C, 3880
 Grunke M, 451
 Grupo Latinoamericano de Estudio del Lupus Eritematoso (GLADEL), 1138
 Gu X, 425, 1993
 Guermazi A, 2814, 3152
 Guiducci S, 3618
 Guilak F, 1632
 Guillemin L, 3792, 4028
 Guis S, 3424
 Gül A, 1836, 2478
 Gulko PS, 322
 Guller U, 3928
 Gunes-Ayata A, 697
 Gunnarsson I, 192, 4050
 Guo L, 620, 3202
 Guo X, 257
 Guo Y, 2541
 Gutekunst DJ, 2026
 Guthrie K, 2768

H

Haak W, 3318
 Haapasaaari J, 1621
 Haas CS, 1907, 3718
 Haas RW, 3413
 Haavardsholm EA, 3860
 Habata T, 3125
 Hachulla E, 3792
 Hafström I, 3360
 Hahn BH, 2396, 2768, 4018
 Haines GK III, 1907, 3718
 Hakala M, 36, 1621
 Hakimiyani A, 468
 Hall FC, 3678
 Hall P, 1325
 Hall SK, 362
 Hallegua DS, 386
 Hamada D, 1371
 Hamann J, 442
 Hamm B, 733
 Hammond L, 2906
 Han C, 1020
 Han KH, 3381
 Han S, 333, 620, 3202
 Han X, 3143
 Handa R, 2584
 Hanft G, 563
 Hanly J, 1481
 Hannonen P, 36
 Hansen A, 2109
 Hara M, 2947, 3054
 Harada M, 3987
 Harder J, 1736
 Hardin JA, 668, 2403
 Harlé JR, 1949
 Härle P, 280, 1305
 Harley JB, 3646, 3966
 Harper J, 2873
 Harris ED Jr., 3324
 Harris EN, 1545
 Harris HE, 3639
 Harris RE, 3660, 3670
 Harrison AA, 2222
 Hasegawa H, 1522
 Hasegawa M, 2889
 Hashimoto J, 3819
 Hassenpflug J, 1736
 Hasson N, 3168
 Hatipoglu OF, 1451
 Hattori K, 3125
 Haugen M, 833, 2051
 Hawkins C, 1694, 2159
 Hawkins D, 554
 Hayashida K, 3004
 Hayes K, 2343, 3515
 Hazes JMW, 787, 3137, 3381, 3520
 He X, 3731
 Hebert LA, 2396
 Heck LW, 2015
 Heiberg MS, 2506
 Heijnen CJ, 770
 Heijnen H, 3479
 Heike T, 3579
 Heilbronner H, 3606
 Heilbrunn KR, 1129
 Hein G, 3850
 Helder PJM, 368
 Hellmich B, 4039
 Helmick CG, 105
 Helsen MM, 975
 Helyes Z, 2955
 Henderson WG, 3143
 Henegar C, 1555
 Herlihy VB, 3682
 Hermann K-GA, 733
 Hermansson Y, 61
 Herzer P, 3403
 Hidaka E, 155
 Hider SL, 670
 Hiepe F, 531
 Hietaharju A, 674
 Higgins GC, 3175

Higgins LD, 3928
 Highton J, 2222
 Hildebrand BA, 865
 Hill CL, 794
 Hinks A, 1694
 Hirakata H, 3987
 Hirakata M, 668, 1571
 Hiramatsu N, 1037
 Hirayama T, 2719
 Hirohata S, 847, 1451, 1670
 Hiromura K, 1037
 Hitman GA, 2906
 Hitt BA, 902
 Hjelmervik TOR, 1534
 Ho P, 752, 3596
 Hobbs K, 987
 Hochberg MC, 105, 1431
 Hoffman E, 1824
 Hoffman GS, 902, 2168
 Hoffmann A, 2109
 Hofman A, 1437
 Hogarth PM, 3220
 Hoggard P, 670
 Holbrook JT, 2168
 Holderbaum D, 3300
 Holers VM, 239
 Holman AJ, 2495
 Holmdahl R, 1897, 2541, 3739
 Holthuysen AEM, 967
 Homey B, 1504
 Homik JE, 1794
 Hong YS, 2080
 Horai R, 3731
 Horizon AA, 4018
 Hörkkö S, 192
 Hörli WH, 2730
 Horneff G, 2873
 Hosoyamada M, 2576
 Hospach T, 3606
 Hostmann B, 531
 Houwing-Duistermaat JJ, 1077, 1443
 Howard P, 554
 Hronowski LJ, 2808
 Hsu H-C, 3257
 Hu JZ, 1129
 Hu Y, 2553
 Huang B, 3554
 Huang G-S, 1950
 Huang H-Y, 1843
 Huber AM, 368
 Huber LC, 3337
 Hudelmaier M, 3132
 Hudson LL, 1148
 Hue S, 608
 Hueber W, 2645
 Hufford M, 3670
 Hugenberg ST, 2015
 Hughes AE, 2040
 Hughes GRV, 841
 Hui ACF, 2578
 Huizinga TWJ, 430, 676, 1443, 1999, 2637, 2948, 3058, 3433
 Hulot J-S, 676
 Humbert M, 3792
 Hunter DJ, 1418, 2814, 3152
 Hunter JC, 2225

Hurley FL, 1129
 Hurwitz D, 3515
 Huston DP, 333, 620
 Hutchinson D, 3675
 Hutt J, 642
 Huynen P, 84
 Hwang K-K, 4018
 Hyun P-M, 345

I

Iademarco MF, 2968
 Ianaro A, 951
 Iannone F, 2519
 Ibrahim SA, 3143
 Ichikawa K, 212
 Ide H, 1670
 Igawa T, 3987
 Ihn H, 1237, 2897
 Iikuni N, 4047
 Ikari K, 2947, 3054
 Ikeda K, 3079
 Ikeda Y, 1571
 Ikemura S, 1293
 Ikeuchi H, 1037
 Ikeuchi K, 3125
 Ilie D, 1555
 Iliopoulos A, 2513
 Im H-J, 800, 2376, 3910
 Imagawa T, 818
 Imai T, 1392, 1522
 Imoto-Egami M, 2133
 Inada S, 1571
 Inanc M, 2478
 Indelicato M, 539
 Ingraham K, 3771
 Iniotaki A, 501
 Inman RD, 885, 1297
 Inoue A, 1522
 Inoue H, 1371
 Intensification et Autogreffe dans les Maladies Auto Immunes Résistantes (ISAMAIR) Study Group, 1555
 International Myositis Assessment and Clinical Studies (IMACS) Group, 2607
 Inui K, 637
 Iobst W, 3771
 Ionescu M, 885, 1118
 Iovino F, 2179
 Irigoyen P, 3813
 Isenberg DA, 1171, 1481, 3955
 Ishii KJ, 651
 Ishimura M, 3125
 Isobe K-i, 2559
 Isomäki H, 1621
 Isordia-Salas I, 2549
 Isozaki T, 1670
 Issazadeh-Navikas S, 3739
 Itakura M, 1371
 Ito MR, 1522
 Ito S, 651
 Iwakura Y, 3731
 Iwamoto M, 2790
 Iwamoto Y, 1293

Iwata N, 818
 Izui S, 2790
 Izzo NJ, 3181

J

Jackson MW, 3934
 Jacobi A, 2109
 Jacobs JWG, 3391
 Jacobs KMG, 1700
 Jacobsen S, 2300
 Jacobsen SJ, 402, 412, 3039
 Jacobsson LT, 369, 1986
 Jagiello P, 4039
 Jahangier ZN, 3391
 Jain NB, 3928
 Jakobsson P-J, 3439
 James M, 1205
 Jamin C, 4028
 Jarret S, 27
 Järvinen P, 36
 Jasin HE, 80
 Jawaheer D, 3433
 Jay GD, 1746
 Jayne DRW, 2461
 Jereb J, 2968
 Jéru I, 1848
 Jiménez-Alonso J, 219
 Jin L, 269, 865
 Jin Y-T, 1319
 Jingushi S, 1293
 Jinks C, 2350
 Jinnin M, 1237, 2897
 Jodo S, 2697
 Joh T, 1129
 Johansson M, 1665
 John S, 752, 1694, 3596
 Johnen C, 531
 Johnson B, 425, 1993
 Johnson K, 1110
 Jonassen I, 1534
 Jones G, 1069, 2033, 2830, 3918
 Jones PBB, 2222
 Jongbloed S, 2686
 Jonker M, 627
 Jonsson R, 1534
 Joos R, 563
 Joosten LAB, 975, 2202, 2313, 3230, 3239
 Jordan JM, 105, 1424, 2366
 Jordan K, 2350
 Jorgensen C, 1595
 Jorgensen TN, 2080
 Joronen K, 3713
 Joseph L, 1481
 Joseph-Ridge N, 916
 Jou I-M, 339
 Jourdan D, 3470
 Jousse S, 4028
 Jouzeau J-Y, 759
 Joven B, 354
 Juillet F, 1081
 Julio M, 2751
 Julkunen H, 2396
 Jung K, 673
 Jüngel A, 856, 3315
 Jüni P, 304, 3536
 Jury EC, 3955

Justiniano ME, 4052
 Jüttner E, 2228
 Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society (PRES), 2873

K

Kabouridis PS, 3955
 Kahaleh B, 3618
 Kahan A, 2882, 3792
 Kahler E, 733
 Kahler KH, 2366
 Kaieda S, 1941
 Kaihara K, 212
 Kaiser WA, 3850
 Kalden JR, 451, 856, 1020, 1227, 3337
 Kaliyaperumal A, 659
 Källberg H, 3676
 Kalled SL, 2080
 Kallenberg CGM, 2589, 2740
 Kamali S, 2478
 Kamatani N, 2576, 2947, 3054, 4047
 Kambe N, 3579
 Kameoka Y, 1670
 Kamino K, 3629
 Kamogawa J, 959
 Kaneko Y, 1037
 Kanzler H, 1504
 Kao AH, 3087
 Kao PN, 1684
 Kaplan CD, 1612
 Kaplan MJ, 697
 Kappler J, 1885
 Kapsogeorgou EK, 1517
 Karasneh J, 1836
 Karim Z, 27
 Karlson EW, 1341
 Karrer S, 280
 Kary S, 3403
 Kasahara M, 4047
 Kasama T, 1670
 Kasapcopur O, 2854
 Kasapoglu E, 2478
 Kasperkovitz PV, 430
 Kastner DL, 3813
 Katakura S, 818
 Kataranovski M, 642
 Katz BP, 2015, 3160
 Katz JD, 3682, 3712
 Katz JN, 1628, 3681, 3928
 Katz PP, 2243
 Katz SI, 707
 Kauf TL, 2366
 Kaufman KM, 3646, 3966
 Kaufmann C, 2506
 Kautiainen H, 36, 1009, 1621
 Kawai M, 2950
 Kavanaugh A, 1227, 2693
 Kavelaars A, 770
 Kaye RD, 3563
 Keeble J, 3248
 Kekow J, 3403
 Keller C, 3360
 Kellermann T, 2581

Kelly JA, 3646
 Keogh KA, 262
 Kere J, 2396
 Kern M, 3813
 Kerstens PJSM, 3381
 Keystone E, 425, 1227, 1993, 2975, 3873
 Khamashta MA, 3868
 Khan MA, 269, 1000, 4048
 Khanna D, 592, 2284, 3030
 Khokhar A, 929
 Khoo S, 670
 Khuri SF, 3143
 Kidd BA, 2645
 Kiel DP, 2814
 Kilpatrick J, 3646
 Kim B-S, 345
 Kim DJ, 1341
 Kim J, 2133
 Kim K-S, 345
 Kim KS, 2080
 Kim MY, 1341
 Kim S-H, 345
 Kim T-H, 885, 1297
 Kimberly R, 3943
 Kimberly RP, 676
 King L, 885
 Kingsley GH, 358
 Kiraz S, 1564, 3679
 Kirkham B, 1227
 Kirou KA, 1491
 Kirwan JR, 673
 Kishimoto T, 818
 Kiss E, 2950
 Kittas C, 2513
 Kiviranta R, 3713
 Klareskog L, 49, 61, 192, 991, 1986, 3439, 3676, 3880
 Klavinskis LS, 3761
 Klein R, 531
 Klein TJ, 1091
 Klinkhoff AV, 1360
 Klinman DM, 651
 Kloetzel P-M, 892
 Kloppenburg M, 1077, 1443
 Kniesch K, 3629
 Knudson CB, 800
 Knudson W, 800
 Kobayashi H, 1585
 Kobayashi M, 128
 Kobayashi N, 164
 Kobayashi T, 479
 Koch AE, 710, 1907, 3718
 Koch GG, 1031
 Kodera M, 2889
 Koenders MI, 975, 3239
 Koes BW, 787, 3137, 3520
 Kohno M, 1522
 Koike T, 212, 637, 2697
 Kokubun S, 3110
 Kollnberger SD, 3586
 Kolls JK, 967, 975, 3239
 Komagata Y, 1920
 Komiya S, 2666
 Komura K, 2889
 Kone-Paut I, 563
 Koneru B, 2607

Kong EK-P, 1058
 Kop EN, 442
 Kop WJ, 296, 3660
 Korkmaz C, 988
 Korn JH, 1812
 Korotkova M, 3439
 Korpela M, 36
 Koshino T, 164
 Koss MN, 2080
 Kostense PJ, 2044
 Kostenuik P, 1604
 Kotzin BL, 1885, 2080, 2790
 Koufany M, 759
 Koutroumanidis M, 841
 Kowal C, 2403
 Kowal K, 3783
 Kowal-Bielecka O, 856, 3783
 Kraan MC, 442
 Kramer A, 3850
 Kraus VB, 105, 1424, 1730, 2366, 2676, 3132
 Kremer JM, 672, 2263
 Kremers HM, 3039
 Kreska D, 3063
 Kressel BR, 3712
 Kroon HM, 1443
 Kruithof E, 2146, 2192, 2323, 3898
 Kubitz R, 1504
 Kuettner KE, 112, 468
 Kuhn A, 877
 Kuis W, 2865
 Kunika K, 1371
 Kuon W, 892
 Kuroiwa T, 1037
 Kusunoki T, 3579
 Kuwahara M, 2947, 3054
 Kuwana M, 668, 1571, 2425
 Kvan NP, 3860
 Kvien TK, 2506, 3860
 Kwakkenbos MJ, 442
 Kwan A, 1993
 Kwok CK, 3143
 Kwon Y-J, 2751
 Kyburz D, 2656
 Kyo F, 2530

L

Labra C, 2751
 Lacombe C, 3603
 Lad B, 358
 Lafeber FPJG, 1700, 3391
 Laffitte E, 1785
 Lafyatis R, 1812
 Laghi-Pasini F, 677
 Lally F, 3460
 Lamb R, 3548
 Lambert C, 84
 Lambert NC, 2768
 Lammi M, 3680
 LaMoreaux LK, 1264
 Lampa J, 61
 Lampropoulos CE, 841
 Landewé R, 49, 1756, 1979
 Lane KA, 2015, 3160
 Lane NE, 1431
 Lane SE, 1620

Langer M, 2470
 Langevitz P, 4011
 Lapadula G, 2519, 3319
 Larsson P, 2686
 Larsson S, 3160
 Lasbleiz S, 1063
 Latchman DS, 1171
 Lau C-S, 1058
 Lau Y-L, 1058
 Lauceviciute I, 1504
 Launay D, 3792
 Laurendeau I, 2917
 LaValley MP, 2814, 3152, 3542
 Laverty S, 181, 1118, 3680
 Lavi I, 924
 Lawlor KE, 3749
 Laxer R, 2873
 Laxer RM, 382, 990, 2103, 2159, 2953, 3570
 Lazzarin P, 1623
 Lazzerini PE, 677
 le Pelletier F, 1785
 Lechat P, 676
 Lechler RI, 1180
 Leclerc N, 929
 LeClerc SA, 1794
 Lee AT, 3813
 Lee BJ, 2645
 Lee C, 1491
 Lee C-C, 1626
 Lee C-H, 1950
 Lee JH, 2386
 Lee S-I, 345
 Lee S-K, 345
 Lee YH, 3966
 Legendre M, 3603
 Leger S, 3470
 Lehman AJ, 1360
 Lehmann G, 3850
 Lehmann P, 1504
 Leirisalo-Repo M, 36, 247
 Lemaire I, 1063
 Lemaire R, 1812
 Lems WF, 1334, 2044, 3381
 Lenhardt A, 563
 Leonardou A, 1337
 Lester MS, 865
 Lesur C, 171
 Leung E, 1180
 Levine TD, 601
 Levinson RD, 269
 Levy BD, 3693
 Levy Y, 4011
 Lewek MD, 2845
 Leyton C, 2751
 Leyton L, 2751
 L'Hoste S, 1848
 Li J, 1431, 2541, 3063, 3701, 3975
 Li L, 659
 Li LM, 2783
 Li T, 2263
 Li W, 3813
 Li X, 94
 Li Z, 3210
 Lian K, 1431
 Lidove O, 911
 Lien G, 833, 2051
 Liew FY, 2686
 Lilleås FG, 3860
 Lilleby V, 2051
 Lim J-S, 345
 Lima JAC, 2125
 Limal N, 911
 Limper AH, 73
 Lin H-H, 442
 Lin L, 984
 Lin PC, 1585
 Lin S-C, 363
 Lin W-S, 4018
 Lindblad S, 1986
 Lingren CM, 2396
 Linnik MD, 1129
 Lionaki S, 501
 Liossis S-NC, 1337
 Liotta LA, 902
 Lipsky PE, 1020, 2109
 Listing J, 2447, 3403, 4049
 Little CB, 1325, 1461
 Liu B, 2549
 Liu C-C, 3087
 Liu J, 3257
 Liu M-F, 1319
 Liu S, 283
 Liu X, 1993, 2120, 3943
 Liu Y, 3063
 Liu-Bryan R, 144, 2936
 LJP 394 Investigator Consortium, 1129
 Lo GH, 2814
 Lobanok T, 885
 Lockman S, 1341
 Lockshin MD, 2243, 3683
 Locksley RM, 1866
 Loeser RF, 2376, 3910
 Loeuille D, 3492
 Lohmander LS, 3160
 Lohse P, 3606
 Loll B, 2581
 López de Castro JA, 3290
 López-Larrea C, 275
 López-Nevot MA, 219
 López-Vázquez A, 275
 Loreau E, 2331
 Lorenz HM, 856
 Losina E, 1628
 Loske K-D, 1334
 Louca K, 1491
 Loughlin J, 3502
 Louis-Plence P, 1595
 Love LA, 2433
 Lovell DJ, 1283, 2854, 3175
 Lövgren T, 1185
 Low-Dose Prednisolone Therapy Study Group, 3371
 Lu C-S, 4018
 Lu L-M, 959
 Lubberts E, 975, 3239
 Luboshitzky R, 924
 Lucas MR, 2439
 Lui L-Y, 1418, 1431
 Lum RF, 3433, 3813
 Lundberg I, 1824
 Lundberg IE, 192, 697

- Lunt M, 2277, 2293
 Luo J, 269
 Lupi E, 548
 LUpus in Minorities Nature
 versus nurture (LUMINA)
 Study Group, 1473
 Luqmani RA, 2168, 2461
 Lurati A, 548
 Luta G, 105
 Lutteri L, 3801
 Lyden AK, 296, 3660
 Ly-Pen D, 612, 2578
 Lysholm J, 1986
- M**
- Ma KM, 3997
 Maas K, 1047
 MacDonald PA, 916
 Machold KP, 2625
 Mackay F, 2080
 Mackay IR, 1897
 Mackensen F, 269
 Mader R, 924
 Maeng PJ, 345
 Magder LS, 514
 Mageed RA, 3955
 Maggiore U, 2926
 Magi A, 3618
 Magnani C, 539
 Magni-Manzoni S, 826, 2092
 Mahajan S, 2366
 Mahowald ML, 312
 Mainard D, 3492
 Maini RN, 1020, 4045
 Maisonneuve T, 2917
 Majeski P, 312
 Majka DS, 239
 Mak A, 3997
 Makrygiannakis D, 3880
 Maksymowych W, 386, 1993
 Malaise M, 84, 3801
 Malich A, 3850
 Malvitz T, 3300
 Maman E, 3611
 Manfredi AA, 11
 Manger B, 1227
 Mannheim LM, 1274
 Manidakis I, 841
 Mannarino E, 3890
 Manno C, 2519
 Manoussakis MN, 1517
 Mansour K, 2740
 Manzi S, 1481, 2015, 3087
 Manzo A, 1773, 3448
 Maradit-Kremers H, 402, 412,
 722
 Marambio P, 522
 Marchesi S, 3890
 Marchini M, 539
 Marder W, 2761
 Margheri F, 3618
 Marier J-F, 181
 Marinova E, 620, 3202
 Marjanovic Z, 1555
 Markind JE, 1205
 Marks SD, 3168
 Marnell LL, 642
- Marolleau JP, 1555
 Marrack P, 1885
 Marson P, 1623
 Martel-Pelletier J, 94, 479, 488
 Martin J, 219
 Martin MU, 2202
 Martin SA, 1264
 Martin TM, 269
 Martinez RJ, 3718
 Martínez-Borra J, 275
 Martinez-Soria E, 2790
 Martinez-Taboada VM, 2226
 Martini A, 563, 687, 826, 2092,
 2854
 Martini G, 2873
 Mason R, 3479
 Massardo L, 1138
 Massarotti E, 3813
 Masutani K, 3987
 Mathieu A, 3319
 Mathieu P, 1411
 Mathis D, 1866
 Matsuda T, 2666
 Matsui K, 2530
 Matsunawa M, 1670
 Matsushita K, 2666
 Matsuura E, 212
 Matsuyama T, 2666
 Matteson EL, 73, 1621, 2996
 Matthey DL, 3675
 Matthias T, 3629
 Matucci-Cerinic M, 856, 3618
 May W, 3701
 Mayes MD, 592, 865, 2125, 2415
 Mazur-Zielinska H, 2873
 Mazzon E, 940, 1929, 3755
 Mazzuca SA, 2015, 3160, 3349
 McCarthy GM, 3681
 McCarthy T, 1481
 McColl GJ, 3322
 McCombie SW, 627
 McCune WJ, 902, 2168, 2761
 McDaniel GE, 1730, 2676
 McDermott MF, 2906
 McDougall JJ, 3210
 McGibbon D, 2040
 McGonagle D, 672, 2355
 McGowan KB, 1091
 McGrath H Jr., 3679
 McGwin G Jr., 1473, 1655, 2060
 McHale T, 3975
 McInnes IB, 2686
 McKenzie CA, 3528
 McKenzie SE, 3220
 McLain D, 2125
 McLaughlin S, 3542
 McLean L, 2222
 McLean RR, 2814
 McLean SA, 3660, 3670
 McLennan CE, 2814
 McLeod HL, 670
 McMurray RW, 3701
 McNulty AL, 2676
 McQueen F, 744
 Mease PJ, 1264, 3279
 Medeiros Bezerra EL, 3073
 Medsger TA Jr., 2425, 2433
- Meeker CT, 1461
 Meenagh GK, 2040
 Meinecke I, 2010
 Melian A, 1205
 Meller S, 1504
 Mellinghoff H-U, 1334
 Meng H-C, 322
 Mentlein R, 1736
 Mentzel HJ, 3850
 Merino R, 2854
 Merkel PA, 902, 2168
 Merriman ME, 2222
 Merriman TR, 2222
 Merville M-P, 84, 3801
 Messier SP, 2026
 METGO Study Group, 1360
 Metzger AL, 4018
 Metzger TE, 2080
 Meulenbelt I, 675, 1077, 1437,
 1443
 Meuwis M-A, 3801
 Mevorach D, 366
 Mewar D, 3868
 Meyer-Hoffert U, 1736
 Michaud K, 3873
 Michel BA, 779, 856, 1402,
 2010, 3315, 3783
 Michou L, 1063
 Middleton J, 2331
 Middleton S, 1604, 3192
 Miehle N, 2228
 Mielants H, 3898
 Migliaresi S, 539
 Micek K, 2452, 3269
 Mikkelsen K, 2506
 Milanese O, 1623
 Milenkovski G, 1325
 Milewicz DM, 257, 865
 Millán I, 612
 Milicamps M, 3470
 Miller ER III, 1843
 Miller FW, 368, 2433, 2607
 Miller ML, 679
 Millett PJ, 3681
 Mimori T, 668, 1571
 Mimura Y, 1237, 2897
 Min JL, 1077
 Min Y-I, 2168
 Minden K, 2854
 Minisola G, 539
 Miossec P, 2307
 Mirakian RM, 2906
 Misselwitz R, 2581
 Mitsak M, 1824
 Mittaz L, 1461
 Miyachi Y, 3579
 Miyake K, 3987
 Miyake S, 1941
 Miyamae T, 818
 Miyamoto T, 1371
 Miyasaka N, 3004
 Miyazaki T, 959
 Mizukami H, 164
 Mizuki S, 959
 Möbius D, 1305
 Mohan C, 659, 3063
 Mok CC, 2774, 3997
- Mola EM, 1766
 Mold C, 642
 Molenaar ETH, 1334
 Molina C, 2751
 Molinaro C, 2133
 Molitor J, 592, 1227
 Moll T, 2790
 Mollenhauer JA, 112
 Möller B, 1665
 Momigliano-Richiardi P, 539
 Momohara S, 2947, 3054
 Momot T, 3966
 Monach P, 2645
 Monk CR, 1180
 Montecucco C, 3448
 Montero D, 1766
 Montesinos MC, 2567
 Monti S, 2926
 Moolenburgh JD, 3391
 Moore DJ, 3868
 Moquin L, 1118
 Morand EF, 1325
 Moreau J-F, 201
 Morel L, 2080, 3063
 Moreland LW, 2015, 2263
 Morgan ME, 2212
 Morgan PE, 2069
 Morgan PR, 1773
 Morgan SL, 356, 1339
 Mori M, 818
 Mori Y, 1248
 Moritani M, 1371
 Morko J, 3713
 Moroldo MB, 239
 Mosher D, 1993
 Moskowitz RW, 3300
 Möttönen T, 36
 Mottram PL, 3220
 Moulin D, 759
 Mounier N, 1555
 Mountz JD, 3257
 Mousa A, 128
 Moutereau S, 3603
 Mouthon L, 3792
 Moutsopoulos HM, 501, 1517,
 4051
 Mouy R, 563
 Mowinckel P, 2506
 Mubarak K, 592
 Mudun A, 2478
 Mueller RB, 451
 Muia C, 1929, 3755
 Mukamel M, 2854, 2873
 Müller A, 1504
 Müller GA, 733
 Müller-Ladner U, 280, 856,
 2010, 2960
 Mundel P, 522
 Mündermann A, 2835
 Muneta T, 2521
 Murabito JM, 1259
 Musicj-Nowakowska E, 2873
 Mustafa Z, 3502
 Myers RR, 2495

N

Nabbe KCAM, 967
 Nagai T, 847, 2666
 Nagaraju K, 1824
 Nagata K, 2530
 Nagatani K, 1920
 Nagayoshi R, 2666
 Naito T, 479
 Nakahata T, 3579
 Nakajima T, 3839
 Nakamura A, 479
 Nakamura T, 2666, 2947, 3054
 Nakamura Y, 155, 2559
 Nakanishi K, 2530
 Nakano K, 1676
 Nakano S, 1371
 Nakashima H, 3987
 Nakashima Y, 1293
 Nakata-Hizume M, 3579
 Nakaya H, 155, 2559
 Nakayama S, 1676
 Namjou B, 3646
 Nandakumar KS, 1897, 3739
 Nanki T, 3004
 Narula SK, 627
 Nash GB, 3460
 Nath SK, 3646
 Naumann H, 1711
 Navratil JS, 3087
 Nawata M, 155, 2559
 Negishi M, 1670
 Neidhart M, 2248, 3315
 Nelissen RGH, 1999
 Nell VPK, 2625
 Nelson JL, 2768
 Netter P, 759, 3492
 Neufing PJ, 3934
 Neumann E, 2960
 Neumann NJ, 1504
 Neumann W, 2010
 Nevitt MC, 1418, 1431, 1623, 3542
 Newman B, 425, 1993, 3596
 Nguyen LT, 1866
 Niang S, 1785
 Nicholas AP, 2323
 Nicks M, 3479
 Nicola PJ, 402, 412, 722, 3039
 Nielsen S, 2873
 Niir H, 3987
 Nikishina I, 563
 Nikkari ST, 674
 Ninomiya Y, 1451
 Nishida K, 1451
 Nishikawa T, 1571
 Nishikomori R, 3579
 Nishimoto N, 818
 Nissim A, 3829
 Niu J, 1418, 3152
 Nived O, 1481
 Nixon J, 2040
 Njajou OT, 1437
 Njobvu PD, 275
 Nobles-Knight D, 1341
 Noël D, 1595
 Nogueira L, 3424
 Noh T, 929

Nojima Y, 1037
 Nomura K, 1371
 Nordmark G, 1185
 Nordvåg B-Y, 2506
 Norkus EP, 1843
 Norris JM, 239
 Nose M, 959, 1522
 Notoya K, 479
 Novarini C, 826
 Nowlan ML, 2952
 Nozawa K, 3079
 Nuamah IF, 2263
 Nuñez-Roldan A, 219
 Ny T, 2541
 Nyberg F, 3639
 Nyquist F, 120

O

Ochi T, 3819
 Ocken SA, 810
 O'Connor PJ, 27
 Odai T, 1670
 O'Daunt S, 987
 Oddis CV, 1571, 2015, 2433, 2439, 2607
 O'Donnell JL, 2222
 Oeser A, 3045, 3651
 O'Fallon WM, 3039
 Ogawa N, 573
 Ogden CA, 378
 Ogilvie E, 3548
 Ognenovski V, 2761
 Ohmori K, 3579
 Ohmura K, 1866
 Ohno S, 800
 Oishi H, 959
 Okabe T, 2559
 Okafuji I, 3579
 Okamoto H, 4047
 Okano Y, 2425
 Okeke L, 1684
 Oki S, 1941
 Okuda K, 164
 O'Leary DH, 3413
 Olivieri AN, 2854
 Olivieri I, 1756
 Ollier WE, 1836
 Olsen C, 296
 Olsen NJ, 1047, 3323
 Olsson LE, 120
 Omar MA, 2366
 Onda M, 2666
 Ong VH, 3772
 Ono M, 959
 Ohashi T, 1451
 Oostveen JCM, 2865
 Oppers-Walgreen B, 975, 3239
 Oreffo ROC, 3110
 Orozco G, 219
 Ortego-Centeno N, 219
 Ory PA, 3279
 Osabe D, 1371
 O'Shea FD, 3681
 Osorio J, 1063
 Ospelt C, 2248, 3315
 Østergaard M, 681, 2300, 3860
 Ota S, 3570

Owen J, 425, 1993
 Ozawa K, 164
 Özbalkan Z, 1564, 3679
 Özçelik T, 1564, 3679
 Ozen S, 697, 2854
 Ozen Z, 620, 3202
 Özer HTC, 3679
 Özer HTE, 1564
 Ozumba D, 3928

P

Pablos JL, 354, 3015
 Pachanov ED, 563
 Pacheco FJ, 2133
 Pacione C, 3910
 Padyukov L, 3639, 3676
 Page G, 2307
 Paladini F, 3319
 Palo WA, 916
 Panayi G, 2686, 3761, 3829
 Pandey JP, 1148, 2425
 Pannu J, 1248
 Pap G, 2010
 Pap T, 1346, 2010
 Papin S, 1848
 Papucci L, 3618
 Paran D, 3611
 Park CC, 1907
 Park GS, 2284, 3030
 Park YW, 1392
 Parker S, 3570
 Parks CG, 1148
 Parren PW, 2686
 Parrish LA, 239
 Pascual-Gómez E, 1766
 Pascual-Salcedo D, 219
 Pasewaldt D, 733
 Passiu G, 3319
 Passo M, 239
 Pastoureaux P, 171
 Patel NSA, 940
 Patey S, 3168
 Patterson AM, 2331
 Patti M, 2179
 Paulsen F, 1736
 Paulus HE, 2284, 3030
 Pautner R, 4011
 Pavone L, 2926
 Payne U, 885
 Pease C, 2355
 Pedersen R, 49
 Pediatric Rheumatology Collaborative Study Group (PRCSG), 2854
 Pediatric Rheumatology International Trials Organization (PRINTO), 563, 2854
 Peerzada J, 1341
 Pellegrin J-L, 201
 Pelletier J-P, 94, 479, 488
 Pelletier M, 3943
 Peng SL, 984
 Pennec Y-L, 2411
 Perdok RJ, 3279
 Pereira Vilar MJ, 3073
 Pérez P, 2751
 Perles Z, 366
 Perrett D, 3829
 Perry MJ, 675
 Pers J-O, 2411
 Peter HH, 2228
 Peter S, 1804
 Peterfy C, 2822
 Petersen J, 2686
 Petersen K, 1534
 Petersen LJ, 2686
 Peterson MGE, 1491
 Petit-Teixeira E, 1063
 Petrella A, 2179
 Petri M, 514, 1341, 1481, 2774, 4003
 Petricoin EF III, 902
 Petrovitch A, 3850
 Petty R, 554
 Petzke FW, 1577
 Pfeil A, 3850
 Pham CTN, 2553
 Pierangeli SS, 1545, 2120
 Pierlot C, 1063
 Pietenpol J, 1047
 Pieterman E, 430
 Pietrobbon R, 3928
 Piette J, 84, 3801
 Piette J-C, 608, 676, 911, 1785, 2583, 2917, 4028
 Pijpe J, 2740
 Pilkington C, 3168
 Pincus T, 1009, 1031, 3045, 3873, 4044
 Ping L, 573
 Pinter E, 3248
 Pinzano-Watrin A, 3492
 Piperno M, 1411
 Pisetsky DS, 676, 3337
 Pistorio A, 826, 2092, 2854
 Pitard V, 201
 Pitzalis C, 1773, 3448
 Pixley RA, 2549
 Plaas AHK, 181
 Plone M, 290
 Plotz PH, 1824, 2433
 Poggi F, 3618
 Poglitsch M, 2730
 Pokorny V, 2222
 Pols HAP, 787, 1077, 1437, 3137, 3520
 Pons-Estel BA, 1138
 Ponticos M, 3772
 Pontikaki I, 548
 Poole AR, 112, 128, 885, 1118, 3680
 Pope J, 1481
 Pope RM, 1907
 Popovic K, 3639
 Porras O, 2854
 Porter AJ, 2768
 Potter C, 2579
 Pounds S, 865
 Pourel J, 3492
 Powell MS, 3220
 Powell RJ, 2952
 Power D, 3220
 Praprotnik S, 369

Prasad PV, 3528
 Pregabalin 1008-105 Study Group, 1264
 Prelog M, 1804
 Pretorius J, 1604
 Prieur AM, 563
 Priori R, 1224
 Pritchard MA, 1461
 Prokunina-Olsson L, 1058
 Proud D, 3210
 Proudfoot AEL, 1907
 Prum B, 1063
 Puéchal X, 1620
 Pufe T, 1736
 Pugliese-Sivo C, 627
 Punzi L, 3319
 Puolakka K, 36
 Putterman C, 522, 2080

Q

Quasniehka HL, 3100
 Quillet P, 1063
 Quinn MA, 27

R

Raben N, 1824
 Rabian C, 1555
 Rachapalli S, 987
 Radbruch A, 531
 Radice A, 2926
 Radstake TRDJ, 1381, 2313, 3020
 Raggi P, 290, 3045
 Rahman MA, 1171, 1481
 Rahman P, 676
 Rainger GE, 3460
 Rajan R, 1481
 Rajapakse VN, 902
 Rajska BM, 269
 Ramanan AV, 3570
 Ramos-Remus C, 1205
 Ramsey DK, 2845
 Ramsey-Goldman R, 1481
 Ranganath VK, 2284
 Ranganathan P, 670
 Ranger P, 94
 Rantapää-Dahlqvist S, 1665, 1986
 Raska K Jr., 2799
 Rasmussen N, 2461
 Rat A-C, 3492
 Rath OP, 2584
 Rau R, 3371, 3403
 Ravaud P, 1858
 Ravazzolo R, 539
 Ravelli A, 826, 2092, 2854, 3554
 Rawat R, 1824
 Raymond J, 2882
 Reed AM, 2607
 Reed SD, 2366
 Reedquist KA, 2003
 Reeve VM, 1371
 Regan E, 3479
 Reich K, 856
 Reichenbach S, 304, 3536
 Reicin AS, 1205
 Reijman M, 787, 3137, 3520
 Rein AJJT, 366
 Reiner A, 112, 1118
 Reisch N, 1402
 Reiter K, 2109
 Relic B, 84
 Remans PHJ, 2003
 Remarque E, 627
 Remmers AE, 3132
 Remmers EF, 322, 3813
 Renner JB, 105, 1424
 Reveille JD, 269, 865, 1473, 1655, 2060, 2433
 Reviron D, 1949
 Rewers M, 239
 Reynolds PPM, 841
 Rhee DK, 1746
 Ribbens C, 84, 3801
 Rider LG, 368, 2607
 Rieker J, 1504
 Riley P, 2854
 Rioux JD, 2396
 Ripley BJM, 1171
 Ritchlin CT, 3279
 Riyazi N, 1077, 1443
 Roach HI, 3110
 Roark CL, 1885
 Roberson J, 1392
 Robinson E, 744
 Robinson WH, 2645
 Rochon J, 1196
 Rødevand E, 2506
 Rodriguez W, 642
 Rodriguez-Valverde V, 1766
 Rodriguez-Valverde V, 49
 Roelofs MF, 2313
 Roger VL, 402, 412, 3039
 Rogerson FM, 1461
 Rojewski J, 3783
 Romanus V, 1986
 Rondan HK, 3381
 Rondina JM, 2783
 Rönnblom L, 1185
 Rönnelid J, 1185
 Roodenburg JLN, 2740
 Roos EM, 3507
 Ros J, 2854, 2873
 Rose DM, 144, 2936
 Roseman JM, 1473, 1655, 2060
 Rosen A, 1160, 1824
 Rosenbaum JT, 269
 Rosendaal FR, 1443
 Rosengren S, 1876
 Rosholm A, 3850
 Rosloniec EF, 1885
 Ross S, 902
 Rossi F, 2092
 Rossi L, 3618
 Rossum MAJ, 2865
 Rotar Z, 369
 Roth J, 3898
 Roth MD, 592
 Rothfield NF, 592
 Roudier J, 3424
 Rovere-Querini P, 11
 Rovin BH, 2396
 Rovis F, 1180

Rowbotham MC, 1264
 Rowley MJ, 1897
 Roy B, 1100
 Rozzo SJ, 2790
 Rubin LA, 425, 1993
 Ruderman EM, 3279
 Rudolph KS, 2845
 Rudwaleit M, 1000
 Rueger DC, 468
 Ruffatti A, 1623
 Ruffing MJ, 3087
 Rühli FJ, 3318
 Rumba I, 2854
 Runstadler JA, 247
 Ruperto N, 563, 2092, 2607, 2854, 2873
 Russell F, 3248
 Russell IJ, 1264
 Russell RGG, 1110
 Russo R, 2873
 Ruth JH, 1907
 Rutkauskaitė E, 2010
 Ruzicka T, 877, 1504
 Ryan M, 239
 Rycke LD, 2192

S

Saadoun D, 911, 2917
 Saag KG, 2485
 Säämänen A-M, 3713
 Sabatini M, 171
 Sabbadini MG, 11, 539
 Sadanaga A, 3987
 Säemann MD, 2730
 Saenger W, 2581
 Sagawa K, 1920
 Sah RL, 1091
 Sällä H, 247
 Sainz IM, 2549
 Saito K, 1676
 Saito M, 3579
 Saito N, 155
 Saito T, 164
 Sakaguchi Y, 2521
 Salmaso A, 548
 Salminen-Mankonen H, 3713
 Salmon J, 2120
 Salvemini D, 1929, 3755
 Sampalis J, 1118
 Sánchez E, 219
 Sanchez ML, 1655
 Sánchez-Guerrero J, 1340
 Sánchez-Olaso A, 612
 Sanders M, 2003
 Sandy JD, 181
 Sano H, 2530
 Sano K, 155
 Santiago B, 354, 3015
 Santiago-Raber M-L, 2790
 Santos L, 1325
 Sany J, 1595
 Saraux A, 2411, 4028
 Sardjono CT, 3220
 Sarkar K, 2433
 Sarraj B, 3269
 Sartor RB, 2549
 Saruhan-Direskeneli G, 2583
 Sato EI, 3073
 Sato K, 2666
 Sato S, 668, 1571, 2889
 Savion N, 4011
 Savolainen A, 247
 Sawai H, 1392
 Saxne T, 1986
 Scafe CR, 1371
 Scaria PV, 1314
 Scarpa R, 3319
 Schäfer ML, 3850
 Schanberg L, 554
 Schanberg LE, 382, 1196
 Schedel J, 2010
 Scheel AK, 733
 Scheidegger P, 1804
 Scheinberg M, 1333
 Schena FP, 2519
 Schett G, 1604, 3192
 Schiff MH, 364, 1205, 1337
 Schiffelers RM, 1314
 Schillaci G, 3890
 Schlegelberger B, 3629
 Schleinitz N, 1949
 Schmidt D, 2470
 Schmidt M, 1711, 1721
 Schmidt RE, 3629, 3966
 Schneider M, 3403
 Schneider R, 2159, 3570
 Schneider U, 1227
 Schnitzer TJ, 2015
 Schoenharting M, 2822
 Schölmerich J, 1305, 1711, 1721
 Scholze J, 2109
 Schorr O, 2656
 Schreuder GMT, 2637, 3058, 3433
 Schrier D, 488
 Schröder J-M, 1736
 Schulman KA, 2366
 Schulze-Koops H, 451
 Schumacher BL, 1091
 Schumacher HR, 269
 Schumacher HR Jr., 916
 Schumann F, 531
 Schurr JR, 3239
 Schuurman J, 2686
 Schwarz EM, 2708
 Schwarz R, 563
 Schwarzenberger P, 3239
 Scioscia C, 2519
 Scleroderma Lung Study Group, 592
 Scofield RH, 3646
 Scorza R, 539
 Scott DGI, 1620, 2293
 Scott F, 3918
 Scott P, 2936
 Sebastiani GD, 539
 Sebbag M, 3424
 Sebillaud S, 759
 See Y, 2854
 Seibold JR, 592
 Seidl BE, 3850
 Seith A, 2584
 Seitz A, 280
 Seki T, 155

- Sekiya I, 2521
 Seldin MF, 247, 3813
 Selvaag AM, 833
 Semanik P, 1274
 Sen A, 3660, 3670
 Sene D, 911
 Senécal JL, 1481
 Seo GS, 794
 Seo P, 2168
 Sereika SM, 2439
 Serrati S, 3618
 Serre G, 3424
 Servin J, 2133
 Sestak AL, 3966
 Seto Y, 42
 Settas L, 49
 Severson RK, 2415
 Seymour AB, 362, 1077
 Sfikakis PP, 501, 2513, 4051
 Sgonc R, 1804
 Shachbazian Y, 563
 Shah R, 2799
 Shahrara S, 1907
 Shankar S, 2584
 Sharma L, 2015, 2343, 3515, 3528
 Sharma R, 659
 Sharma U, 1264
 Sharp JT, 2284, 3279
 Shaw J, 2331
 Shaw JS, 3460
 Shelley DM, 2355
 Shen H, 1402
 Shenkman B, 4011
 Shergy W, 2263
 Shiao A-L, 339
 Shibaki A, 2954
 Shieh D-B, 339
 Shigeyama Y, 2010
 Shih V, 1274
 Shimaoka T, 3004
 Shimizu S, 3987
 Shimizu T, 2559
 Shinohara S, 1371
 Shinomiya F, 1371
 Shintani AK, 3045
 Shipley JM, 1812
 Shir Y, 3685
 Shiwen X, 3772
 Shoenfeld Y, 2599, 3890, 4011
 Shovali A, 366
 Shuto T, 1293
 Siambi V, 1337
 Sibilila J, 2263, 3792
 Sibley J, 1481
 Siebert S, 1287, 2952
 Siegel JN, 1637, 2968
 Sieper J, 582, 892, 1000, 2447, 2582, 4049
 Sierakowski S, 3783
 Sigmund R, 563
 Signore A, 1224
 Silbert JE, 2808
 Silman A, 1694, 2579, 3596
 Silman AJ, 1836, 2277, 2293
 Silver RM, 592, 2425
 Silverman ED, 554, 2159, 3570
 Silverman GJ, 371
 Šimelyte E, 1876
 Simianer S, 563
 Siminovitch KA, 425, 1993
 Simkin PA, 2257
 Simkins HMA, 2222
 Simmen BR, 1402
 Simpson KM, 3030
 Sims TJ, 3100
 Singh JA, 312
 Sinico RA, 2926
 Sinsheimer JS, 3502
 Skapenko A, 451
 Skwara A, 810
 Slagboom PE, 675, 1077, 1437, 1443
 Slocombe RF, 3220
 Sloetjes AW, 967, 1381
 Smeets RL, 2202
 Smeets TJM, 430, 442, 2003
 Smith AJ, 675
 Smith E, 929, 3460
 Smith JR, 269
 Smith P, 2984
 Smolen JS, 1020, 1227, 2625, 2730, 2975, 3333, 4045
 Sneller MC, 1
 Snyder-Mackler L, 2845
 So A, 2227
 Söder S, 468
 Soeder S, 136
 Sokka T, 1009, 3045
 Solinger AM, 1283
 Solomon DH, 1628, 1968
 Somers EC, 2761
 Sønnderstrup G, 2645
 Sonesson S-E, 366
 Song J, 1274, 2343, 3515
 Sont JK, 421, 2272
 Sorrentino R, 3319
 Sørskaa D, 833
 Soussi F, 2882
 Spachidou M, 1180
 Specks U, 262, 902, 2168, 2237
 Spettell CM, 2485
 Spiegel L, 554, 3570
 Spiera RF, 902, 2168
 Spijkervet FKL, 2740
 Sprong T, 2313
 Sprott H, 856, 1402
 Squires GR, 112, 128
 Srikanth V, 1069
 St. Pierre Y, 1481
 Stabler TV, 105, 2676
 Stacey M, 442
 Stamm T, 2625
 Stankovich J, 2830
 Starr A, 3248
 Stassi G, 2179
 St. Clair EW, 902, 1148, 2168
 Steen VD, 592, 3698
 Steensma RW, 627
 Steer S, 358
 Stein CM, 1349, 3045, 3651
 Steinfeld P, 3371
 Steinfeld SD, 2263, 3279
 Steinman JB, 1684
 Steinsson K, 1481
 Sterz MG, 592
 Stevens AM, 2768
 Stevenson AW, 3220
 Stewart N, 744
 Stivers DN, 865
 Stohl W, 2080
 Stolina M, 1604, 3192
 Stone JH, 262, 902, 2168, 2243
 Stone M, 885
 Stone MA, 3460
 Stone RA, 3143
 Storm G, 1314
 Stoyanova-Scholz M, 3403
 Strand V, 554, 1129
 Strangfeld A, 3403
 Stratigos A, 2513
 Straub RH, 16, 1305, 1711, 1721
 Strauss BJG, 461
 Stricker BHC, 3137
 Stringer K, 3175
 Strizki J, 627
 Struglics A, 3160
 Struharova S, 1721
 Stuart JM, 3731
 Stucki G, 779
 Stuhlmüller B, 451
 Stulnig TM, 2730
 Sturfelt G, 1481
 Sturgess AD, 2069
 Sugai S, 573
 Sugiyama N, 3987
 Sunahara N, 2666
 Susic G, 2854
 Suter LG, 1259
 Suwa A, 668, 1571
 Svensson B, 3360, 3424
 Svenungsson E, 192
 Sweep FCGJ, 3020
 Swen WAA, 3391
 Swerlick R, 1545
 Sydlaske A, 2936
 Symmons DPM, 2277, 2293, 3596
 Szabó Z, 2452
 Szántó S, 2452, 3269
 Szegedi G, 2950
 Szekanecz Z, 2452
 Szer J, 3322
 Szkudlarek M, 681
 Sztajnbock F, 2854
 Szuwart T, 810
- T**
- 't Hart B, 627
 Taccari E, 3319
 Tada M, 637
 Tagat JR, 627
 Tak PP, 430, 442, 2003, 3676
 Takagawa S, 1248
 Takahashi N, 2202, 3819
 Takakura Y, 3125
 Takaoka K, 155, 637, 2559
 Takata Y, 1371
 Takehara K, 2889
 Takken T, 368
 Tamaki K, 1237, 2897
 Tamarin I, 4011
 Tan AL, 672, 2355
 Tan FK, 257, 865, 3305
 Tanaka Y, 1676, 3125
 Tang SSK, 2774
 Tanigami A, 155
 Taniguchi A, 2576
 Taniguchi K, 3004
 Tanner SF, 2355
 Tanzer M, 128
 Tardif G, 488
 Targoff IN, 2433
 Tarlton JF, 3100
 Tashkin DP, 592
 Tateishi H, 2530
 Taupin J-L, 201
 Taurog JD, 3323
 Taylor Z, 2968
 Tazelaar HD, 73
 Tchernitchko D, 3603
 Teichtahl AJ, 461
 Teige I, 3739
 Tektonidou MG, 989
 ten Cate R, 2865
 Teng YKO, 2272
 Tensho K, 2559
 ter Borg E-J, 3391
 Terada M, 1522, 2530
 Terencio MC, 3230
 Terkeltaub RA, 144, 1110, 2936
 Terlain B, 759
 Terris B, 2882
 Teske GJD, 442
 Tezenas du Montcel S, 1063
 Thapliyal R, 1824
 Theander E, 369
 Theodore A, 592
 Therneau TM, 3039
 Thibault DL, 1684
 Thiel A, 892
 Thiernemann C, 940
 Thomas M, 171
 Thompson SD, 239
 Thompson SJ, 3761
 Thomsen HS, 2300
 Thomson W, 1694, 3548
 Thornton S, 3175
 Tibesku CO, 810
 Tiderius CJ, 120
 Tiev KP, 3792
 Tighe PJ, 2952
 Tiku ML, 2799
 Tilley S, 3110
 Tillmann B, 1736
 Timmer TCG, 430
 Tindall EA, 1951, 2263
 Tipping P, 1325
 Tiraloch G, 1118
 To CH, 2774, 3997, 4003
 Tobin A, 2984
 Todaro M, 2179
 Todd I, 2952
 Toes REM, 1999, 2212, 2637, 2948, 3058, 3433
 Tolboom TCA, 1999
 Toloza SMA, 2060
 Toma LD, 2926

Tomatsu T, 2947, 3054
Tomooka BH, 2645

Tomsic M, 369
Tonello M, 1623
Toonen LWJ, 1381
Torres B, 219
Torres DD, 2519
Torres L, 2343
Tosoni C, 2926
Totterman S, 794
Toubert A, 1555
Toubi E, 2599
Toussaint F, 3492
Towbin RB, 3563
Tran D, 3570
Tran HB, 3934
Tran K, 3479
Treadwell EL, 1148
Treschow AP, 3739
Trick D, 3629
Triolo G, 2179
Trojanowska M, 1248
Trollmo C, 61, 3439
Tsai C-S, 339
Tsao BP, 2396, 2768
Tse SML, 2103
Tsubaki T, 959
Tsuboi H, 3819
Tsubota A, 2954
Tsuji W, 1216
Tsujiura S, 1676
Tsutsui H, 2530
Tugal-Tutkun I, 2478
Tullus K, 3168
Tunyogi-Csapo M, 1612
Tuomilehto J, 247
Tuomilehto-Wolf E, 247
Turco MC, 2179
Turesson C, 73, 1621
Turner MD, 2906
Tutuncu Z, 1227, 2693
Tuzova M, 522
Tvede N, 2686
Tylee TS, 2768
Tyrell PN, 2159, 3570

U

Uchanska-Ziegler B, 2581
Udagawa N, 3819
Uebelhart D, 779
Ueki K, 1037
Uesugi M, 164
Ugele B, 1721
Uhl M, 2470
Uhlig TA, 3860
Ulfgren A-K, 61, 3439, 3880
Ullman S, 2873
Ulrich-Bochsler S, 3318
Unno S, 479
Urano W, 2576
Urbanus RT, 1949
Urgancioglu M, 2478
Urowitz M, 1481
Utz PJ, 1684, 2645
Uziel Y, 2854

V

Vachon P, 181
Vail TP, 1730, 2366, 2676
Vaith P, 2470
Valesini G, 1224, 1773
Vallejo AN, 2996
Vallongo C, 2873
Vamvakopoulos J, 361
van Baarsen LGM, 430
van Damme M-P, 1897
van de Loo FAJ, 2202
van de Velde NC, 3220
van de Winkel JGJ, 2686
van den Berg WB, 967, 975, 995, 1381, 2202, 2313, 3230, 3239
van den Bersselaar L, 975, 3239
Van den Bosch F, 2192, 3898
van den Hoogen FH, 2313
van den Hout WB, 2272
van der Heijde D, 49, 386, 582, 1020, 1205, 1756, 1979, 3360
van der Helm-van Mil AHM, 1999, 2637, 2948, 3058, 3433
van der Linden S, 1979
van der Net J, 368
van der Pouw Kraan TCTM, 430
van der Vleuten MAJ, 770
van der Voort R, 1381
van Duijn CM, 675, 1077, 1437
van Duivenvoorde LM, 2212
van Ewijk W, 2212
van Gaalen FA, 3058, 3433
van Groenendaal JHLM, 3381
van Imhoff GW, 2740
van Krugten MV, 3381
van Laar JM, 421, 2003, 2212, 2272
van Lent PLEM, 967
van Lieshout AWT, 1381, 2313
van Luijk WHJ, 2865
van Oene M, 425, 1993
van Oosterhout M, 2003
van Riel PLCM, 995, 2616, 3020
van Rooijen N, 3749
van Roon JAG, 1700
van Schaardenburg D, 1443
van Soesbergen RM, 2865
van Suijlekom-Smit LWA, 2865
van Venrooij WJ, 2645
van Vollenhoven RF, 991
van Zeben D, 3381
Vandekerckhove B, 2323
Vandooren B, 2146
Varga J, 592, 1248
Varoga D, 1736
Varon D, 4011
Varon-Graidy M, 3611
Vassallo R, 73
Vaudo G, 3890
Vázquez MN, 3290
Vecchio F, 2926
Veenstra TD, 902
Vega-Ostertag M, 1545, 2120
Végyvári A, 2452
Veit V, 1949

Venegoni E, 2926
Venhoff N, 2228
Venning H, 2854
Verbeek JS, 967, 1612
Verbeet NL, 430
Verburg RJ, 421, 2272
Vermeulen SHM, 3020
Vernillet L, 916
Verpoort KN, 3058
Verweij CL, 430
Verweij MC, 1700
Vesely R, 2873
Vestergaard A, 2300
Veys EM, 2146, 2192, 2323, 3898
Viallard J-F, 201
Vidaud M, 2917
Vierboom MPM, 627
Vigklis V, 501
Vignon E, 779, 1411
Vignon M, 1411
Vilá LM, 1473, 1655, 2060
Villa AR, 1138
Villiger PM, 304
Vincent C, 3424
Vinje O, 833
Viola S, 826, 2092
Vissink A, 2740
Vitali C, 3890
Vitolo B, 3448
Vögelin E, 304
Vogt T, 280
Vokonas PS, 2808
Volkmer D, 2010
Vollenhoven Rv, 4050
von Hinüber U, 3403
von Kempis J, 1334
von Mikecz A, 877
Voskuyl AE, 2044
Vries Nd, 3676
Vuk-Pavlovic Z, 73
Vuorio E, 3713
Vyse TJ, 2396

W

Wade NK, 269
Wagenleiter SEN, 4039
Wahren-Herlenius M, 366, 3639
Waka A, 531
Wakitani S, 155, 2559
Waldhäusl W, 2730
Waldmann TA, 2585
Walker UA, 2228
Wallace CA, 3554
Wallace DJ, 1227, 2396, 4018
Wallis DD, 257, 865
Wanders A, 1756
Wang BWE, 1336
Wang C-R, 339, 1319
Wang ECY, 1287
Wang J, 1431
Wansley D, 620, 3202
Ward MM, 1634, 1646, 2625
Ward-Able C, 2125
Warman ML, 1746
Warnatz K, 2470
Warner JJP, 3681

Wassenberg S, 1227, 3371
Watson PF, 3868
Watt I, 3536
Watts RA, 1620
Weaver AL, 1205
Wechsler B, 608, 2583
Wedderburn LR, 3586
Wegener's Granulomatosis
Etanercept Trial (WGET)
Research Group, 902, 2168
Wehenkel L, 3801
Weiben O, 2470
Weidler C, 1711, 1721
Weier R, 1227
Weinberg CR, 2433
Weinberg MA, 3279
Weinstein E, 522
Weinstein M, 990, 2953
Weisman MH, 386, 1227, 3326, 3813, 4018
Weiss J, 3175
Weissman NW, 2485
Welsing PMJ, 2616, 3020
Wendler J, 451
Wener MH, 3433, 3813
Wenting-van Wijk M, 1700
Werwitzke S, 3629
Wesoly J, 2948
West MR, 620
Westedt ML, 3381
Western Consortium of
Practicing Rheumatologists,
2284
Westfall AO, 2485
Westfall M, 1047
Westman M, 3439
Weyand CM, 73, 1392, 2996, 3839
White J, 42
Whittingham S, 1897
Wick G, 1804
Wicks IP, 3220, 3322, 3749
Wiehler S, 3210
Wientroub S, 3611
Wieringa H, 2865
Wiesner U, 1504
Wigley FM, 592, 2125
Wilder RL, 322
Wilder T, 2567
Wilke S, 2485
Wilkes MR, 2439
Williams A, 3528
Williams BD, 1287, 2952
Williams DA, 296, 1577, 3660, 3670
Williams S, 3536
Williamson P, 582
Wilson AG, 3868
Wiltshire T, 2567
Winoto A, 333
Winterberg F, 1504
Winthrop KL, 2968
Wintle RF, 425, 1993
Winyard PG, 3829
Wipff J, 2882
Wirth W, 3132
Witkowski JM, 2996

Witte T, 3629, 3966
 Witter F, 514
 Witteveen HJ, 2212
 Witzum JL, 192
 Wluka AE, 461, 2033
 Wofsy D, 395
 Wolbink GJ, 2740
 Wolfe F, 2015, 3873
 Wollina U, 2953
 Wong PKK, 3749
 Wong S-M, 2578
 Wong WH-S, 1058
 Woo P, 818, 2873, 3168
 Woodard J, 105
 Woodie MC, 1314
 Woods AM, 3761
 Woods JM, 1907
 Wooley PH, 3761
 Wordsworth BP, 1110
 Worrell T, 1730
 Worthington J, 752, 1694, 1836, 2579, 3596
 Wortmann RL, 916
 Wouters C, 2873
 Wright GD, 2040
 Wu C-L, 339, 1319
 Wu H, 2396
 Wu P, 892
 Wu R, 192, 3890
 Wu Y, 3257
 Wulffraat NM, 2865
 Wylam ME, 262

X

Xiao X, 3975
 Xie C, 3063

Xie H-G, 1349
 Xie S, 659
 Xin K-Q, 164
 Xing L, 2708
 Xiong M, 3305
 Xu D, 2080
 Xu J, 1314
 Xu L, 1418
 Xu X, 3257
 Xue J, 1325
 Xue S, 257

Y

Yagishita K, 2521
 Yajima N, 1670
 Yamada N, 3110
 Yamamoto D, 212
 Yamamoto H, 959
 Yamamoto K, 847, 1920
 Yamamoto T, 1293
 Yamamura T, 1941
 Yamanaka H, 2576, 2947, 3054
 Yamanaka M, 2576
 Yamanaka Y, 2719
 Yamane K, 1237, 2897
 Yamashita Y, 2697
 Yammani RR, 2376
 Yan A, 1794
 Yan SD, 2376
 Yanaba K, 2889
 Yanagida T, 847
 Yang H, 136
 Yang P, 3257
 Yang Y-H, 1626
 Yang YH, 1325
 Yao Z, 2708

Yarlett NC, 322
 Yasuda S, 212, 2697
 Yasui N, 1371
 Yavuz S, 1564, 3679
 Yazdanpanah M, 425, 1993
 Yazici Y, 4044
 Ye X, 3975
 Yelin EH, 2243
 Yeoman S, 744
 Yocum DE, 2015
 Yokoo N, 164
 Yokota S, 818
 Yonehara S, 3004
 Yonezawa T, 1451
 Yoshida K, 80
 Yoshie O, 1522
 Yoshikawa H, 2559, 3819
 Yoshimoto M, 3579
 Yoshioka T, 3579
 Yoshizaki K, 818
 Youinou P, 2411, 4028
 Young H, 3596
 Young JP Jr., 1264
 Young-Min S, 3868
 Yousaf N, 2906
 Yow E, 1196
 Ytterberg SR, 2168
 Yu CY, 2396
 Yu W, 1418

Z

Zack DJ, 1604, 3192
 Zaim S, 2822
 Zavadny PJ, 627
 Zeidler H, 1756, 3371
 Zerilli M, 2179

Zeyda M, 2730
 Zha YY, 1907
 Zhai G, 1069, 2830
 Zhang C, 3210
 Zhang G, 269
 Zhang Q, 2708
 Zhang X, 333, 620, 885, 1297, 3202, 3839
 Zhang Y, 1110, 1418, 2814
 Zhao H, 3943
 Zhao Z, 522
 Zhen B-G, 1637
 Zheng B, 333, 620, 3202
 Zhou F, 3731
 Zhou T, 3943
 Zhou X, 257, 865, 3305
 Zhou Z, 2403
 Zhu F, 1297
 Zhu J, 3063
 Zhu L, 1604, 3192
 Zhu T, 3975
 Ziegler A, 2581
 Zink A, 3403
 Ziprian T, 2109
 Ziswiler H-R, 304
 Zlabinger GJ, 2730
 Zlotnik A, 1504
 Zmuda JM, 1431
 Zoma A, 1481
 Zukor DJ, 128
 Zulian F, 563, 2854, 2873
 Zummer M, 1481
 Zvaifler N, 2693
 Zwinderman AH, 2865, 3381, 3676

SUBJECT INDEX

Arthritis & Rheumatism, Volume 52, Numbers 1-12, 2005

A

- Abatacept (CTLA-4Ig), RA treatment with, 2229, 2263
- Academic rheumatology, status of women in, 694, 697
- Acetabular dysplasia, as predictor of hip OA, 787
- Acinar cells, SS, acinar damage and MMP-3/TIMP-1 and MMP-9/TIMP-1 imbalance and, 2751
- Acquired immunodeficiency syndrome (AIDS), HLA-B*5703 in HIV infection and SpA, 275
- Acrocyanosis, APS, dermatologic manifestations of, 1785
- Acute anterior uveitis, unique genetic region on chromosome 9p and, 269
- Acute myocardial infarction, COX-2 inhibitors and, 1968
- Adalimumab
 - for POPP, 280
 - PsA treatment with, 3279
 - psoriasis onset during treatment, 2513
- ADAM15, OA, metalloproteinase disintegrin ADAM15 and degenerative cartilage remodeling, 1100
- Adamalysin, OA, metalloproteinase disintegrin ADAM15 and degenerative cartilage remodeling, 1100
- ADAMTS-4, abnormal expression in OA chondrocytes and epigenetic "unsilencing," 3110
- ADAMTS-9, induced by IL-1 β and TNF α in inflammatory arthritides, 1451
- Adeno-associated virus
 - autologous transplantation of basic fibroblast growth factor gene-transduced chondrocytes with, 164
 - collagen-induced arthritis, thrombospondin 1 gene therapy for, rat study, 339
 - RA, kallistatin gene therapy for, rat study, 1319
 - SLE, prevention and reversal by costimulatory blockade with adeno-associated virus-mediated gene transfer, 3975
- Adjuvant-induced arthritis
 - bone-protective effects of anabolic treatment used with RANKL and TNF inhibition, rat studies, 1604
 - chemokine receptor expression in, 3718
 - electroporation to enhance MTX effect, 637
 - Met-RANTES, amelioration by, rat study, 1907
 - osteoclastogenesis, kinetics of, rat study, 3192
 - peripheral μ -opioid receptors as potential therapy targets, 2955
 - plasminogen deficiency of in different RA models, 2541
- Adrenocorticotrophic hormone (ACTH), in SLE, 3701
- Adult-onset Still's disease, anakinra for treatment, 1794, 1960
- African Americans, OA, serum hyaluronan levels as biomarker of radiographic OA, 105
- Age
 - RA, age and OA at onset of symptoms, association with radiographic damage in, 2284
 - as risk factor for venous thrombosis in LUMINA study patients, 2060
- Aggrecan, ADAMTS-1 in cartilage growth, development, and inflammatory arthritis, mouse study, 1461
- Aggrecanases, ADAMTS-9 in inflammatory arthritides, 1451
- Air-pouch model, MTX, genetic resistance to in air-pouch model of acute inflammation, 2567
- Alendronate, TNF prevents alendronate-induced osteoclast death, mouse study, 2708
- α -Actinin, cross-reactive anti-dsDNA/anti- α -actinin antibodies and induction of renal disease, 522
- Alveolitis, SS, correlation of dyspnea with health-related quality of life in SS with alveolitis, 592
- American College of Rheumatology (ACR)
 - 2004 Slide Competition winners, 679
 - ACR-N index of improvement in RA, con argument, 1642
 - ACR-N index of improvement in RA, pro argument, 1637
 - call for new RA classification criteria, 3333
 - continuous indices of core data set measures in clinical trials, 1031
 - decision tree format for RA classification evaluation over 5 years, 2277
 - presidential address, 395
- 5-Aminoimidazole-4-carboxamide, folic and folinic acid supplements and MTX treatment, 1338, 1339
- Amyloidosis, reactive systemic AA amyloidosis, infliximab treatment, 2519
- Anabolic agent, bone-protective effects of anabolic treatment used with RANKL and TNF inhibition, rat studies, 1604
- Anakinra
 - for adult-onset Still's disease, 1794, 1960
 - for *Moraxella catarrhalis*-induced septic arthritis of prosthetic knee joint, 1337, 1338
 - neonatal-onset multisystem inflammatory disease, IL-1 blockade by improves symptoms, 1283
 - RA, infections in patients treated with biologic agents, 3403
 - RA, nonresponse to after failure of TNF blockade, 364, 365
 - Schnitzler syndrome treated with, 2226
- Analgesics, spontaneous circadian behavior in monarthritic rats, 3470
- Anetoderma
 - APS, dermatologic manifestations of, 1785
 - in SLE with antiphospholipid antibodies, 2228
- Angiogenesis
 - RA, bone destruction and, 1346
 - SSc, tissue kallikreins in endothelial cells, 3618
- Angiography-negative primary CNS vasculitis, in children, 2159
- Angiotensin receptor blockers, for amelioration of collagen-induced arthritis, mouse study, 1920, 3678, 4047
- Animal models. *See also names of specific animals*
 - chronic arthritis, peripheral μ -opioid receptor expression down-regulated in, 3210
 - RA, RANK/RANKL/osteoprotegerin system in, 2960
- ANKH gene, sporadic chondrocalcinosis, ANKH sequence variants and, 1110
- Ankle
 - OA, acoustic properties of knee and ankle joint cartilage, 3125
 - OA, matrix metabolism in cartilage lesions, 112
 - RA, leukocyte trafficking into ankle joint in mouse model, 3269
- Ankylosing spondylitis (AS)
 - anterior uveitis, anti-TNF therapy decreases uveitis flares in, 2447
 - anterior uveitis, unique genetic region on chromosome 9p and, 269
 - cartilage biomarkers in, 885
 - diagnosis and classification of early AS, 1000
 - etanercept, MRI assessment of spinal inflammation before and after treatment, 1216
 - etoricoxib, efficacy in, 1205
 - HLA-B27, molecular evidence of in historical case, 3318
 - HLA-B27-restricted CD8+ T cell response to cartilage-derived peptides in, 892, 2581, 2582
 - HLA-B27 subtypes, cell surface properties of, 3290
 - infliximab efficacy and safety in, 582
 - measurement of treatment effect on spinal radiographic progression in, 1979
 - NSAIDs and, 1634
 - NSAIDs for reduction of radiographic progression, 1756
 - prevalence of, 4048, 4049
 - recommendations for clinical trials, 386

- Ankylosing spondylitis (AS) (*cont'd*)
 TNF blockers in, 2506
- Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy (ASSERT) Study Group, 582
- Anterior cruciate ligament
 cartilage glycosaminoglycan loss in acute phase of anterior cruciate ligament injury, gadolinium-enhanced MRI, 120
 integrity of in knee OA, 794
 laxity in early-stage knee OA, guinea pig study, 3100
- Anterior uveitis
 AS, anti-TNF therapy decreases anterior uveitis flares in, 2447
 unique genetic region on chromosome 9p and, 269
- Anteroposterior stability, OA, anteroposterior laxity and knee OA progression, 2343
- Anti- $\alpha\beta 5$ antibody, SSc, TGF β signaling and, 2897
- Antiapoptotic proteins, NF- κ B protection of T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins in Behçet's disease, 2179
- Antibody-induced arthritis, V α 14 NKT cells in murine arthritis, 1941
- Anticardiolipin antibodies, APS, tissue plasminogen activator, polyclonal and monoclonal antibodies against, 4018
- Anti-CCP antibody-negative RA, HLA-DR3 associated with, 3058
- Anti-CD20, for SLE, 371
- Anti-citrullinated protein antibodies
 RA, citrullinated proteins in humoral autoimmunity, 2323
 RA, HLA-DR genes and production of, 3424
- Anti-cyclic citrullinated peptide (anti-CCP) antibodies
 in JRA, 239
 regulation in RA, 3813
- Anti-DNA antibodies
 cross-reactive anti-dsDNA/anti- α -actinin antibodies and induction of renal disease, 522
 protective autoantibodies, homeostasis, clinical importance, and therapeutic potential, 2559
 SLE, anti-dsDNA antibody levels and renal flare in, 1129
 SLE, glomerulonephritis and, 2403
 SLE, inhibition by IgM anti-dsDNA antibodies, mouse study, 3629
- Antiferritin antibodies, RA, radiographic damage and, 3868
- Anti-folate receptor β antibody, RA, targeting of synovial macrophages with anti-folate receptor β antibody and truncated *Pseudomonas* exotoxin, 2666
- Antigen-induced arthritis, promotion of MTX induction and anti-inflammatory effects by sonoporation, rabbit study, 2559
- Antigen microarray profiling, of RA autoantibodies, 2645
- Antigen-presenting cells, disruption of T cell/antigen-presenting cell interaction by teriflunomide, 2730
- Anti-interleukin-6 receptor antibody, in JIA, 818
- Anti-Ku autoantibodies, and DPB1*, 668
- Antimicrobial peptides, OA, human β -defensin in tissue remodeling, mouse study, 1736
- Antimuscarinic antibodies, in SS, 2984
- Antineutrophil cytoplasmic antibodies (ANCA)
 Churg-Strauss syndrome, 2589, 2926
 refractory ANCA-associated vasculitis, B lymphocyte depletion for, 262
 rituximab and WG, B cells and vasculitis, 1
- Antineutrophil cytoplasmic antibody-associated vasculitis, MTX vs. cyclophosphamide to induce remission, 2461
- Antinuclear antibody (ANA), JIA and, 826
- Anti-P antibodies, in SLE, 847
- Antiphospholipid antibodies
 anetoderma in SLE with, 2228
 antiphospholipid antibody-mediated thrombophilia, complement activation and, mouse study, 2120
 p38 MAPK and antiphospholipid antibody-induced up-regulation of tissue factor on HUVECs, 1545
- Antiphospholipid syndrome (APS)
 antiphospholipid antibodies in pathogenesis of, 988
 dermatologic manifestations of, 1785
 involvement of p38 MAPK in antiphospholipid antibody-induced up-regulation of tissue factor on HUVECs, 1545
 lupus anticoagulant and prolonged bleeding time, 1949
 psychiatric symptoms, electroencephalographic assessment, 841
 thrombotic events in, 4011
 tissue plasminogen activator, polyclonal and monoclonal antibodies against, 4018
 valine²⁴⁷ β_2 -glycoprotein I and risk of APS, 212
- Antiplatelet antibodies, lupus anticoagulant and prolonged bleeding time, 1949
- Anti-RNA polymerase III antibody, ELISA for detection of, 2425
- Anti-SSA/Ro antibodies
 congenital heart block in family members of different generations, 1623, 1625
 corrected QT interval in anti-SSA-positive adults with connective tissue disease, 676, 677
 fetal heart block and, 366, 3079
 maternal antibody specificity and fetal congenital heart block, 3079
 up-regulation of 52-kd Ro/SSA by TNF α via TNF receptor I, 531
- Antisynthetase-associated ILD, tacrolimus treatment, 2439
- Anti-TNF
 AS, anterior uveitis flares decreased by, 2447
 Disease Activity Score as sole criterion for initiation and evaluation of anti-TNF therapy, 3873
 Fc γ receptor type IIIA polymorphisms and treatment outcomes with TNF α blockade, 2693
 JIA, infliximab for, 548
 juvenile SpA treated with, 2103
 POPP, adalimumab treatment, 280
 RA, etanercept and infliximab and apoptosis induction in joint macrophages, 61
 RA, modulation of CD28 induced by, 2996
 RA, tuberculosis risk and, 1986, 2968
- Anti-type II collagen antibodies, arthritogenic capacity of, mouse study, 1897
- Apoptosis
 anti-endothelial cell antibodies in vasculitis-associated systemic autoimmune diseases, 4028
 NF- κ B protection of T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins in Behçet's disease, 2179
 RA, anti-TNF therapy and induction of in joint macrophages, 61
 RA, TP53 and apoptosis effects in, 1047
 SS, Fas and CD40 in salivary epithelial cell death, 573
 TNF prevents alendronate-induced osteoclast death, mouse study, 2708
- Apoptotic cells, exposure and binding of La/SSB epitopes on, 3934
- Aromatase inhibitors, estrogen deprivation arthralgia and, 2594
- Arterial disease, SLE, raised lipid peroxidase in associated with arterial disease, 192
- Arthralgia, estrogen deprivation arthralgias, 2594
- Arthritis
 ADAMTS-1 in cartilage growth, development, and inflammatory arthritis, mouse study, 1461
 ADAMTS-9 induced by IL-1 β and TNF α in inflammatory arthritis, 1451
 adaptive immunity in p53 regulation of arthritis, mouse study, 1876
 IL-4 promotion of, mouse study, 1866
 nomenclature and classification in chronic childhood arthritis, 382
 protease-activated receptor, role in arthritis severity in mice, 1325
- Arthritis & Rheumatism (A&R)*
 in appreciation of editor David S. Pisetsky, 1627
 introducing new editor Michael D. Lockshin, 1951
 new journal policy regarding registration of clinical trials, 2243
 policies and procedures for A&R, 3683

Arthritis & Rheumatism (A&R) (cont'd)

- review of manuscripts, 915, 1332
- Arthropathy**
arthropathy-accelerating MRL locus in DBA/1 mice, 959
cat-scratch disease-associated arthropathy, 3611
hereditary cartilage debonding syndrome, 3300
- Arthroplasty**
OA, surgical outcomes following knee or hip arthroplasty, racial/ethnic differences and, 3143
trends in total knee arthroplasty in US 1990-2000, 3928
- Ascorbic acid, dehydroascorbate transport in human chondrocytes, 2676
- ASPN gene, asporin polymorphism and OA etiology, 3502
- Asporin, polymorphism and OA etiology, 3502
- Assessment in Ankylosing Spondylitis, International Working Group/Spondylitis Association of America recommendations for clinical trials, 386
- Assessment instruments**
Childhood Myositis Assessment Scale, validation and clinical significance of, 368
JIA, development and validation of clinical index for, 2092
JIA, Dijkstra score for assessment of radiographic change, 2865
- Atherosclerosis**
in RA, 3045
relative contribution of cardiovascular risk factors and RA to, 3413
SS, precocious intima-media thickening in SS patients, 3890
- ATTRACT study, RA, infliximab plus MTX, benefit in patients without clinical improvement, 1020, 4044, 4045
- Autoantibodies. See also names of specific autoantibodies**
protective autoantibodies: homeostasis, clinical importance, and therapeutic potential, 2599
RA, antigen microarray profiling of, 2645
SLE, autoantibody clustering to predict clinical subsets and damage, 4003
that bind glomeruli, 2403
- Autoantigens, SSc, proteasome-dependent processing of topoisomerase I, 877**
- Autoimmune diseases. See also names of specific diseases**
familial aggregation of autoimmune diseases in SLE patients, 1138
- Autoimmune thyroid disease, SLE/autoimmune thyroid disease susceptibility gene at 5q14.3-15, 3646**
- Autoimmunity, dendritic cells and, 11**
- Autologous chondrocyte transplantation, of basic fibroblast growth factor gene-transduced chondrocytes with adeno-associated virus vector, rabbit study, 164**
- Autologous stem cell transplantation (ASCT)**
RA, effect of ASCT and high-dose chemotherapy on joint damage, 421
RA, high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation, long-term followup of health status, 2272
SSc, immune reconstitution following, 1555
- Axial SpA, AS, diagnosis and classification, 1000

B

- Backcross studies, SLE, genetic origin of in SWR/NZB hybrids, 659
- Back pain, opioid use for, 312
- Bacteria. See names of specific bacteria**
- Bacterial antigens, autoantibodies that bind glomeruli, 2403
- BAFF receptor, expression and occupancy of in SLE, 3943
- Barrett's esophagus, in SSc, 2882
- Bartonella henselae*, cat-scratch disease-associated arthropathy, 3611
- Basic calcium phosphate crystals, rotator cuff disorders, 3681
- Basic fibroblast growth factor**
autologous transplantation of basic fibroblast growth factor gene-transduced chondrocytes with adeno-associated virus vector, rabbit study, 164

Basic fibroblast growth factor (cont'd)

- and chondrocyte anabolic activity promoted by insulin-like growth factor I and osteogenic protein 1, 3910
- B cell-activating factor (BAFF)**
expression and occupancy of BAFF receptors in SLE, 3943
overexpression of and accelerated glomerular disease in mice predisposed to SLE, 2080
and periodontal disease in patients with dry mouth, 2411
- B cells**
lupus nephritis, therapeutic B cell depletion therapy, 501, 4080, 4081
SLE, Lyn expression, 3955
SS, chemokine receptor expression and function by, 2109
SSc, immune reconstitution following ASCT, 1555
WG treated with rituximab and ANCA-associated vasculitis, 1
- Behçet's disease**
infliximab in treatment-resistant Behçet's uveitis, 2478
NF- κ B in pathogenesis of, 2179
TNFRSF1A R92Q mutation and risk of venous thrombosis in, 608, 2582
whole-genome screen for susceptibility genes in, 1836
- BeSt study, 3326, 3381
- Biomarkers**
AS, cartilage biomarkers, 885
clinically amyopathic dermatomyositis, anti-CADM-140 in Japanese with, 1571
congenital heart block, PR interval as, 1341, 1342
OA and early RA, type II collagen helical peptide in, 1081
OA, of lipid peroxidation in OA cartilage, 2799
OA, MMP-3 as biomarker of OA progression, 3160
OA, serum hyaluronan levels as biomarker of radiographic OA, 105
pulmonary fibrosis in SSc, serum pulmonary and activation-regulated chemokine/CCL18 levels in, 2889
RA, RANK/RANKL system in inflammation, 2307
RA, using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry-based protein chip approach, 3801
SLE, C4d-bearing reticulocytes as disease activity markers, 3087
SLE/autoimmune thyroid disease susceptibility gene at 5q14.3-15, 3646
WG, serum proteomic profiling to gauge state of remission, 902
- Bisphosphonates**
OA, vitamin D supplementation and, 1622, 1623
TNF prevents alendronate-induced osteoclast death, mouse study, 2708
- Bleeding, lupus anticoagulant and prolonged bleeding time, 1949**
- Blood sampling, SLE, MMP-9 in patients with neuropsychiatric SLE and brain MRI abnormalities, 673, 674**
- B lymphocyte depletion**
for refractory ANCA-associated vasculitis, 262
in refractory childhood SLE, 3168
- Body composition, and knee cartilage volume in healthy subjects, 461**
- Body weight, weight loss and reduction of knee-joint load in knee OA in older obese adults, 2026**
- Bone**
bone-protective effects of anabolic treatment used with RANKL and TNF inhibition, rat studies, 1604
Egr2/Krox20 in dexamethasone-mediated osteocalcin repression, mouse study, 929
kinetics of osteoclastogenesis, rat study, 3192
OA, local BMD associated with bone marrow lesions, 2814
OA, MRI bone marrow abnormalities and cartilage degradation in knee OA, 2822
POPP, 280, 2954
RA, angiogenesis and bone destruction, 1346
RA, RANK/RANKL/osteoprotegerin system: animal studies, 2960
RA, subchondral bone marrow and, 3448
SLE, osteopenia in childhood-onset SLE, 2051
SLE, vertebral fractures in SLE patients and low BMD, 2044

Bone (*cont'd*)
 subchondral femoral head insufficiency fracture after renal transplantation, 1293
 Bone anabolic agent, bone-protective effects of anabolic treatment used with RANKL and TNF inhibition, rat studies, 1604
 Bone destruction
 gene therapy targeting Tie2 attenuates collagen-induced arthritis, 1585
 OA, MRI bone marrow abnormalities and cartilage degradation in knee OA, 2822
 RA, angiogenesis and, 1346
 RA, RANK/RANKL/osteoprotegerin system, animal studies, 2960
 TNF prevents alendronate-induced osteoclast death, mouse study, 2708
 Bone erosion, STAT-6-VT inhibition of osteoclastogenesis and bone erosion, mouse study, 2719
 Bone loss
 OA, bone loss on knee radiographs, 3536
 RA, nurse-like cells from RA patients and, 3819
 Bone marrow
 OA, BMD associated with bone marrow lesions, 2814
 OA, MRI bone marrow abnormalities and cartilage degradation in knee OA, 2822
 RA, subchondral bone marrow and, 3448
 Bone mass, in children with early JIA, 833
 Bone mineral content, osteopenia in childhood-onset SLE, 2051
 Bone mineral density (BMD)
 OA, local BMD associated with bone marrow lesions, 2814
 SLE, osteopenia in childhood-onset SLE, 2051
 SLE, raloxifene for postmenopausal women with SLE, 3997
 SLE, vertebral fractures and low BMD, 2044
 Bone morphogenetic protein 2, for tissue engineering in cartilage repair, 155
 Bone turnover, in children with early JIA, 833
 Boundary lubrication, synovial fluid boundary lubrication following injury, rabbit study, 1746
 Bovine studies
 hyaluronan oligosaccharide-induced activation of transcription factors in bovine articular chondrocytes, 800
 tonic activation of hypoxia-inducible factor 1 α in avascular articular cartilage, 3181
 Brain
 APS and SLE, electroencephalographic assessment of neuropsychiatric symptoms in, 841
 SLE, cerebral and corpus callosum atrophy in, 2783
 SLE, MMP-9 in patients with neuropsychiatric SLE and brain MRI abnormalities, 673, 674
 Brn-3, expression in SLE, 1171
 Butyrate, regulation of TNF α production by in RA synoviocytes, 2697

C

C4d-bearing reticulocytes, as SLE disease activity markers, 3087
 CADM-140, anti-CADM-140 in Japanese with clinically amyopathic dermatomyositis, 1571
 Calcium-based phosphate binders, reduction in serum uric acid with, 290
 Canadian population, association of PTPN22 variant with RA in, 1993
 Cancer
 dysphagia after testicular cancer, 3712
 in SLE, 1481
 SSc, Barrett's esophagus in, 2882
 SSc, risk of malignancy and, 2415
 CARD15, PsA, common genetic control pathways of inflammation for Crohn's disease and PsA, 3596
 Cardiovascular disease
 anti-SSA-positive adults with connective tissue disease, corrected QT interval in, 676, 677

Cardiovascular disease (*cont'd*)
 atherosclerosis, relative contribution of cardiovascular risk factors and RA to, 3413
 inflammatory polyarthritis, baseline C-reactive protein levels and prediction of death from, 2293
 RA, cardiovascular death in, 722
 RA, increased coronary-artery atherosclerosis in, 3045
 RA, increased unrecognized coronary heart disease and sudden death in, 402
 RA, risk of heart failure in, 412, 3039
 SLE, raised lipid peroxidase in associated with arterial disease, 192
 SLE, thromboembolism in, risk factors and incidence, 2774
 Cardiovascular events, COX-2 inhibitors and, 1968
 Carpal tunnel syndrome
 surgery vs. steroid injection in, 612, 2578
 value of sonography in patients with suspected carpal tunnel syndrome, 304
 Cartilage
 ADAMTS-1 in cartilage growth, development, and inflammatory arthritis, mouse study, 1461
 anterior cruciate ligament injury, glycosaminoglycan loss in acute phase, gadolinium-enhanced MRI, 120
 AS, cartilage biomarkers in, 885
 AS, HLA-B27-restricted CD8 $^{+}$ T cell response to cartilage-derived peptides in, 892, 2581, 2582
 body composition and knee cartilage volume in healthy subjects, 461
 bone morphogenetic protein 2 for tissue engineering in cartilage repair, 155
 cartilage defects and knee cartilage loss in healthy adults, 2033
 coefficient of friction, the slippery slope of arthritis, 1632
 dehydroascorbate transport in human chondrocytes, 2676
 hereditary cartilage debonding syndrome, 3300
 mechanical injury, gene expression after, 2386
 OA, acoustic properties of early cartilage lesions in knee and ankle joints, 3125
 OA, acoustic properties of knee and ankle joint cartilage, 3125
 OA, chondroitin 4 and 6 sulfate treatment of knee OA, 779
 OA, correlates of hip cartilage volume, 1069
 OA, extracellular superoxide dismutase and oxidant damage in, 3479
 OA, human β -defensin in remodeling of, mouse study, 1736
 OA, IL-1 and TNF α in matrix degradation, 128
 OA, IL-8 and phosphate transporter/retrovirus receptor in chondrocyte phosphate uptake, 144
 OA, inhibition of MMPs in cartilage loss in vitro, and in the guinea pig model, 171
 OA, lateral view radiography to evaluate tibiofemoral joint space width, 3542
 OA, matrix metabolism in lesions of knee and ankle joints, 112
 OA, metalloproteinase disintegrin ADAM15 and degenerative cartilage remodeling, 1100
 OA, moderate exercise and glycosaminoglycan content in cartilage, 3507
 OA, molecular markers of lipid peroxidation in, 2799
 OA, MRI bone marrow abnormalities and cartilage degradation in knee OA, 2822
 OA, PD0200347 in experimental OA, dog study, 488
 OA, quantitative MRI assessment of cartilage morphology, 3132
 osteogenic protein 1 antisense inhibition and cartilage integrity, 468
 prevalent and incident knee cartilage defects, loss of tibial and patellar cartilage, 3918
 RAGE expression by articular chondrocytes, 2376
 synovitis and cartilage degeneration and overexpression of cathepsin K, mouse study, 3713
 T cell IL-17 overexpression in IL-1-deficient arthritic mice, 975
 tonic activation of hypoxia-inducible factor 1 α in avascular articular cartilage, 3181
 Cartilage defects, knee cartilage loss in healthy adults and, 2033

Cartilage degeneration

OA, moderate exercise and glycosaminoglycan content in cartilage, 3507
and synovitis, overexpression of cathepsin K and, mouse study, 3713

Cartilage degradation

IL-17 receptor and cartilage destruction in streptococcal cell wall-induced arthritis, mouse study, 3239
OA, acoustic properties of knee and ankle joint cartilage, 3125
OA, MRI bone marrow abnormalities and cartilage degradation in knee OA, 2822
OA, oral glucosamine in, rabbit study, 1118, 3680
OA, PD0200347 in experimental OA, dog study, 488
osteogenic protein 1 antisense inhibition and cartilage integrity, 468
synovial fluid boundary lubrication following injury, rabbit study, 1746

Cartilage loss

knee OA, chondroitin 4 and 6 sulfate treatment, 779
OA, cartilage loss on MRI and radiographic progression in, 3152
OA, inhibition of MMPs in cartilage loss in vitro, and in the guinea pig model, 171
prevalent and incident knee cartilage defects, loss of tibial and patellar cartilage, 3918

Cartilage remodeling, OA, metalloproteinase disintegrin ADAM15 and degenerative cartilage remodeling, 1100

Cartilage repair

bone morphogenetic protein 2 for tissue engineering in, 155
proteoglycan 4 in synovial fluid, inhibition by, 1091

Cartilage volume, OA, correlates of hip cartilage volume, 1069

Cathepsins

involvement in topoisomerase I cleavage in necrosis, 2133
synovitis and cartilage degeneration and overexpression of cathepsin K, mouse study, 3713

Cat-scratch disease, arthropathy associated with, 3611

CCL18, pulmonary fibrosis in SSc, serum pulmonary and activation-regulated chemokine/CCL18 levels in, 2889

CCL21, SS, CXCL13 and CCL21 expression and lymphoid features in, 1773

CCR2, SSc, chemokine receptor CCR2 expression by fibroblasts, 3772
CCR5, CCR5 antagonist for inhibition of rhesus monkey collagen-induced arthritis, 627

CD4+ T cells

CD4+ T lymphocyte-dependent IL-1-driven arthritis, IL-2, IFN γ , IL-4, joint macrophages, granulocyte-macrophage colony-stimulating factor, IL-6, and leukemia inhibitory factor and, 3749
class II MHC-peptide tetramers for detection of, mouse study, 1885
RA, association of with interstitial pneumonitis, 73
RA, fractalkine and T cell-synoviocyte interaction in, 1392
RA, IL-7 stimulates cell contact-dependent activation of, 1700
RA, tissue trafficking patterns of effector memory CD4+ T cells in, 3839

SLE, reduced sensitivity to CD4+, CD25+ regulatory T cells in murine lupus, 1180

CD4+ T lymphocyte-dependent IL-1-driven arthritis, IL-2, IFN γ , IL-4, joint macrophages, granulocyte-macrophage colony-stimulating factor, IL-6, and leukemia inhibitory factor and, 3749

CD8+

AS, HLA-B27-restricted CD8+ T cell response to cartilage-derived peptides in, 892, 2581, 2582

SLE, activated CD8+ lymphocytes in SLE pathogenesis, 201

CD25+ regulatory T cells

collagen-induced arthritis, treatment with, 2212
SLE, reduced sensitivity to CD4+, murine lupus, 1180

CD28, RA, TNF α -induced modulation of CD28, 2996

CD35, bound to immune complexes in sera of SLE patients, 2950

CD40, SS, Fas and CD40 in salivary epithelial cell death, 573

CD44, OA, CD44v6 expression on chondrocytes in rabbits with OA, 810

CD64+ monocytes, RA, Toll-like receptor 2 and 4 expression on, 2227
CD95, NF- κ B protection of T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins in Behçet's disease, 2179

CD97, epidermal growth factor-TM7 receptor expression in rheumatoid synovial tissue, 442

Celecoxib

cardiovascular events and, 1968
spontaneous circadian behavior in monoarthritic rats, 3470

Central nervous system (CNS)

Afrin-induced CNS vasospasm and thunderclap headache, 3314
angiography-negative primary CNS vasculitis in children, 2159

SLE, cerebral and corpus callosum atrophy in, 2783

Cerebrovascular accident, COX-2 inhibitors and, 1968

Chebularic acid, suppression of collagen-induced arthritis, mouse study, 345

Chemokine receptors

adjuvant-induced arthritis, expression in rats, 3718
RA, chemokines and their receptors as future targets, 710

SS, on B cells in primary SS, 2109

SSc, chemokine receptor CCR2 expression by fibroblasts, 3772

Chemokines

adjuvant-induced arthritis, amelioration by Met-RANTES, rat study, 1907

CCR5 antagonist for inhibition of rhesus monkey collagen-induced arthritis, 627

collagen-induced arthritis, CXCL13 neutralization and disease severity, mouse study, 620

cutaneous lupus erythematosus, amplification cycle triggering, 1504
in hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy, 2917

IL-8, role in phosphate transporter/retrovirus receptor expression and CSCR1-mediated inorganic phosphate uptake in chondrocytes, 144

juvenile DM, angiostatic ELR-CXC chemokines and vasculopathy in, 3175

lupus nephritis, effect of fractalkine antagonist on, mouse study, 1522

RA, chemokines and their receptors as future targets, 710

RA, CXCL12 stromal cell-derived factor 1 chemokine gene variant and radiographic progression, 354

RA, CXCL8 binding site on endothelial syndecan-3 in synovium, 2331

RA, fractalkine and T cell-synoviocyte interaction in, 139

SLE, elevated levels of soluble fractalkine in, 1670

SS, CXCL13 and CCL21 expression and lymphoid features in, 1773
SSc, serum pulmonary and activation-regulated chemokine/CCL18 levels in, 2889

Chicken study, TGF β 2, effects on procollagen α 2 type I messenger RNA variants in embryonic fibroblasts, 1804

Childhood Myositis Assessment Scale, validation and clinical significance of, 368

Children. See also Juvenile

angiography-negative primary CNS vasculitis in, 2159

Childhood Myositis Assessment Scale, validation and clinical significance of, 368

classification of childhood arthritis, 382, 826

DM, angiostatic ELR-CXC chemokines and vasculopathy in, 3175

DM, calcinosis universalis as complication, 1626

Hodgkin's disease, hypertrophic osteoarthropathy in, 2584

JIA, corticosteroid intraarticular injection for temporomandibular joint arthritis in children with, 3563

juvenile SpA, anti-TNF α blockade in treatment of, 2103

neonatal-onset multisystem inflammatory disease, IL-1 blockade by anakinra improves symptoms, 1283

polyarticular arthritis, daily stress and mood in, 1196

SLE, B lymphocyte depletion therapy in, 3168

SLE, criteria for evaluating response to therapy, 2854

Children. *See also* Juvenile (*cont'd*)

- SSc, juvenile localized, extracutaneous manifestations of, 2873
- Chinese population
 - RA, PD-1 polymorphism and development of, 362
 - RA, *PDCD1* haplotype associated with, 1058
- Chlamydia trachomatis*, innate immunity in infection-triggered arthritis, mouse study, 1297
- Chloroquine, clofazimine compared with for SLE, 3073
- Chondrocalcinosis, sporadic chondrocalcinosis, *ANKH* sequence variants and, 1110
- Chondrocytes
 - ADAMTS-9 induced by IL-1 β and TNF α in inflammatory arthritis in, 1451
 - autologous transplantation of basic fibroblast growth factor gene-transduced chondrocytes with adeno-associated virus vector, rabbit study, 164
 - basic fibroblast growth factor inhibits insulin-like growth factor I and osteogenic protein 1 in, 3910
 - dehydroascorbate transport in, 2676
 - hyaluronan oligosaccharide-induced activation of transcription factors in bovine articular chondrocytes, 800
 - IL-8 and phosphate transporter/retrovirus receptor in chondrocyte phosphate uptake, 144
 - OA, CD44v6 expression on chondrocytes in rabbit with OA, 810
 - OA, matrix-degrading enzyme expression in, 3110
 - OA, molecular markers of lipid peroxidation in OA cartilage, 2799
 - OA, PD0200347 in experimental OA, dog study, 488
 - OA, reactivity of OA chondrocytes to IL-1 β , 136
 - RAGE expression by articular chondrocytes, 2376
- Chondroitin sulfate
 - epidermal growth factor-TM7 receptor expression in rheumatoid synovial tissue, 442
 - knee OA, chondroitins 4 and 6 sulfate treatment, 779
 - OA, clinical trials of disease-modifying OA drugs, lessons learned, 3349
- Chondrosarcoma cells, ADAMTS-9 induced by IL-1 β and TNF α in inflammatory arthritides in, 1451
- Chronic fatigue syndrome (CFS), monitoring of activity and symptoms, 296
- Chronic infantile neurologic, cutaneous, articular (CINCA) syndrome.
 - See also* Neonatal-onset multisystem inflammatory disease
 - CIAS1* somatic mosaicism in, 3579
- Churg-Strauss syndrome
 - ANCA, prevalence and clinical significance of in, 2926
 - definitions and classification criteria, 2589
- Cia10*, pristane-induced arthritis: severity, pannus formation, and joint damage and, rat study, 322
- CIAS1* gene
 - CINCA syndrome, *CIAS1* somatic mosaicism in, 3579
 - systemic multisystem syndromes and anakinra, 1960
- Cigarette smoking
 - RA, HLA-DR shared epitope alleles in, 3675, 3676
 - as SLE risk factor, 1340, 1341
- Circadian behavior, spontaneous, in monarthritic rats, 3470
- Citrullinated proteins
 - in humoral autoimmunity, 2323
 - RA phenotype based on specificity of HLA-DRB1 shared epitope for, 3433
- Classification
 - childhood arthritis, 382, 826
 - early AS, 1000
 - RA, call for new ACR classification criteria, 3333
 - RA, evaluation of ACR decision tree format for RA classification over 5 years, 2277
 - RA, HLA-DRB1 alleles, new classification in, 1063
- Clinical trials
 - AS, recommendations for, 386

Clinical trials (*cont'd*)

- carpal tunnel syndrome, surgery vs. steroid injection, 612, 2578
- continuous indices of core data set measures in, 1031
- idiopathic inflammatory myopathies, consensus guidelines for myopathy trials, 2607
- JIA, meloxicam vs. naproxen for, 563
- new journal policy regarding registration of, 2243
- OA, disease-modifying drugs, lessons learned, 3349
- OA, importance of alignment in knee radiography for clinical trials of structure-modifying drugs, 1343, 1411
- RA, ACR-N index of improvement: con argument, 1642
- RA, ACR-N index of improvement: pro argument, 1637
- RA, early suppression of disease activity and maintenance of work capacity, 36
- RA, presentation and analysis of radiographic data, 49
- reduction in serum uric acid with sevelamer and calcium-based phosphate binders, 290
- Clinically amyopathic DM (C-ADM), anti-C-ADM-140 in Japanese with, 1571
- Clofazimine, compared with chloroquine for SLE, 3073
- Coculture model, RA, neutrophil recruitment in coculture model of, 3460
- Cognitive impairment, SLE, cerebral and corpus callosum atrophy in, 2783
- COL1A1* gene, polymorphism, hip OA, and genetics in elderly women, 1431
- Collagen
 - arthritogenic capacity of anti-type II collagen antibodies, mouse study, 1897
 - microfibril-associated glycoprotein 2, increased expression of type I collagen and, mouse study, 1812
 - OA and early RA, type II collagen helical peptide in, 1081
 - OA, *COL9A1* gene and hip OA, 1437
 - OA, matrix metabolism in cartilage lesions of knee and ankle joints, 112
 - RA, neoantigenic epitopes after posttranslational modification of type II collagen, 3829
 - specific inhibition of SPARC and decreased expression of type I collagen, 257
 - SSc, microfibril-associated glycoprotein 2, increased expression of type I collagen and, mouse study, 1812
- Collagen degradation, OA and early RA, type II collagen helical peptide in, 1081
- Collagen-induced arthritis
 - adaptive immunity in p53 regulation of arthritis, mouse study, 1876
 - angiotensin receptor blockers for amelioration of, mouse study, 1920, 3678, 4047
 - bone-protective effects of anabolic treatment used with RANKL and TNF inhibition, rat studies, 1604
 - CCR5 antagonist for inhibition of rhesus monkey collagen-induced arthritis, 627
 - chebulagic acid, suppression by, mouse study, 345
 - combination therapy with M40403 and dexamethasone in, rat study, 1929
 - combination therapy with M40403 and MTX, rat study, 3755
 - CXCL13 neutralization and disease severity, mouse study, 620
 - dipeptidyl peptidase I and, mouse study, 2553
 - erythropoietin effects on, 940
 - exacerbation in IFN β -deficient mice, 3739
 - gene therapy targeting Tie2 in, 1585
 - heme oxygenase 1 modulation in progression of, 3230
 - lymphotoxin regulates T cell response and autoimmunity, 3202
 - mesenchymal stem cells, reversal of immunosuppressive properties by TNF α , mouse study, 1595
 - Nur77 overexpression and, mouse study, 333
 - osteoclastogenesis, kinetics of, rat study, 3192
 - plasminogen deficiency of in different RA models, 2541

- Collagen-induced arthritis (*cont'd*)
 small interfering RNA and joint inflammation in mice, 1314
 soluble IL-1 receptor accessory protein to ameliorate, 2202
 sympathetic nervous system and chronic collagen-induced arthritis in mice, 1305
 thrombospondin 1 gene therapy for, rat study, 339
 treatment with CD25⁺ regulatory T cells, 2212
 V α 14 NKT cells in murine arthritis, 1941
- Combination therapy
 Behçet's uveitis, infliximab efficacy for treatment-resistant, 2478
 BeSt study, 3326, 3381
 collagen-induced arthritis, combination therapy with M40403 and dexamethasone, rat study, 1929
 DM, juvenile, MTX plus aggressively tapered corticosteroids for, 3570
 JIA, hydroxychloroquine and serum MTX concentrations in children with, 1621
 JIA, infliximab plus MTX in refractory polyarticular JIA, 548
 RA, combination MTX-intramuscular gold therapy, 1360
 RA, early suppression of disease activity and maintenance of work capacity, 36
 RA, efficacy of, 2975
 RA, etanercept plus MTX, presentation and analysis of clinical trial radiographic data, 49
 RA, infliximab plus MTX, benefit in patients without clinical improvement, 1020, 4044, 4045
 RA, infliximab plus MTX for poor-prognosis RA, 27
 RA, MTX plus abatacept (CTLA-4Ig) treatment, 2229, 2263
 RA, prednisolone plus DMARDs in early RA, 3324, 3360, 3371
- Complement activation, antiphospholipid antibody-mediated thrombophilia and, mouse study, 2120
- Complement receptor 1, bound to immune complexes in sera from SLE patients, 2950
- Congenital heart block
 anti-SSA/Ro 52-kd antibodies and, 366
 in family members of different generations, anti-SSA/Ro antibodies and, 1623, 1625
 maternal antibody specificity and fetal congenital heart block, 3079
 PR interval as early marker, 1341, 1342
- Congestive heart failure, risk of in RA, 412
- Connective tissue disease, corrected QT interval in anti-SSA-positive adults with, 676, 677
- Core data set, clinical trials, continuous indices of core data set measures in, 1031
- Coronary artery atherosclerosis, in RA, 3045
- Coronary heart disease. *See* Cardiovascular disease
- Corticosteroids
 intraarticular methylprednisolone therapy and cortisol secretion, 924
 JIA, intraarticular injection for temporomandibular joint arthritis in children with, 3563
 juvenile DM, MTX plus aggressively tapered corticosteroids for, 3570
 SLE, lymphocyte expression of P-glycoprotein and steroid resistance, 1676
- Cortisol
 FM, momentary relationship between symptoms and cortisol secretion, 3660
 intraarticular methylprednisolone therapy and cortisol secretion, 924
 RA, reactivation of glucocorticoids in synovial cells, 1711
- Costimulatory blockade, SLE, prevention and reversal by costimulatory blockade with adeno-associated virus-mediated gene transfer, 3975
- Covalent RNA-protein complexes, generation of by ultraviolet B irradiation, 1160
- Cranial arteries, GCA, cranial involvement in by MRI, 2470
- C-reactive protein
 inflammatory polyarthritis, baseline C-reactive protein levels and prediction of death from cardiovascular disease in, 2293
 lupus nephritis, single-dose C-reactive protein therapy, mouse study, 378
 RA, C-reactive protein as predictor of infliximab treatment outcome, 42
 reversal of proteinuria in autoimmune mice by treatment with, 642
- Criteria
 Churg-Strauss syndrome, classification of, 2589
 RA, disease activity states, 2625
 SLE, evaluating response to therapy in children, 2854
- Crohn's disease
 common genetic control pathways of inflammation in Crohn's disease and PsA, 3596
 SLC22A4 polymorphisms, lack of association with, 425
- Cruciate ligament
 integrity of in knee OA, 794
 laxity in early-stage knee OA, guinea pig study, 3100
- Cryoglobulinemia, systemic vasculitis, PEGylated IFN α -2b and ribavirin treatment for hepatitis C virus-related systemic vasculitis, 911
- CTLA-4Ig (abatacept), RA treatment with, 2229, 2263
- Cutaneous lupus erythematosus
 amplification cycle triggering, 1504
 high mobility group box chromosomal protein 1 in skin lesions, 3639
 up-regulation of 52-kd Ro/SSA by TNF α via TNF receptor 1, 531
- Cutaneous necrosis, APS, dermatologic manifestations of, 1785
- CX3CL1
 lupus nephritis, effect of fractalkine antagonist on, mouse study, 1522
 RA, fractalkine and T cell-synoviocyte interaction in, 1392
 SLE, elevated levels of soluble fractalkine in, 1670
- CXC chemokines
 lupus nephritis, effect of fractalkine antagonist on, mouse study, 1522
 RA, chemokines and their receptors as future targets, 710
 RA, fractalkine and T cell-synoviocyte interaction in, 1392
 SLE, elevated levels of soluble fractalkine in, 1670
- CXCL8, RA, binding site on endothelial syndecan-3 in synovium, 2331
- CXCL12, RA, stromal cell-derived factor 1 chemokine gene variant and radiographic progression, 354
- CXCL13
 collagen-induced arthritis and, mouse study, 620
 SS, CXCL13 and CCL21 expression and lymphoid features in, 1773
- CXCL16
 RA, CXCL16 recruits memory T cells into rheumatoid joints, 1381
 RA, pathogenic role of CXCL16-CXCR6 pathway in, 3004
- CXCR1, IL-8, role in phosphate transporter/retrovirus receptor expression and CXCR1-mediated inorganic phosphate uptake in chondrocytes, 144
- CXCR6, RA, pathogenic role of CXCL16-CXCR6 pathway in, 3004
- Cyclooxygenase 2 (COX-2) gene transcription in human synovial fibroblasts, regulation by 15-deoxy- $\Delta^{12,14}$ -prostaglandin J₂, 94
- Cyclooxygenase 2 (COX-2) inhibitors
 AS, NSAIDs for reduction of radiographic progression, 1756
 cardiovascular events and, 1968
 etoricoxib for AS, 1205
- Cyclophosphamide
 ANCA-associated vasculitis, MTX vs. cyclophosphamide to induce remission, 2461
 RA, effect of high-dose chemotherapy and ASCT on joint damage, 421
 SLE, gonadotropin-releasing hormone analog for ovarian protection during, 2761
- CYP2C9 polymorphism, molecular mechanisms and variability in drug response, 1349

CYP2C19 polymorphism, molecular mechanisms and variability in drug response, 1349
CYP2D6 polymorphism, molecular mechanisms and variability in drug response, 1349
CYP3A polymorphism, molecular mechanisms and variability in drug response, 1349
CYP7B, RA, proinflammatory cytokines and *CYP7B* expression and activity in fibroblast-like synoviocytes, 770
 Cytochrome P450 enzymes, molecular mechanisms and variability in drug response, 1349
 Cytokines
 in hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy, 2917
 OA, variations in innate cytokine activity and risk of OA, 1443
 RA, proinflammatory cytokines and *CYP7B* expression and activity in fibroblast-like synoviocytes, 770
 SLE, anti-P antibodies and proinflammatory cytokine expression by human monocytes, 847
 SLE, high mobility group box chromosomal protein 1 in skin lesions, 3639
 Cytotoxic T lymphocyte-associated antigen 4, Epstein-Barr virus and SLE, 1148

D

- Dalmation defect, hepatic endocrinopathy of urate transport, 2257
 Damage accrual, SLE, hydroxychloroquine and reduction of damage risk in, 1473
 Data analysis
 continuous indices of core data set measures in clinical trials, 1031
 methodologic issues in superiority trials assessing structural outcomes, 1858
 RA, presentation and analysis of clinical trial radiographic data, 49
 Debonding syndrome, hereditary cartilage, 3300
 Decision tree format, for RA classification, evaluation over 5 years, 2277
 Deep vein thrombosis, Behçet's disease, association of *R92Q TNFRSF1A* mutation and risk of, 608, 2582
 Defensin, OA, human β -defensin in tissue remodeling, mouse study, 1736
 Dehydroascorbate transport, in chondrocytes, 2676
 Dehydroepiandrosterone (DHEA)
 RA, proinflammatory cytokines and *CYP7B* expression and activity in fibroblast-like synoviocytes, 770
 RA, TNF inhibition of conversion of DHEA sulfate to DHEA, 1721
 Dendritic cells
 in autoimmunity and disease, 11
 RA, RANK/RANKL system in inflammation, 2307
 RA, Toll-like receptors 3, 4, and 7/8 and, 2313
 SLE, tolerance breaking by dendritic cells without SLE disease expression, 225
 15-Deoxy- $\Delta^{12,14}$ -prostaglandin J_2
 COX-2 gene transcription in human synovial fibroblasts, regulation by, 94
 rosiglitazone-induced IL-1Ra in rat synovial fibroblasts, 759
 Depot leuprolide acetate, SLE, gonadotropin-releasing hormone analog for ovarian protection during cyclophosphamide treatment, 2761
 Depression, neural activations in depression and chronic pain, 1577
 Dermatan sulfate, epidermal growth factor-TM7 receptor expression in rheumatoid synovial tissue, 442
 Dermatomyositis (DM)
 anti-CADM-140 in Japanese with clinically amyopathic DM, 1571
 antisynthetase-associated ILD, tacrolimus treatment, 2439
 calcinosis universalis as complication in juvenile DM, 1626
 Childhood Myositis Assessment Scale, validation and clinical significance of, 368
 Dermatomyositis (DM) (*cont'd*)
 children, angiostatic ELR-CXC chemokines and vasculopathy in, 3175
 consensus guidelines for myopathy trials, 2607
 malignancy-associated, 3712
 rituximab treatment, 601
 seasonal associations with, 2433
 Dexamethasone
 collagen-induced arthritis, combination therapy with M40403, rat study, 1929
 Egr2/Krox20 in dexamethasone-mediated osteocalcin repression, mouse study, 929
 Diacerein, OA, clinical trials of disease-modifying OA drugs, lessons learned, 3349
 Dietary protein, OA, serum sulfate levels and development of, 2808
 Dietary supplements
 OA, oral glucosamine in rabbit, 1118, 3680
 synovial fluid level and serum pharmacokinetics of oral glucosamine, 181
 Diffusion chambers, bone morphogenetic protein 2 for tissue engineering in cartilage repair, 155
 Digital gangrene, APS, dermatologic manifestations of, 1785
 Digital x-ray radiogrammetry, as RA diagnostic tool, 3850
 Dijkstra score, JIA, assessment of radiographic change in, 2865
 Dipeptidyl peptidase 1, collagen-induced arthritis and, mouse study, 2553
 Disability
 FM and CFS, monitoring of activity and symptoms, 296
 knee pain in older adults, influence of "pain elsewhere" on outcomes in, 2350
 OA, hand strength in relation to radiographic features in, 1424
 RA, early suppression of disease activity and maintenance of work capacity, 36
 risk factors for functional decline in older adults with arthritis, 1274
 Disease activity
 JIA, patterns in, 3554
 juvenile SLE, criteria for evaluating response to therapy, 2854
 RA, defining criteria for, 2625
 RA, mildness of disease course, 2616
 SLE, as risk factor for venous thrombosis in LUMINA study patients, 2060
 SLE, C4d-bearing reticulocytes as disease activity markers, 3087
 SLE, criteria for evaluating response to therapy, 2854
 SLE, lymphocyte expression of P-glycoprotein and steroid resistance, 1676
 SLE, raloxifene for postmenopausal women with SLE, 3997
 Disease Activity Score in 28 Joints (DAS28)
 RA, defining criteria for disease activity states, 2625
 as sole criterion for initiation and evaluation of anti-TNF therapy, 3873
 Disease flare
 polyarticular arthritis, daily stress and mood in children with, 1196
 SLE, anti-dsDNA antibody levels and renal flare in, 1129
 Disease-modifying antirheumatic drugs (DMARDs). *See also names of individual drugs*
 BeSt study, 3326, 3381
 OA, clinical trials of disease-modifying OA drugs, lessons learned, 3349
 RA, combination therapy, efficacy of, 2975
 RA, early suppression of disease activity and maintenance of work capacity, 36
 RA, prednisolone plus DMARDs in early RA, 3324, 3360, 3371
 Disease progression
 AS, measurement of treatment effect on spinal radiographic progression in, 1979
 AS, NSAIDs for reduction of radiographic progression, 1756

Disease progression (cont'd)

- collagen-induced arthritis, heme oxygenase 1 modulation in progression of, 3230
 - lupus nephritis, effect of fractalkine antagonist on, mouse study, 1522
 - OA and early RA, type II collagen helical peptide in, 1081
 - OA, anteroposterior laxity and knee OA progression, 2343
 - OA, hip abduction moment and protection against progression, 3515
 - OA, NSAIDs and radiologic progression of, 3137
 - OA, oral doxycycline to slow radiographic progression, 1956, 2015
 - RA, age and OA at onset of symptoms, association with radiographic damage in, 2284
 - RA, effect of high-dose chemotherapy and ASCT on joint damage, 421
 - RA, mildness of disease course, 2616
 - RA, prednisolone plus DMARDs in early RA, 3324, 3360, 3371
 - RA, stromal cell-derived factor 1 chemokine gene variant and radiographic progression, 354
 - WG, serum proteomic approach to gauging state of remission, 902
- #### Disease severity
- collagen-induced arthritis and Nur77 overexpression, mouse study, 333
 - collagen-induced arthritis, CXCL13 neutralization and disease severity, mouse study, 620
 - OA, correlating disease severity and MRI findings, 3492
 - OA, delayed gadolinium-enhanced MRI of knee OA, 3528
 - OA, health state preferences, impact of disease severity and gastrointestinal side effects on, 2366
 - pristine-induced arthritis, *Cia10* effects on, rat study, 322
 - protease-activated receptor, role in arthritis severity in mice, 1325
 - RA, DERA-encoding HLA alleles and RA severity and susceptibility, 2637
 - RA, migration inhibitory factor, correlation with, 3020
 - RA, *PTPN22* codon R602W and, 358
- #### Disease symptoms, polyarticular arthritis, stress, mood, and symptoms in children with, 1196
- #### Disintegrins, OA, metalloproteinase disintegrin ADAM15 and degenerative cartilage remodeling, 1100
- #### Dog studies
- Dalmation defect, hepatic endocrinopathy of urate transport, 2257
 - PD-0200347 in experimental OA, 488
- #### Doppler echocardiography, fetal heart block, anti-SSA/Ro 52-kd antibodies and, 366
- #### Doxycycline
- OA, clinical trials of disease-modifying OA drugs, lessons learned, 3349
 - OA, to slow radiographic progression, 1956, 2015
- #### Drug efficacy
- AS, measurement of treatment effect on spinal radiographic progression in, 1979
 - methodologic issues in superiority trials assessing structural outcomes, 1858
 - RA, gene expression analysis of drug effects, 2248
 - spontaneous circadian behavior in monarthritic rats, 3470
- #### Drugs. See names of individual drugs
- #### Dysphagia, malignancy-associated DM, 3712
- #### Dyspnea, SSc, correlation of dyspnea with health-related quality of life in SSc with alveolitis, 592

E

- Early onset RA, *PTPN22* codon R602W and, 358
- Effector memory cells, RA, tissue trafficking patterns of effector memory CD4+ T cells in, 3839
- Egr2/Krox20, in dexamethasone-mediated osteocalcin repression, mouse study, 929
- Eicosanoids, in pathogenesis of SSc lung disease, 3693, 3783
- Elderly. See Older adults

- Electroencephalography (EEG), neuropsychiatric symptom assessment in APS and SLE, 841
- Electroporation, to enhance MTX effect in adjuvant-induced arthritis, 637
- ELR-CXC chemokines, angiostatic, and vasculopathy in juvenile DM, 3175
- Endomorphin 1, chronic arthritis, peripheral μ -opioid receptor expression down-regulated in, 3210
- Endoplasmic reticulum stress response, in myositis, 1824
- Endothelial cells
 - anti-endothelial cell antibodies in vasculitis-associated systemic autoimmune diseases, 4028
 - involvement of p38 MAPK in antiphospholipid antibody-induced up-regulation of tissue factor on HUVECs, 1545
 - RA, CXCL8 binding site on endothelial syndecan-3 in synovium, 2331
 - RA, neutrophil recruitment in coculture model of, 3460
 - SSc, tissue kallikreins in endothelial cells, 3618
- Enthesitis-related arthritis, KIR3DL2 in, 3586
- ELISA, detection of anti-RNA polymerase III antibody, 2425
- EO6, SLE, raised lipid peroxidase is associated with arterial and renal disease, 192
- Epidermal growth factor-TM7 receptor, expression in rheumatoid synovial tissue, 442
- Epithelial cells
 - CXCL13 and CCL21 expression and lymphoid features in SS, 1773
 - Fas and CD40 in salivary epithelial cell death in SS, 573
- Epstein-Barr virus, SLE and, 1148
- Equine studies, synovial fluid levels and serum pharmacokinetics of oral glucosamine, 181
- Errata, 678, 986, 1342, 1619, 2951, 3321, 3659
- Erythema, APS, dermatologic manifestations of, 1785
- Erythropoietin, collagen-induced arthritis, effects on, 940
- Estrogen deprivation arthralgias, 2594
- Etanercept
 - AS, anti-TNF therapy decreases anterior uveitis flares in, 2447
 - AS, MRI assessment of spinal inflammation before and after treatment, 1216
 - psoriasis onset during treatment, 2513
 - RA, apoptosis induction in joint macrophages, 61
 - RA, C-reactive protein as predictor of infliximab treatment outcome and subsequent response to etanercept, 42
 - RA, infections in patients treated with biologic agents, 3403
 - RA, infection with *Strongyloides stercoralis* during treatment, 1336
 - RA, presentation and analysis of clinical trial radiographic data, 49
 - RA, prostaglandin E_2 biosynthetic pathway and, 3439
 - in RA and AS, 2506
 - sarcoid arthritis treated with intraarticular etanercept, 987
 - septic arthritis due to *Listeria monocytogenes* in etanercept-treated patient, 987
 - SpA, etanercept for peripheral joint synovitis in, 3898
 - WG, damage caused by WG and its treatment, 2168
- Ethnicity
 - OA, surgical outcomes following knee or hip arthroplasty, racial/ethnic differences and, 3143
 - thromboembolism in SLE, incidence and risk factors, 2774
- Etoricoxib, AS, efficacy in, 1205
- Exercise
 - FM and CFS, monitoring of activity and symptoms, 296
 - OA, moderate exercise and glycosaminoglycan content in cartilage, 3507
 - risk factors for functional decline in older adults with arthritis, 1274
- Exosomes, salivary gland epithelial cell, 1517

F

- Familial Mediterranean fever
 - MEFV* analysis in western European patients, 3603

Familial Mediterranean fever (*cont'd*)

- regulation of pyrin subcellular localization by 14.3.3 proteins, 1848
- Familiality
- acute anterior uveitis, unique genetic region on chromosome 9p and, 269
- Behçet's disease, whole-genome screen for susceptibility genes in, 1836
- congenital heart block and anti-SSA/Ro antibodies in family members of different generations, 1623, 1625
- OA, variations in innate cytokine activity and risk of OA, 1443
- SLE, aggregation of autoimmune diseases, 1138
- SLE, *PTPN22* R620W polymorphism in families, 2396
- Fas, Fas and CD40 in salivary epithelial cell death in SS, 573
- Fcγ receptor type I, and joint inflammation in IFNγ-enhanced immune complex-mediated arthritis, 967
- Fcγ receptor type IIa, in autoimmune inflammation, 3220
- Fcγ receptor type III, in development of proteoglycan-induced arthritis, mouse study, 1612
- Febuxostat, for gout, safety and efficacy, 916
- Feet
 - POPP, 280, 2954
 - RA, sensitivity to change of MRI and radiography, 2300
- Femoral intercondylar notch narrowing, in early-stage knee OA, guinea pig study, 3100

Femur

- osteopenia in childhood-onset SLE, 2051
- subchondral femoral head insufficiency fracture after renal transplantation, 1293

Fetal heart block

- anti-SSA/Ro 52-kd antibodies and, 366
- maternal antibody specificity and, 3079
- PR interval as early marker for, 1341, 1342

Fetal loss, SLE, increased lupus activity and obstetric outcomes, 514

Fibrinogen, HLA-DR genes and production of RA-specific anti-CCP antibodies to citrullinated fibrinogen, 3424

Fibroblast-like synoviocytes

- RA, invasiveness of and joint destruction, 1999
- RA, proinflammatory cytokines and CYP7B expression and activity in fibroblast-like synoviocytes, 770
- RA, synovial tissue heterogeneity and, 430
- RA and OA, kappa and delta opioid receptors in, 1402

Fibroblasts

- C43S TRAPS mutation and TNFα-induced signaling, 1287, 2952
- FK-506, effects on normal and SSc fibroblasts, 1237
- membrane type 1-MMP inhibition and reduced invasiveness of RA synovial fibroblasts, 2010
- osteoclast formation promoted by RANKL in spontaneous erosive arthritis, mouse study, 3257
- RA, activation by necrotic synovial fluid cells via Toll-like receptor 3, 2656
- RA, neutrophil recruitment in coculture model of synovium, 3460
- regulation of COX-2 gene transcription by 15-deoxy-Δ^{12,14}-prostaglandin J₂, 94
- rosiglitazone-induced IL-1Ra in rat synovial fibroblasts, 759
- specific inhibition of SPARC and decreased expression of type I collagen, 257
- SSc, αvβ5-mediated TGFβ signaling in, 2897
- SSc, chemokine receptor CCR2 expression by fibroblasts, 3772
- SSc, fibroblast gene expression profiles in twins, 3305
- SSc, p300 and profibrotic response to TGFβ, 1248
- SSc, transcriptosome analysis of nonlesional dermal fibroblasts in, 865
- TGFβ2 effects on procollagen α2 type I messenger RNA variants, chicken study, 1804

Fibromyalgia (FM)

- cortisol secretion, momentary relationship between symptoms and, 3660

Fibromyalgia (FM) (*cont'd*)

- monitoring of activity and symptoms, 296
- neural activations in depression and chronic pain, 1577
- pain variability in, 3670
- pramipexole treatment of, 2495
- pregabalin treatment, 1264

Fibrosis

- specific inhibition of SPARC and decreased expression of type I collagen, 257
- SSc, microfibril-associated glycoprotein 2, increased expression of type I collagen and, mouse study, 1812
- SSc, transcriptosome analysis of nonlesional dermal fibroblasts in, 865
- TGFβ2, effects on procollagen α2 type I messenger RNA variants in embryonic fibroblasts, chicken study, 1804

Fingers. *See also* Hand

- OA, high-resolution MRI for assessment, 2355
- POPP, 2954
- RA, sensitivity to change of MRI and radiography, 2300
- RA, ultrasonographic synovitis scoring system for finger joint inflammation, 733

FK-506, effects on normal and SSc fibroblasts, 1237

Folate receptor β, RA, targeting of synovial macrophages with anti-folate receptor β antibody and truncated *Pseudomonas* exotoxin, 2666

Folic acid, and MTX treatment, 1338, 1339, 3030

Folinic acid, and MTX treatment, 1338, 1339

Follicle-stimulating hormone (FSH), in SLE, 3701

Forefeet, RA, sensitivity to change of MRI and radiography, 2300

Fractalkine

- lupus nephritis, effect of fractalkine antagonist on, mouse study, 1522
- RA, fractalkine and T cell-synoviocyte interaction in, 1392
- SLE, elevated levels of soluble fractalkine in, 1670

Fractures

- subchondral femoral head insufficiency fracture after renal transplantation, 1293
- vertebral fractures in SLE patients and low BMD, 2044

Free radicals, production of by rheumatoid synovial T lymphocytes, 2003

Frizzled-related protein gene (*FRZB*), OA and *FRZB* gene variants, 1077

Functional abilities

- OA, health state preferences, impact of disease severity and gastrointestinal side effects on, 2366
- RA, high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation, long-term followup of health status, 2272
- RA, improvement in functional status from 1985 to 2000, 991, 1009
- risk factors for functional decline in older adults with arthritis, 1274
- SLE, obesity and, 3651
- SSc, correlation of dyspnea with health-related quality of life in SSc with alveolitis, 592

G

Gabapentin, PD0200347 in experimental OA, dog study, 488

Gait

- knee OA, hip abduction moment and protection against progression, 3515
- knee OA, secondary gait changes in, 2835

Gangrene, APS, dermatologic manifestations of, 1785

Gene expression analysis, drug effects in RA and, 2248

Gene therapy

- autologous transplantation of basic fibroblast growth factor gene-transduced chondrocytes with adeno-associated virus vector, rabbit study, 164
- collagen-induced arthritis, intranasal IL-10 delivery system, 3761

Gene therapy (cont'd)

- collagen-induced arthritis, thrombospondin 1 gene therapy for, rat study, 339
- RA, kallistatin for, rat study, 1319
- RA, targeting Tie2 attenuates collagen-induced arthritis, mouse study, 1585
- Gene transfer
 - membrane type 1-MMP inhibition and reduced invasiveness of RA synovial fibroblasts, 2010
 - SLE, prevention and reversal by costimulatory blockade with adeno-associated virus-mediated gene transfer, 3975
- Genetics. *See also* Familiality; Gene therapy; Mutations; Polymorphism
 - acute anterior uveitis, unique genetic region on chromosome 9p and, 269
 - ADAMTS9* gene and inflammatory arthritis, 1451
 - APS, valine²⁴⁷ β 2-glycoprotein 1 and risk of, 212
 - arthropathy-accelerating MRL locus in DBA/1 mice, 959
 - Behçet's disease, *TNFRSF1A* R92Q mutation and risk of venous thrombosis in, 608, 2582
 - Behçet's disease, whole-genome screen for susceptibility genes in, 1836
 - C43S TRAPS mutation and TNF α -induced signaling, 1287, 2952
 - CINCA syndrome, *CIAS1* somatic mosaicism in, 3579
 - Crohn's disease, lack of association with *SLC22A4* polymorphisms, 425
 - 15-deoxy- $\Delta^{12,14}$ -prostaglandin J₂, regulation of COX-2 gene transcription in human synovial fibroblasts by, 94
 - determining ethnicity and phenotypes for pooling association studies, 676
 - experimental SpA, genetic control of, mouse study, 2452
 - gene expression after cartilage injury, 2386
 - gout, *SLC22A12* mutation as suppressing factor for, 2576
 - haplotype association studies enhanced by examining more polymorphic loci, 674
 - hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy, chemokines and Th1 cytokines in, 2917
 - hereditary cartilage debonding syndrome, 3300
 - hyperimmunoglobulinemia D with periodic fever syndrome, pseudodominant inheritance of, 3606
 - IL-1 β gene promoter polymorphism and levels of IL-1 β protein, 361, 362
 - JIA, *PTPN22* as autoimmunity gene, 1694
 - JIA, *SLC11A1* (*NRAMP1*) genetics in, 247
 - JIA, WISP3 polymorphisms and susceptibility to, 3548
 - knee structure, heritability of longitudinal changes in, 2830
 - MMPs, abnormal expression in OA chondrocytes and epigenetic "unsilencing", 3110
 - molecular mechanisms and variability in drug response, 1349
 - MTX, resistance to in air-pouch model of acute inflammation, 2567
 - OA, abnormal expression of MMPs in chondrocytes and epigenetic "unsilencing", 3110
 - OA, asporin polymorphism and OA etiology in, 3502
 - OA, *COL1A1* polymorphism, hip OA, and genetics in elderly women, 1431
 - OA, *COL9A1* gene and hip OA, 1437
 - OA, *FRZB* gene variants and, 1077
 - OA, IL-1 gene cluster polymorphisms and pathogenesis of, 674
 - OA, no association between locus on chromosome 6 and hip OA, 2040
 - OA, reactivity of chondrocytes to IL-1 β , 136
 - OA, variations in innate cytokine activity and risk of, 1443
 - osteoarthritis, protein 1 antisense inhibition and cartilage integrity, 468
 - pharmacogenetics and rheumatology, 1349
 - pristane-induced arthritis, *Cia10* effects on severity, pannus formation, and joint damage, rat study, 322

Genetics. *See also* Familiality; Gene therapy; Mutations; Polymorphism (cont'd)

- proteoglycan-induced spondylitis, genetic control of, mouse study, 2452
- PsA, common genetic control pathways of inflammation for Crohn's disease and, 3596
- PTPN22* as autoimmunity gene, 1694
- RA, association of *PTPN22* variant with, 1993, 2222
- RA, association of single-nucleotide polymorphisms in *SEC8L1* gene in Japanese, 1371
- RA, DERA-encoding HLA alleles and disease severity and susceptibility, 2637
- RA, Fc γ receptor type IIIA polymorphisms and treatment outcomes with TNF α blockade, 2693
- RA, HLA-DR genes and production of anti-citrullinated protein antibodies, 3424
- RA, HLA-DR shared epitope alleles and cigarette smoking, 3675, 3676
- RA, HLA-DRB1 alleles, new classification in, 1063
- RA, *IL1RN* gene and disease susceptibility in Spanish population, 3015
- RA, IL-1 receptor antagonist deficiency and, 3731
- RA, migration inhibitory factor, correlation with severity, 3020
- RA, no association with *SLC22A4* polymorphisms, 425, 2947
- RA, *PADI4* and, 3054
- RA, PD-1 polymorphism and development of, 362
- RA, *PDCD1* haplotype associated with, 1058
- RA, phenotype based on specificity of HLA-DRB1 shared epitope for citrullinated proteins, 3433
- RA, proinflammatory cytokines and CYP7B expression and activity in fibroblast-like synoviocytes, 770
- RA, *PTPN22* as autoimmunity gene, 1694
- RA, *PTPN22* C1858T single-nucleotide polymorphism in, 2948
- RA, *PTPN22* codon R602W and early onset/disease severity effect, 358
- RA, *PTPN22* locus associated with in New Zealand Caucasian cohort, 2222
- RA, *PTPN22* polymorphisms in, 219
- RA, regulation of anti-CCP antibodies in, 3813
- RA, *SLC22A4* gene, no association with RA in Japanese population, 2947
- RA, *SLC22A4* gene, no association with RA in UK population, 752
- RA, stromal cell-derived factor 1 chemokine gene variant and radiographic progression, 354
- RA, *TNFR2* not associated with RA susceptibility in Caucasian population, 2579
- RA, *TP53* and apoptosis effects in, 1047
- recurrent fever in western European patients, *MEFV* analysis and, 3603
- SLE, familial aggregation of autoimmune diseases in SLE, 1138
- SLE, genetic origin of in SWR/NZB hybrids, 659
- SLE, high mobility group box chromosomal protein 1 in skin lesions, 3639
- SLE, mannose-binding lectin gene polymorphisms and, 3966
- SLE, maternal HLA class II compatibility in men with, 2768
- SLE, osteopontin single-nucleotide polymorphisms and susceptibility to, 539
- SLE, PD-1 polymorphism and development of, 362
- SLE, *PDCD1* polymorphism and renal manifestations in mice, 1665
- SLE, *PTPN22* polymorphisms in, 219
- SLE, *PTPN22* R620W polymorphism in families, 2396
- SLE, *Sle2*-associated component lupus phenotypes, deficiency of type I interferon contribution to, mouse study, 3063
- SLE, *Yaa* gene-linked monocytosis, mouse study, 2790
- SLE/autoimmune thyroid disease susceptibility gene at 5q14.3-15, 3646
- SpA, HLA-B*5703 in HIV infection and, 275

Genetics. *See also* Familiarity; Gene therapy; Mutations; Polymorphism (*cont'd*)

sporadic chondrocalcinosis, *ANKH* sequence variants and, 1110
SS, gene expression profiling of minor salivary glands, 1534
SSc, fibroblast gene expression profiles in twins, 3305
SSc, tissue kallikreins in endothelial cells, 3618
SSc, transcriptome analysis of nonlesional dermal fibroblasts in, 865
SSc, X chromosome inactivation in women, 1564, 3679
TRAPS mutation and TNF α -induced signaling, 1287, 2952
TRAPS-related TNF receptor 1 mutants, 2906
WG, *PTPN22* 620W allele as risk factor for, 4039

Genome screen, Behçet's disease, whole-genome screen for susceptibility genes in, 1836

Giant cell arteritis (GCA), cranial involvement in by MRI, 2470
Glomerular binding assay, autoantibodies that bind glomeruli, 2403

Glucocorticoids

Egr2/Krox20 in dexamethasone-mediated osteocalcin repression, mouse study, 929
intraarticular glucocorticoid treatment reduces inflammation in synovial infiltrations, 3880
knee, radiation synovectomy vs. intraarticular glucocorticoid treatment, 3391
osteoporosis induced by, temporal trends in prevention of, 2485
RA, prednisolone in early RA, 3324, 3360, 3371
RA, prostaglandin E₂ biosynthetic pathway and, 3439
RA, reactivation of glucocorticoids in synovial cells, 1711
SLE, dose as risk factor for venous thrombosis in LUMINA study patients, 2060

Glucosamine

OA, clinical trials of disease-modifying OA drugs, lessons learned, 3349
in rabbit OA, 1118, 3680
synovial fluid levels and serum pharmacokinetics of oral glucosamine, 181

Glucose transporters, dehydroascorbate transport in human chondrocytes, 2676

Glycoproteins

APS, valine²⁴⁷ β_2 -glycoprotein I and risk of APS, 212
microfibril-associated glycoprotein 2, increased expression of type I collagen and, mouse study, 1812

Glycosaminoglycan

anterior cruciate ligament injury, cartilage glycosaminoglycan loss in acute phase, gadolinium-enhanced MRI, 120
OA, moderate exercise and glycosaminoglycan content in cartilage, 3507

Gold, RA, combination MTX-intramuscular gold therapy, 1360

Gonadotropin-releasing hormone analog, for ovarian protection during cyclophosphamide treatment of SLE, 2761

Gout

febuxostat for, safety and efficacy, 916
inflammation and Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression, mouse study, 2936
reduction in serum uric acid with sevelamer, 290
SLC22A12 mutation as suppressing factor for, 2576
tophaceous gout of symphysis pubis, 4082
uric acid levels and diet, NHANES-III, 283

Granulocyte-macrophage colony-stimulating factor, acute CD4⁺ T lymphocyte-dependent IL-1-driven arthritis and, 3749

Granzyme B, SLE, activated CD8⁺ lymphocytes in SLE pathogenesis, 201

Graves' disease, SLE/autoimmune thyroid disease susceptibility gene at 5q14.3-15, 3646

Grip strength, OA, hand strength in relation to radiographic features in, 1424

Growth hormone, in SLE, 3701

Guinea pig studies

OA, cruciate ligament laxity and femoral intercondylar notch narrowing in early-stage knee OA, 3100
OA, inhibition of MMPs in cartilage loss, 171
pioglitazone in experimental OA, 479

H

Hand. *See also* Fingers

OA, hand OA as predictor for future hip or knee OA, 3520
OA, hand strength in relation to radiographic features in, 1424
OA, high-resolution MRI for assessment, 2355
pachydermodactyly, 990, 2953
RA, age and OA at onset of symptoms, association with radiographic damage in, 2284

Haplotype analysis

number of polymorphic loci examined and, 674
RA, *PDCD1* haplotype associated with, 1058
Hashimoto thyroiditis, SLE/autoimmune thyroid disease susceptibility gene at 5q14.3-15, 3646

Headache, Afrin-induced CNS vasospasm and thunderclap headache, 3314

Health-related quality of life, SSc, correlation of dyspnea with in SSc with alveolitis, 592

Health state, OA, health state preferences, impact of disease severity and gastrointestinal side effects on, 2366

Health status

RA, high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation, long-term followup of health status, 2272

RA and AS, TNF blockers in, 2506

Heart block. *See* Congenital heart block; Fetal heart block

Heart disease. *See* Cardiovascular disease

Heart failure, risk of in RA, 412, 3039

Heat-shock protein, anti-endothelial cell antibodies in vasculitis-associated systemic autoimmune diseases, 4028

Hematopoietic stem cell transplantation

RA, high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation, long-term followup of health status, 2272

seronegative arthritis, sustained remission of, 3322

Heme oxygenase 1, collagen-induced arthritis, modulation in progression of, 3230

Hemodialysis, reduction in serum uric acid with sevelamer, 290

Heparan sulfate proteoglycans, RA, CXCL8 binding site on endothelial syndecan-3 in synovium, 2331

Hepatitis B virus, reactive systemic AA amyloidosis, infliximab treatment, 2519

Hepatitis C virus

chemokines and Th1 cytokines in HCV-associated mixed cryoglobulinemia vasculitis neuropathy, 2917

systemic vasculitis, PEGylated IFN alfa-2b and ribavirin treatment for, 911

Heredity. *See also* Familiarity; Genetics

cartilage debonding syndrome, newly described, 3300

High-dose chemotherapy

RA, effect of ASCT and high-dose chemotherapy on joint damage, 421

RA, high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation, long-term followup of health status, 2272

seronegative arthritis, sustained remission of, 3322

High mobility group box chromosomal protein 1, in SLE skin lesions, 3639

Hip

OA, hip abduction moment and protection against knee OA progression, 3515

OA, acetabular dysplasia predicts incident hip OA, 787

Hip (cont'd)

- OA, *COL1A1* polymorphism and genetics in elderly women, 1431
- OA, *COL9A1* gene and, 1437
- OA, correlates of hip cartilage volume, 1069
- OA, hand OA as predictor for future hip or knee OA, 3520
- OA, IL-1 gene cluster polymorphisms and pathogenesis of, 674
- OA, no association between locus on chromosome 6 and hip OA, 2040
- OA, NSAIDs and radiologic progression of, 3137
- OA, surgical outcomes following arthroplasty, racial/ethnic differences and, 3143
- subchondral femoral head insufficiency fracture after renal transplantation, 1293

HLA

- HLA-B*5703 in HIV infection and SpA, 275
- RA, DERA-encoding HLA alleles and RA severity and susceptibility, 2637
- SLE, maternal HLA class II compatibility in men with, 2768

HLA-B27

- AS, cell surface properties of HLA-B27 subtypes, 3290
- AS, HLA-B27-restricted CD8+ T cell response to cartilage-derived peptides in, 892, 2581, 2582
- AS, molecular evidence of HLA-B27 in historical case, 3318
- SpA, association with in Sardinia and Italy, 3319

HLA-DR genes

- anti-citrullinated protein antibody production and, 3424
- RA, HLA-DR shared epitope alleles and cigarette smoking, 3675, 3676

HLA-DR3

- anti-CCP antibody-negative RA, association with, 3058
- RA, regulation of anti-CCP antibodies in, 3813

HLA-DRB1 genes

- RA, DEAA-encoding HLA alleles and severity and susceptibility, 2637
- RA, HLA-DRB1 alleles, new classification in, 1063
- RA phenotype based on specificity of HLA-DRB1 shared epitope for citrullinated proteins, 3433

- Hodgkin's disease, hypertrophic osteoarthropathy in children, 2584
- Horse studies, synovial fluid levels and serum pharmacokinetics of oral glucosamine, 181

- Hospital and attending physician volume of admissions and in-hospital mortality, 1628, 1646

- Hsp60, anti-endothelial cell antibodies in vasculitis-associated systemic autoimmune diseases, 4028

- Human immunodeficiency virus (HIV), HLA-B*5703 in HIV infection and SpA, 275

- Human synovial fibroblasts. *See* Fibroblasts

- Human umbilical vein endothelial cells (HUVECs), APS, involvement of p38 MAPK in antiphospholipid antibody-induced up-regulation of tissue factor on, 1545

- HuMax-IL15, IL-15 as therapeutic target in RA, 2585, 2686

- Humoral autoimmunity, citrullinated proteins in, 2323

- Humoral immunity, infliximab treatment of SpA, 2192

Hyaluronan

- hyaluronan oligosaccharide-induced activation of transcription factors in bovine articular chondrocytes, 800
- OA, clinical trials of disease-modifying OA drugs, lessons learned, 3349

- OA, serum hyaluronan levels as biomarker of radiographic OA, 105

- Hydroxyapatite crystals, rotator cuff disorders and, 3681

Hydroxychloroquine

- JIA, serum MTX concentrations in children and, 1621
- RA, combination therapy, efficacy of, 2975
- SLE, reduction of damage risk in, 1473

- Hyperimmunoglobulinemia D with periodic fever syndrome, pseudodominant inheritance of, 3606

- Hypertrophic osteoarthropathy, in childhood Hodgkin's disease, 2584

Hyperuricemia

- febuxostat for gout, safety and efficacy, 916
- sevelamer to reduce serum uric acid, 290
- uric acid levels and diet, NHANES-III, 283

- Hypoxia-inducible factor 1 α , tonic activation of in avascular articular cartilage, 3181

I

Idiopathic inflammatory myopathy

- antisynthetase-associated ILD, tacrolimus treatment, 2439
- consensus guidelines for myopathy trials, 2607
- seasonal associations with, 2433

Idiopathic vasculitides, Churg-Strauss syndrome, 2589, 2926

- IgG, RA, T cell response to oxidative modification, 80
- IgM anti-dsDNA antibodies, SLE, inhibition by, mouse study, 3629
- IL-1 gene, cluster polymorphisms and OA pathogenesis, 674

- IL1B* gene, IL-1 β gene promoter polymorphism and levels of IL-1 β protein, 361, 362

- ILIRN* gene, RA susceptibility in Spanish population and, 3015

Imaging

- angiography-negative primary CNS vasculitis in children, 2159
- anterior cruciate ligament injury, cartilage glycosaminoglycan loss in acute phase, gadolinium-enhanced MRI, 120

- AS, measurement of treatment effect on spinal radiographic progression in, 1979

- AS, MRI assessment of spinal inflammation before and after etanercept treatment, 1216

- AS, NSAIDs for reduction of radiographic progression, 1756

- body composition and knee cartilage volume in healthy subjects, 461
- carpal tunnel syndrome, value of sonography in patients with suspected, 304

- cartilage defects and knee cartilage loss in healthy adults, 2033

- GCA, cranial involvement in by MRI, 2470

- hypertrophic osteoarthropathy in childhood Hodgkin's disease, 2584

- JIA, assessment of radiographic change in, 2865

- mechanical bull myopathy in SSc patient, 3682

- mouse study, 951

- OA, acetabular dysplasia predicts incident hip OA, 787

- OA, acoustic properties of knee and ankle joint cartilage, 3125

- OA, alignment in knee radiography for clinical trials of structure-modifying drugs, 1343, 1411

- OA, bone loss on knee radiographs, 3536

- OA, bone marrow abnormalities and cartilage degradation in knee OA, 2822

- OA, cartilage loss on MRI and radiographic progression in, 3152

- OA, correlates of hip cartilage volume, MRI, 1069

- OA, correlating disease severity and MRI findings, 3492

- OA, cruciate ligament integrity in knee OA, 794

- OA, delayed gadolinium-enhanced MRI of knee OA, 3528

- OA, high-resolution MRI for assessment of hand OA, 2355

- OA, knee-alignment angle, radiographic assessment, 1730

- OA, lateral view radiography to evaluate tibiofemoral joint space width, 3542

- OA, MRI bone marrow abnormalities and cartilage degradation in knee OA, 2822

- OA, quantitative MRI assessment of cartilage morphology, 3132

- OA, serum hyaluronan levels as biomarker of radiographic OA, 105
- osseous sarcoidosis, radiographic healing, 2225

- RA, age and OA at onset of symptoms, association with radiographic damage in, 2284

- RA, antiferritin antibodies and radiographic damage in, 3868

- RA, digital x-ray radiogrammetry as diagnostic tool, 3850

- RA, predicting tendon rupture through MRI evidence, 744

- RA, presentation and analysis of clinical trial radiographic data, 49
- RA, sensitivity to change of MRI and radiography, 2300

- RA, stromal cell-derived factor 1 chemokine gene variant and radiographic progression, 354

Imaging (cont'd)

- RA, ultrasonographic synovitis scoring system for finger joint inflammation, 733
- RA, ultrasonography for assessing, 681
- SLE, MMP-9 in patients with neuropsychiatric SLE and brain MRI abnormalities, 673, 674
- STAT-6-VT inhibition of osteoclastogenesis and bone erosion, mouse study, 2719
- Study, 171
- subchondral femoral head insufficiency fracture after renal transplantation, 1293
- topoisomerase I cleavage during necrotic cell death, cathepsins and, 2133
- tuberculous rice bodies of wrist, 1950
- winners of 2004 Slide Competition, 679
- Imatinib, lupus nephritis treatment, mouse study, 3987
- Immune complex-mediated arthritis, IFN γ in, 967
- Immunity
 - adaptive, regulation of arthritis by p53, mouse study, 1876
 - innate, in infection-triggered arthritis, mouse study, 1297
 - SSc, autologous stem cell transplantation, immune reconstitution following, 1555
- Immunologic synapse, disruption of T cell/antigen-presenting cell interaction by teriflunomide, 2730
- Immunotoxins, RA, targeting of synovial macrophages with anti-folate receptor β antibody and truncated *Pseudomonas* exotoxin, 2666
- In appreciation, editor David S. Pisetsky, 1627
- Inclusion body myositis, consensus guidelines for myopathy trials, 2607
- Infection
 - HIV, HLA-B*5703 in, 1297
 - Moraxella catarrhalis*-induced septic arthritis of prosthetic knee joint, anakinra treatment of, 1337, 1338
 - RA, fatal tuberculosis during infliximab treatment, 1334
 - RA, *Strongyloides stercoralis* infection during etanercept treatment, 1336
 - RA treated with biologic agents, 3403
 - TNF antagonists and reactivation of latent tuberculosis, 1766
 - tuberculosis risk and anti-TNF treatment of RA, 1986, 2968
- Infection-triggered arthritis, innate immunity and, mouse study, 1297
- Inflammation
 - AS, MRI assessment of spinal inflammation before and after etanercept treatment, 1216
 - collagen-induced arthritis in mice, effect of small interfering RNA, 1314
 - dendritic cells and autoimmunity, 11
 - Fc γ receptor type I and joint inflammation in IFN γ -enhanced immune complex-mediated arthritis, 967
 - Fc γ receptor type IIa in autoimmune inflammation, 3220
 - genetic control pathways of in Crohn's disease and PsA, 3596
 - gout, Toll-like receptors and, mouse study, 2936
 - joint, transient receptor potential vanilloid 1 in, mouse study, 3248
 - kininogen-deficient rats, modulation of, 2549
 - microparticles as regulators of, 3337
 - NEMO-binding domain peptide, antiinflammatory effects of, mouse study, 951
 - OA, correlating disease severity and MRI findings, 3492
 - RA, RANK/RANKL system in, 2307
 - RA, subchondral bone marrow and, 3448
 - RA, ultrasonographic synovitis scoring system for finger joint, 733
 - SLE, obesity and, 3651
- Inflammatory polyarthritis
 - baseline C-reactive protein levels and prediction of death from cardiovascular disease in, 2293
 - subchondral bone marrow and, 3448
- Infliximab
 - AS, anti-TNF therapy decreases anterior uveitis flares in, 2447
 - AS, efficacy and safety in, 582, 2506

Infliximab (cont'd)

- JIA, refractory polyarticular, use in, 548
- PsA, treatment of dermatologic and articular manifestations, 1227
- psoriasis onset during treatment, 1333, 1334, 2513
- RA, apoptosis induction in joint macrophages, 61
- RA, C-reactive protein as predictor of treatment outcome, 42
- RA, fatal tuberculosis during treatment, 1334
- RA, infections in patients treated with biologic agents, 3403
- RA, infliximab plus MTX, benefit in patients without clinical improvement, 1020, 4044, 4045
- RA, infliximab plus MTX for poor-prognosis RA, 27
- RA, prostaglandin E $_2$ biosynthetic pathway and, 3439
- in RA and AS, 2506
- reactive systemic AA amyloidosis, improvement of renal function and disappearance of hepatitis B virus, 2519
- SpA, intraarticular treatment, 1224
- TNF α blockade and humoral immunity, 2192
- uveitis, efficacy for treatment-resistant Behçet's uveitis, 2478
- Injury. See Mechanical injury; Traumatic injury
- In memoriam, Morris Ziff, 3323
- Innate immunity, in infection-triggered arthritis, mouse study, 1297
- Inorganic phosphate, OA, IL-8 and phosphate transporter/retrovirus receptor in chondrocyte phosphate uptake, 144
- Insulin-like growth factor 1, chondrocyte anabolic activity promoted by, 3910
- Integrin, disruption of T cell/antigen-presenting cell interaction by teriflunomide, 2730
- Intent-to-treat principle, methodologic issues in superiority trials assessing structural outcomes, 1858
- Intercondylar notch narrowing, in early-stage knee OA, guinea pig study, 3100
- Interferon (IFN)
 - Sle2*-associated component lupus phenotypes, contribution of type I deficiency, mouse study, 3063
 - SS, type I IFN in, 1185
- Interferon- α (IFN α)
 - SLE, activation of IFN α pathway, 1491
 - SS, type I IFN in, 1185
 - systemic vasculitis, PEGylated IFN α 2b and ribavirin treatment for hepatitis C virus-related systemic vasculitis, 911
- Interferon- β (IFN β)-deficient mice, exacerbation of collagen-induced arthritis, 3739
- Interferon- γ (IFN γ)
 - acute CD4 $^{+}$ T lymphocyte-dependent IL-1-driven arthritis and, 3749
 - in immune complex-mediated arthritis, 967
- Interferon-inducible genes, SLE, activation of IFN α pathway, 1491
- Interferon type I (IFN-I) deficiency, *Sle2*-associated component lupus phenotypes, mouse study, 3063
- Interleukin-1 (IL-1)
 - blockade, 1960
 - IL-17 receptor deficiency and impaired expression of, 3239
 - neonatal-onset multisystem inflammatory disease, IL-1 blockade by anakinra improves symptoms, 1283
 - OA, IL-1 in cartilage matrix degradation, 128
 - soluble IL-1 receptor accessory protein in collagen-induced arthritis, 2202
 - in systemic inflammation, 1960
 - T cell IL-17 overexpression in IL-1-deficient arthritic mice, 975
- Interleukin-1 β (IL-1 β)
 - ADAMTS-9 induced by inflammatory arthritides in, 1451
 - IL-1 β gene promoter polymorphism and levels of IL-1 β protein, 361, 362
 - IL-1 β -induced COX-2 gene expression in human synovial fibroblasts, regulation by 15-deoxy- $\Delta^{12,14}$ -prostaglandin J $_2$, 94
 - OA, chondrocytes, reactivity to, 136
 - OA, variations in innate cytokine activity and risk of, 1443

- Interleukin-1 β (IL-1 β) (*cont'd*)
 RA, proinflammatory cytokines and CYP7B expression and activity in fibroblast-like synoviocytes, 770
 RA, stimulation of IL-6 receptor shedding by, 84
- Interleukin-1 receptor antagonist (IL-1Ra)
 gene, polymorphism of and RA susceptibility, 3015
 RA and deficiency of, 3731
 rosiglitazone-induced IL-1Ra in rat synovial fibroblasts, 759
- Interleukin-2 (IL-2), acute CD4 $^{+}$ T lymphocyte-dependent IL-1-driven arthritis and, 3749
- Interleukin-4 (IL-4)
 acute CD4 $^{+}$ T lymphocyte-dependent IL-1-driven arthritis and, 3749
 regulator of inflammatory arthritis, mouse study, 1866
- Interleukin-6 (IL-6)
 acute CD4 $^{+}$ T lymphocyte-dependent IL-1-driven arthritis and, 3749
 RA, neutrophil recruitment in coculture model of synovium, 3460
 RA, stimulation of IL-6 receptor shedding by IL-1 β and TNF α , 84
 reactive arthritis and, mouse study, 2530
 systemic JIA, anti-IL-6 receptor antibody in, 818
 systemic JIA, IL-6 receptor as treatment, 687
- Interleukin-7 (IL-7), RA, stimulation of cell contact-dependent activation of, 1700
- Interleukin-8 (IL-8)
 OA, phosphate transporter/retrovirus receptor and CXCR2-mediated inorganic phosphate uptake in chondrocytes, 144
 RA, CXCL8 binding site on endothelial syndecan-3 in synovium, 2331
- Interleukin-10 (IL-10)
 collagen-induced arthritis, intranasal gene therapy delivery system, 3761
 variations in innate cytokine activity and risk of OA, 1443
- Interleukin-10 receptor, RA, receptor α chain expression in synovium, animal models, 3315
- Interleukin-12 (IL-12), acute CD4 $^{+}$ T lymphocyte-dependent IL-1-driven arthritis and, 3749
- Interleukin-15 (IL-15), as therapeutic target in RA, 2585, 2686
- Interleukin-17A (IL-17A), T cell IL-17 overexpression in IL-1-deficient arthritic mice, 975
- Interleukin-17 receptor, streptococcal cell wall-induced arthritis and, mouse study, 3239
- Interleukin-18 receptor, SLE, signaling and autoantibody production and end-organ disease in, mouse study, 984
- Interleukin-21 receptor, SSc, expression altered in keratinocytes, 856
- Interleukin-22 (IL-22), in RA, 1037
- Intermargin distance, OA, alignment in knee radiography for clinical trials of structure-modifying drugs, 1411
- Interstitial lung disease, antisyntetase-associated, tacrolimus treatment, 2439
- Interstitial pneumonitis, in RA, association of CD4 $^{+}$ T cells with, 73
- Intima-media thickening, in SS, 3890
- Intraarticular injection
 antigen-induced arthritis, promotion of MTX induction and anti-inflammatory effects by sonoporation, rabbit study, 2559
 glucocorticoid treatment reduces inflammation in synovial cell infiltrations, 3880
 JIA, corticosteroids for temporomandibular arthritis in children with JIA, 3563
 knee, radiation synovectomy vs. intraarticular glucocorticoid treatment, 3391
 methylprednisolone therapy and cortisol secretion, 924
 OA, clinical trials of disease-modifying OA drugs, lessons learned, 3349
 sarcoid arthritis, etanercept treatment, 987
 SpA, infliximab in, 1224
- Intranasal delivery, collagen-induced arthritis, IL-10 gene therapy, 3761
- Intravital video microscopy, leukocyte trafficking into ankle joint in chronic RA mouse model, 3269
- In vitro studies
 ADAMTS-1 in cartilage growth, development, and inflammatory arthritis, mouse study, 1461
 ADAMTS-9 induced by IL-1 β and TNF α in inflammatory arthritis, 1451
 antigen microarray profiling of RA autoantibodies, 2645
 APS, involvement of p38 MAPK in antiphospholipid antibody-induced up-regulation of tissue factor on HUVECs, 1545
 C43S TRAPS mutation and TNF α -induced signaling, 1287, 2952
 dehydroascorbate transport in human chondrocytes, 2676
 gene expression after cartilage injury, 2386
 generation of covalent RNA-protein complexes by ultraviolet B irradiation, 1160
 membrane type 1-MMP inhibition and reduced invasiveness of RA synovial fibroblasts, 2010
 OA, IL-1 and TNF α in cartilage degradation, 128
 OA, IL-8 and phosphate transporter/retrovirus receptor in chondrocyte phosphate uptake, 144
 OA, inhibitor of MMPs in cartilage loss, 171
 OA, molecular markers of lipid peroxidation in OA cartilage, 2799
 OA, reactivity of OA chondrocytes to IL-1 β , 136
 OA, variations in innate cytokine activity and risk of OA, 1443
 proteoglycan 4 in synovial fluid, inhibition of integrative cartilage repair by, 1091
 RA, CXCL8 binding site on endothelial syndecan-3 in synovium, 2331
 RA, IL-7 stimulates cell contact-dependent activation of CD4 $^{+}$ T cells and macrophages, 1700
 RA, neutrophil recruitment in coculture model of, 3460
 RA, prostaglandin E $_2$ pathway, antirheumatic treatments with, 3439
 RA, stimulation of IL-6 receptor shedding by IL-1 β and TNF α , 84
 RA, targeting of synovial macrophages with anti-folate receptor β antibody and truncated *Pseudomonas* exotoxin, 2666
 RA, T cell response to oxidatively modified IgG, 80
 RA and OA, kappa and delta opioid receptors in fibroblast-like synoviocytes in, 1402
 regulation of pyrin subcellular localization by 14.3.3 proteins, 1848
 salivary gland epithelial cell exosomes, 1517
 SLE, reduced sensitivity to CD4 $^{+}$, CD25 $^{+}$ regulator T cells in murine lupus, 1180
 SSc, transcriptosome analysis of nonlesional dermal fibroblasts in, 865
 TNF α production in RA synoviocytes, regulation by butyrate, 2697
 topoisomerase I cleavage during necrotic cell death, cathepsins and, 2133
- Ischemic cerebrovascular accident, COX-2 inhibitors and, 1968

J

- Japanese population, RA, association of single-nucleotide polymorphisms in *SEC8L1* gene in, 1371
- JNK, inhibition of bone erosion by STAT-6-VT by blockade of, mouse study, 2719
- Joint arthroplasty, OA, surgical outcomes following knee or hip arthroplasty, racial/ethnic differences and, 3143
- Joint damage. *See also* Joints
 JIA, development and validation of clinical index for, 2092
 knee OA, MRI bone marrow abnormalities and cartilage degradation, 2822
 OA and early RA, type II collagen helical peptide in, 1081
 pristane-induced arthritis, *Cia10* effects on, rat study, 322
 RA, age and OA at onset of symptoms, association with radiographic damage in, 2284
 RA, early, prednisolone plus DMARDs in, 3324, 3360, 3371

Joint damage. *See also* Joints (*cont'd*)

- RA, effect of high-dose chemotherapy and ASCT on, 421
- RA, sensitivity to change of MRI and radiography, 2300
- RA, ultrasonography for assessing, 681

Joint degeneration, cartilage coefficient of friction, 1632

Joint destruction

- RA, fibroblast-like synoviocyte invasiveness and, 1999
- RA, infliximab plus MTX, benefit in patients without clinical improvement, 1020, 4044, 4045
- RA, sensitivity to change of MRI and radiography, 2300

Joint fluid. *See* Synovial fluid

Joint lubrication, synovial fluid boundary lubrication following injury, rabbit study, 1746

Joint repair

- autologous transplantation of basic fibroblast growth factor gene-transduced chondrocytes with adeno-associated virus vector, rabbit study, 164
- bone morphogenetic protein 2 for tissue engineering in cartilage repair, 155

Joints. *See also* Joint damage

- collagen-induced arthritis, small interfering RNA and joint inflammation in mice, 1314
- dehydroascorbate transport in human chondrocytes, 2676
- Fcγ receptor I and joint inflammation in IFNγ-enhanced immune complex-mediated arthritis, 967
- OA, knee, weight loss and reduction of knee-joint load in older obese adults, 2026
- pachydermodactyly, 990, 2953
- RA, anti-TNF therapy and apoptosis induction in joint macrophages, 61
- RA, articular, radiographic, laboratory, and functional status improved from 1985 to 2000, 991, 1009
- RA, CXCL16 recruits memory T cells into rheumatoid joints, 1381
- RA, individual joint pathology in, 672, 673
- RA, ultrasonography for assessing, 681
- transient receptor potential vanilloid 1 in joint inflammation, mouse study, 3248

Joint space narrowing

- MMP-3 as biomarker of OA progression, 3160
- OA, alignment in knee radiography for clinical trials of structure-modifying drugs, 1343, 1411
- OA, oral doxycycline to slow radiographic progression, 1956, 2015
- RA, age and OA at onset of symptoms, association with radiographic damage in, 2284

Joint space width, RA, digital x-ray radiogrammetry as diagnostic tool, 3850

Joint stability, OA, anteroposterior laxity and knee OA progression, 2343

Juvenile Arthritis Damage Index (JADI), clinical index for JIA, 2092

Juvenile chronic arthritis (JCA), nomenclature and classification in chronic childhood arthritis, 382

Juvenile enthesitis-related arthritis, KIR3DL2 in, 3586

Juvenile idiopathic arthritis (JIA)

- ANA in, 826
- assessment of radiographic change in, 2865
- bone mass and bone turnover in early JIA, 833
- damage assessment in, 2092
- disease activity patterns in, 3554
- hydroxychloroquine and serum MTX concentrations in children with, 1621
- IL-6 receptor as treatment, 687
- infliximab, efficacy and safety of, 548
- meloxicam vs. naproxen for, clinical trial, 563
- nomenclature and classification in chronic childhood arthritis, 382
- psychological stress and exacerbation of, 16
- PTPN22 as autoimmunity gene, 1694
- SLC11A1 (NLRP1) genetics in, 247

Juvenile idiopathic arthritis (JIA) (*cont'd*)

- systemic onset, efficacy of anti-IL-6 receptor antibody, 818
- WISP3 polymorphisms and susceptibility to, 3548

Juvenile rheumatoid arthritis (JRA)

- anti-CCP antibodies in, 239
- nomenclature and classification in chronic childhood arthritis, 382
- polyarticular course, safety and efficacy of leflunomide, 554
- Juvenile SpA, anti-TNFα treatment of, 2103

K

Kallikrein, tissue pattern of endothelial cells in SSc, 3618

Kallikrein-kinin system, kininogen deficiency to modulate inflammation of arthritis, 2549

Kallistatin, gene therapy for RA, rat study, 1319

Kidneys

- APS, antiphospholipid antibodies in pathogenesis of, 988
- BAFF overexpression and accelerated glomerular disease in mice predisposed to SLE, 2080
- Dalmation defect: hepatic endocrinopathy of urate transport, 2257
- lupus nephritis, anti-CD20 therapy, 371
- lupus nephritis, cross-reactive anti-dsDNA/anti-α-actinin antibodies and induction of renal disease, 522
- lupus nephritis, effect of fractalkine antagonist on, mouse study, 1522
- lupus nephritis, single-dose C-reactive protein, mouse study, 378
- lupus nephritis, therapeutic B cell depletion therapy, 501, 4080, 4081
- reduction in serum uric acid with sevelamer in hemodialysis patients, 290
- SLE, anti-DNA antibodies and glomerulonephritis, 2403
- SLE, anti-dsDNA antibody levels and renal flare in, 1129
- SLE, BAFF overexpression and accelerated glomerular disease, 2080
- SLE, *PDCD1* polymorphism and renal manifestations in mice, 1665
- SLE, enhanced lipid peroxidation associated with renal disease, 192
- SLE, reversal of proteinuria in autoimmune mice by treatment with C-reactive protein, 642
- subchondral femoral head insufficiency fracture after renal transplantation, 1293
- suppressive oligodeoxynucleotides of lupus-like disease, mouse study, 651

Killer immunoglobulin-like receptors, SpA, KIR3DL2 in, 3586

Kininogen deficiency modulates inflammation of arthritis, 2549

Knee

- anterior cruciate ligament injury, cartilage glycosaminoglycan loss in acute phase, gadolinium-enhanced MRI, 120
- antigen-induced arthritis, promotion of MTX induction and anti-inflammatory effects by sonoporation, rabbit study, 2559
- arthroplasty, trends in US 1990-2000, 3928
- BMD associated with bone marrow lesions, 2814
- body composition and knee cartilage volume in healthy subjects, 461
- cartilage defects and knee cartilage loss in healthy adults, 2033
- chronic arthritis, peripheral μ-opioid receptor expression down-regulated in, 3210
- heritability of longitudinal changes in knee structure, 2830
- immune complex-mediated arthritis, IFNγ in, 967
- OA, acoustic properties of knee and ankle joint cartilage, 3125
- OA, alignment in radiography for clinical trials of structure-modifying drugs, 1343, 1411
- OA, anteroposterior laxity and OA progression, 2343
- OA, assessment of knee-alignment angle, 1730
- OA, association of knee height and knee pain, 1418
- OA, BMD associated with bone marrow lesions, 2814
- OA, bone loss on knee radiographs, 3536
- OA, cartilage loss on MRI and radiographic progression in, 3152
- OA, chondroitins 4 and 6 sulfate treatment, 779
- OA, correlating disease severity and MRI findings, 3492
- OA, cruciate ligament integrity in, 794

Knee (cont'd)

- OA, cruciate ligament laxity and femoral intercondylar notch narrowing in early-stage disease, guinea pig study, 3100
- OA, delayed gadolinium-enhanced MRI of, 3528
- OA, experimental, PD-0200347 in, dog study, 488
- OA, experimental, pioglitazone in, guinea pig study, 479
- OA, hand, as predictor for future hip or knee OA, 3520
- OA, hip abduction moment and protection against progression, 3515
- OA, knee stabilization in medial compartment, 2845
- OA, lateral view radiography to evaluate joint space width, 3542
- OA, matrix metabolism in cartilage lesions, 112
- OA, medial compartment, secondary gait changes in, 2835
- OA, MMP-3 as biomarker of disease progression, 3160
- OA, moderate exercise and glycosaminoglycan content in cartilage, 3507
- OA, MRI bone marrow abnormalities and cartilage degradation in knee OA, 2822
- OA, NSAIDs and radiologic progression of, 3137
- OA, oral doxycycline to slow radiographic progression, 1956, 2015
- OA, radiation synovectomy vs. intraarticular glucocorticoid treatment, 3391
- OA, radiographic, serum hyaluronan levels as biomarker of, 105
- OA, surgical outcomes following arthroplasty, racial/ethnic differences and, 3143
- OA, weight loss and reduction of knee-joint load in older obese adults, 2026
- pain, in older adults, influence of "pain elsewhere" on outcomes, 2350
- prevalent and incident knee cartilage defects, loss of tibial and patellar cartilage, 3918
- SpA, intraarticular infliximab in, 1224
- synovial fluid boundary lubrication following injury, rabbit study, 1746
- T cell IL-17 overexpression in IL-1-deficient arthritic mice, 975
- transient receptor potential vanilloid 1 in knee inflammation, mouse study, 3248
- Ku protein, anti-Ku autoantibodies and DPB1*, 668

L

- La/SSB epitopes, exposure and binding of on apoptotic cells, 3934
- Leflunomide
 - disruption of T cell/antigen-presenting cell interaction by teriflunomide, 2730
 - JRA, polyarticular course, leflunomide safety and efficacy in, 554
 - Leg length, association of knee height, knee pain, and knee OA, 1418
- Leukemia inhibitory factor, acute CD4+ T lymphocyte-dependent IL-1-driven arthritis and, 3749
- Leukocytes
 - cutaneous lupus erythematosus, amplification cycle triggering, 1504
 - RA, neutrophil recruitment in coculture model of synovium, 3460
 - RA, trafficking into ankle joint in mouse model, 3269
- Leuprolide acetate, SLE, gonadotropin-releasing hormone analog for ovarian protection during cyclophosphamide treatment, 2761
- Lipid peroxidation, molecular markers of in OA cartilage, 2799
- Lipid raft signaling, in B lymphocytes in SLE, 3955
- Lipopolysaccharide, variations in innate cytokine activity and risk of OA, 1443
- Listeria monocytogenes*, septic arthritis in etanercept-treated patient, 987
- Livedo reticularis, APS, dermatologic manifestations of, 1785
- Liver, Dalmation defect, hepatic endocrinopathy of urate transport, 2257
- Local injection-induced arthritis, plasminogen deficiency of in different RA models, 2541
- Lockshin, Dr. Michael D., new editor, 1951
- LUMINA cohort
 - SLE, influence of menopause in study patients, 1655

LUMINA cohort (cont'd)

- SLE, risk factors for venous thrombosis in study patients, 2060
- Lumiracoxib, cardiovascular events and, 1968
- Lungs
 - antisynthetase-associated interstitial lung disease, tacrolimus treatment, 2439
 - pulmonary arterial hypertension, prevalence in community practices, 2125
 - SSc, eicosanoids in pathogenesis of lung disease in, 3693, 3783
 - SSc, pulmonary arterial hypertension in diagnosis of, 3698, 3792
 - SSc, serum pulmonary and activation-regulated chemokine/CCL18 levels in, 2889
- Lupus anticoagulant
 - prolonged bleeding time and, 1949
 - as risk factor for venous thrombosis in LUMINA study patients, 2060
- Lupus nephritis
 - anti-CD20 therapy, 371
 - anti-DNA antibodies and glomerulonephritis, 2403
 - cross-reactive anti-dsDNA/anti- α -actinin antibodies and induction of renal disease, 522
 - fractalkine antagonist and, mouse study, 1522
 - imatinib treatment, mouse study, 3987
 - single-dose C-reactive protein, mouse study, 378
 - therapeutic B cell depletion therapy, 501, 4080, 4081
- Luteinizing hormone, in SLE, 3701
- Lymph nodes, RA, RANK/RANKL system in inflammation, 2307
- Lymphocytes
 - RA, free radical production by rheumatoid synovial T lymphocytes, 2003
 - RA, T cell response to oxidatively modified IgG in, 80
 - refractory ANCA-associated vasculitis, B lymphocyte depletion for, 262
 - SLE, activated CD8+ lymphocytes in pathogenesis, 201
 - SLE, P-glycoprotein expression and relevance to steroid resistance, 1676
- Lymphoid neogenesis, RA, subchondral bone marrow and, 3448
- Lymphopenia, SS, CXCL13 and CCL21 expression and lymphoid features in, 1773
- Lymphotoxin, in autoimmune arthritis, 3202
- Lyn, SLE, expression in B cells in, 3955
- Lysosomes, topoisomerase I cleavage during necrotic cell death, cathepsins and, 2133

M

- M40403
 - collagen-induced arthritis, combination therapy with dexamethasone, rat study, 1929
 - collagen-induced arthritis, combination therapy with MTX, rat study, 3755
- Macrophage colony-stimulating factor, nurse-like cells from RA patients and bone loss, 3819
- Macrophages
 - acute CD4+ T lymphocyte-dependent IL-1-driven arthritis and, 3749
 - RA, anti-TNF therapy and apoptosis induction in joint macrophages, 61
 - RA, CXCL16 recruits memory T cells into rheumatoid joints, 1381
 - RA, IL-7 stimulates cell contact-dependent activation of, 1700
 - RA, migration inhibitory factor, correlation with severity, 3020
 - RA, targeting of synovial macrophages with anti-folate receptor β antibody and truncated *Pseudomonas* exotoxin, 2666
- Magnetic resonance imaging (MRI)
 - AS, spinal inflammation before and after etanercept treatment, 1216
 - gadolinium-enhanced, cartilage glycosaminoglycan loss in acute phase of anterior cruciate ligament injury, 120
 - GCA, cranial involvement in by MRI, 2470

Magnetic resonance imaging (MRI) (*cont'd*)

- OA, cartilage loss on MRI and radiographic progression in, 3152
 - OA, correlates of hip cartilage volume, 1069
 - OA, correlating disease severity and MRI findings, 3492
 - OA, cruciate ligament integrity in knee OA, 794
 - OA, hand, high-resolution MRI for assessment of, 2355
 - OA, knee, bone marrow abnormalities and cartilage degradation in, 2822
 - OA, knee, delayed gadolinium-enhanced MRI of, 3528
 - OA, quantitative assessment of cartilage morphology, 3132
 - RA, individual joint pathology in, 672, 673
 - RA, infliximab plus MTX for poor-prognosis RA, evidence of synovitis and damage, 27
 - RA, predicting tendon rupture through MRI evidence, 744
 - RA, sensitivity to change of MRI and radiography, 2300
 - SLE, MMP-9 in patients with neuropsychiatric SLE and brain MRI abnormalities, 673, 674
 - subchondral femoral head insufficiency fracture after renal transplantation, 1293
 - tuberculous rice bodies of wrist, 1950
- Major histocompatibility complex (MHC)
- class II MHC-peptide tetramers for detection of CD4+ T cells, mouse study, 1885
 - RA, TNF and class II MHC expression on myeloid cells, 451
- Malignancy
- DM associated with, 3712
 - risk of in SSc, 2415
 - SLE and cancer, international cohort study, 1481
- Mannose-binding lectin, gene polymorphisms in SLE, 3966
- Marennostin, regulation of pyrin subcellular localization by 14.3.3 proteins, 1848
- Maternal HLA class II compatibility in men with SLE, 2768
- Matrix metalloproteinase 3 (MMP-3)
- biomarker of OA progression, 3160
 - IL-17 receptor deficiency and impaired expression of, 3239
 - SS, acinar damage and MMP-3/TIMP-1 and MMP-9/TIMP-1 imbalance and, 2751
- Matrix metalloproteinase 9 (MMP-9)
- IL-17 receptor deficiency and impaired expression of, 3239
 - SLE, increased MMP-9 in patients with neuropsychiatric SLE and brain MRI abnormalities, 673, 674
 - SS, acinar damage and MMP-3/TIMP-1 and MMP-9/TIMP-1 imbalance and, 2751
- Matrix metalloproteinase 13 (MMP-13)
- IL-17 receptor deficiency and impaired expression of, 3239
- Matrix metalloproteinases (MMPs)
- abnormal expression in OA chondrocytes and epigenetic "unsilencing," 3110
 - OA, inhibition of MMPs in cartilage loss in vitro, and in guinea pig model, 171
 - RA, membrane type 1-MMP inhibition and reduced invasiveness of synovial fibroblasts, 2010
- Mechanical bull myopathy, in SSc patient, 3682
- Mechanical injury
- anterior cruciate ligament injury, cartilage glycosaminoglycan loss in acute phase, gadolinium-enhanced MRI, 120
 - gene expression after cartilage injury, 2386
 - synovial fluid boundary lubrication following injury, rabbit study, 1746
- Medial compartment knee OA
- knee stabilization in, 2845
 - secondary gait changes in, 2835
- Medial-tibial cartilage volume, body composition and knee cartilage volume in healthy subjects, 461
- Medial tibial plateau alignment, OA, alignment in knee radiography for clinical trials of structure-modifying drugs, 1411

MEFV gene

- recurrent fever in western European patients, 3603
 - regulation of pyrin subcellular localization by 14.3.3 proteins, 1848
- Meloxicam, vs. naproxen in JIA, 563
- Membrane type 1-MMP, inhibition of and reduced invasiveness of RA synovial fibroblasts, 2010
- Menopause, influence of in LUMINA study patients, 1655
- Mesenchymal stem cells
- synovium as superior source of, 2521
 - TNF α , reversal of immunosuppressive properties in collagen-induced arthritis, mouse study, 1595
- Metalloproteinases
- disintegrin ADAM15 and degenerative cartilage remodeling in OA, 1100
 - OA, human β -defensin in tissue remodeling, mouse study, 1736
- Methotrexate (MTX)
- adjuvant-induced arthritis, electroporation to enhance effect, 637
 - ANCA-associated vasculitis, MTX vs. cyclophosphamide to induce remission, 2461
 - antigen-induced arthritis, promotion of MTX induction and antiinflammatory effects by sonoporation, rabbit study, 2559
 - collagen-induced arthritis, combination therapy with M40403, rat study, 3755
 - folic acid and folic acid supplements and, 1338, 1339, 3030
 - genetic resistance to in air-pouch model of acute inflammation, 2567
 - JIA, hydroxychloroquine and serum MTX concentrations in children with, 1621
 - JIA, refractory polyarticular, infliximab plus MTX in, 548
 - juvenile DM, MTX plus aggressively tapered corticosteroids for, 3570
 - RA, combination therapy with intramuscular gold, 1360
 - RA, combination therapy, efficacy of, 2975
 - RA, drug efflux transporters, 670, 671, 672
 - RA, reduction of efficacy by folic acid, 3030
 - RA, infliximab plus MTX, benefit in patients without clinical improvement, 1020, 4044, 4045
 - RA, infliximab plus MTX for poor prognosis, 27
 - RA, MTX plus abatacept (CTLA-4Ig) treatment, 2229, 2263
 - RA, phenotypes in metabolism of MTX to 7-hydroxymethotrexate, 356
 - RA, presentation and analysis of clinical trial radiographic data, 49
 - superoxide dismutase mimetic, synergistic interaction between, rat study, 3755
 - for WG, 2237
- Methylenetetrahydrofolate reductase, molecular mechanisms and variability in drug response, 1349
- Methylprednisolone, intraarticular corticosteroid therapy and cortisol secretion, 924
- Met-RANTES, adjuvant-induced arthritis, amelioration by, rat study, 1907
- Microarrays, antigen microarray profiling of RA autoantibodies, 2645
- Microbubble-enhanced ultrasound, antigen-induced arthritis, promotion of MTX induction and antiinflammatory effects by sonoporation, rabbit study, 2559
- Microchimerism, SLE, maternal HLA class II compatibility in men with SLE, 2768
- Microfibril-associated glycoprotein 2, increased expression of type I collagen and, mouse study, 1812
- Microparticles, as regulators of inflammation, 3337
- Microscopic polyangiitis, ANCA-associated vasculitis, MTX vs. cyclophosphamide to induce remission, 2461
- Microscopy, RA, leukocyte trafficking into ankle joint in mouse model, 3269
- Microsomal prostaglandin E synthase 1, RA treatment and expression of, 3439
- Microvascular thrombosis, APS, dermatologic manifestations of, 1785
- MIF gene, correlation with RA severity, 3020

- Minor salivary glands, SS, gene expression profiling of, 1534
- Miscarriage. *See* Fetal loss
- Mixed connective tissue disease, pulmonary arterial hypertension, prevalence in community practices, 2125
- Mixed cryoglobulinemia
chemokines and Th1 cytokines in hepatitis C virus-associated cryoglobulinemia vasculitis neuropathy with, 2917
systemic vasculitis, PEGylated IFN- α -2b and ribavirin treatment for hepatitis C virus-related systemic vasculitis, 911
- Monarthritis
peripheral μ -opioid receptor expression down-regulated in, 3210
peripheral μ -opioid receptors as potential therapy targets, 2955
spontaneous circadian behavior in monarthritic rats, 3470
- Monkey studies
CCR5 antagonist for inhibition of rhesus monkey collagen-induced arthritis, 627
RAGE expression by articular chondrocytes, 2376
- Monoclonal antibodies. *See* names of individual drugs
- Monocytes
RA, CD64+, Toll-like receptor 2 and 4 expression on, 2227
or 2 and 4 expression on CD64+ monocytes, 2227
ribosomal P epitope expression by, 847
- Monocytosis, SLE, *Yaa* gene-linked, mouse study, 2790
- Mononuclear cells
RA, targeting of synovial macrophages with anti-folate receptor β antibody and truncated *Pseudomonas* exotoxin, 2666
RA, *TP53* and apoptosis effects in, 1047
- Monosodium urate monohydrate, gouty inflammation and Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression, mouse study, 2936
- Mood, polyarticular arthritis, stress, and symptoms in children with, 1196
- Moraxella catarrhalis*-induced septic arthritis, of prosthetic knee joint, anakinra treatment, 1337, 1338
- Mortality
hospital and attending physician volume of admissions and in-hospital mortality, 1628, 1646
inflammatory polyarthritis, baseline C-reactive protein levels and prediction of death from cardiovascular disease in, 2293
RA, cardiovascular death in, 722
RA, increased unrecognized coronary heart disease and sudden death in, 402
SS, mortality and causes of death in primary SS, 369
- Mouse studies
ADAMTS-1 in cartilage growth, development, and inflammatory arthritis, 1461
adaptive immunity in p53 regulation of arthritis, 1876
antiphospholipid antibody-mediated thrombophilia, complement activation and, 2120
anti-type II collagen antibodies, arthritogenic capacity of, 1897
arthropathy-accelerating MRL locus in DBA/1 mice, 959
BAFF overexpression and accelerated glomerular disease in mice predisposed to SLE, 2080
class II MHC-peptide tetramers for detection of CD4+ T cells, 1885
collagen-induced arthritis, angiotensin receptor blockers for amelioration of, 1920, 3678, 4047
collagen-induced arthritis, CXCL13 and, 620
collagen-induced arthritis, dipeptidyl peptidase I and, 2553
collagen-induced arthritis, erythropoietin effects on, 940
collagen-induced arthritis, exacerbation in IFN- β -deficient mice, 3739
collagen-induced arthritis, gene therapy targeting Tie2, 1585
collagen-induced arthritis, heme oxygenase 1 modulation in progression of, 3230
collagen-induced arthritis, intranasal IL-10 gene therapy delivery system, 3761
collagen-induced arthritis, Nur77 overexpression and, 333
- Mouse studies (*cont'd*)
collagen-induced arthritis, reversal of immunosuppressive properties of mesenchymal stem cells by TNF α , 1595
collagen-induced arthritis, small interfering RNA and joint inflammation, 1314
collagen-induced arthritis, soluble IL-1 receptor accessory protein to ameliorate, 2202
collagen-induced arthritis, suppression by chebulagic acid, 345
collagen-induced arthritis, sympathetic nervous system and, 1305
collagen-induced arthritis, treatment with CD25+ regulatory T cells, 2212
Egr2/Krox20 in dexamethasone-mediated osteocalcin repression, 929
Fc γ receptor type IIa in autoimmune inflammation, 3220
gouty inflammation, Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression and, 2936
IL-17 receptor and cartilage destruction in streptococcal cell wall-induced arthritis, 3239
inflammatory arthritis, IL-4 as regulator of, 1866
innate immunity in infection-triggered arthritis, 1297
La/SSB epitopes, exposure and binding of on apoptotic cells, 3934
lupus nephritis, effect of fractalkine antagonist on, 1522
lupus nephritis, imatinib treatment, 3987
lupus nephritis, single-dose C-reactive protein therapy, 378
lymphotoxin regulates T cell response and autoimmunity, 3202
membrane type 1-MMP inhibition and reduced invasiveness of RA synovial fibroblasts, 2010
MTX, genetic resistance to in air-pouch model of acute inflammation, 2567
Myeloid differentiation factor 88, gouty inflammation and, 2936
myositis, endoplasmic reticulum stress response in, 1824
NEMO-binding domain peptide, antiinflammatory effects of, 951
OA, extracellular superoxide dismutase and oxidant damage in, 3479
OA, human β -defensin in tissue remodeling, 1736
OA, metalloproteinase disintegrin ADAM15 and degenerative cartilage remodeling, 1100
oligodeoxynucleotides, suppressive oligodeoxynucleotides of lupus-like disease, 651
osteoblasts, osteocalcin, Egr2/Krox20 in dexamethasone-mediated osteocalcin repression, 929
plasminogen deficiency of in different RA models, 2541
protease-activated receptor, role in arthritis severity, 1325
proteoglycan-induced arthritis, Fc γ receptor type III involvement in development of, 1612
proteoglycan-induced arthritis, imaging inflammation in chronic murine ankle arthritis, 3269
proteoglycan-induced spondylitis, genetic control of, 2452
RA, IL-1 receptor antagonist deficiency and, 3731
RA, RANK/RANKL/osteoprotegerin system in, 2960
reactive arthritis, IL-6 contribution to, 2530
reversal of proteinuria in autoimmune mice by treatment with C-reactive protein, 642
SLE, genetic origin of in SWR/NZB hybrids, 659
SLE, granzyme B in autoimmunity, 1684
SLE, IL-18 receptor signaling and autoantibody production and end-organ disease in, 984
SLE, inhibition by IgM anti-dsDNA antibodies, 3629
SLE, PDCD1 polymorphism and renal manifestations, 1665
SLE, prevention and reversal by costimulatory blockade with adeno-associated virus-mediated gene transfer, 3975
SLE, reduced sensitivity to CD4+, CD25+ regulator T cells in, 1180
SLE, *Sle2*-associated component lupus phenotypes, 3063
SLE, tolerance breaking by dendritic cells without SLE disease expression, 225
SLE, *Yaa* gene-linked monocytosis, 2790
SSc, microfibril-associated glycoprotein 2, increased expression of type I collagen and, 1812

Mouse studies (cont'd)

- STAT-6-VT inhibition of osteoclastogenesis and bone erosion, 2719
- suppressive oligodeoxynucleotides of lupus-like disease, 651
- synovitis and cartilage degeneration and overexpression of cathepsin K, 3713
- T cell IL-17 overexpression in IL-1-deficient arthritic mice, 975
- Toll-like receptors 2 and 4, gouty inflammation and myeloid differentiation factor 88 expression, 2936
- TNF prevents alendronate-induced osteoclast death, 2708
- Toll-like receptors, reactive arthritis, 2233
- transient receptor potential vanilloid 1 in knee inflammation, 3248
- V α 14 NKT cells in murine arthritis, 1941
- Muscle, autoimmune myositis, endoplasmic reticulum stress response in, 1824
- Muscle mass, body composition and knee cartilage volume in healthy subjects, 461
- Muscle strength, Childhood Myositis Assessment Scale, validation and clinical significance of, 368
- Mutations. *See also* Genetics; Polymorphism
 - Behçet's disease, *TNFRSF1A* R92Q mutation and risk of venous thrombosis in, 608, 2582
 - C43S TRAPS mutation and TNF α -induced signaling, 1287, 2952
 - CINCA syndrome, *CIAS1* somatic mosaicism in, 3579
 - gout, *SLC22A12* mutation as suppressing factor for, 2576
 - hyperimmunoglobulinemia D with periodic fever syndrome, pseudodominant inheritance of, 3606
 - recurrent fever in western European patients, *MEFV* analysis and, 3603
 - SLE, *Yaa* gene-linked monocytosis, mouse study, 2790
 - sporadic chondrocalcinosis, *ANKH* sequence variants and, 1110
 - TRAPS-related TNFR1 mutants, 2906
- Mycobacterium tuberculosis*, tuberculous rice bodies of wrist, 1950
- Myeloid differentiation factor 88, gouty inflammation and, mouse study, 2936
- Myocardial infarction, COX-2 inhibitors and, 1968
- Myopathy, mechanical bull myopathy in SSc patient, 3682
- Myositis
 - endoplasmic reticulum stress response in, 1824
 - idiopathic inflammatory myopathies, consensus guidelines for myopathy trials, 2607
 - seasonal associations with, 2433

N

- N-Acetyltransferase, molecular mechanisms and variability in drug response, 1349
- NALP3* gene, systemic multisystem syndromes and anakinra, 1960
- Naproxen, JIA, meloxicam vs. naproxen for, clinical trial, 563
- National Bone and Joint Decade, 707
- Natural killer cells (NK cells), killer immunoglobulin-like receptor KIR3DL2 in SpA, 3586
- Necrosis
 - RA, fibroblast activation by necrotic synovial fluid cells via Toll-like receptor 3, 2656
 - topoisomerase I cleavage in, 2133
- NEMO-binding domain peptide, antiinflammatory effects of, 951
- Neonatal lupus syndrome, fetal heart block, anti-SSA/Ro 52-kd antibodies and, 366
- Neonatal-onset multisystem inflammatory disease (NOMID). *See also* Chronic infantile neurologic, cutaneous, articular syndrome
 - IL-1 blockade by anakinra improves symptoms, 1283
- Nephritis, lupus. *See* Lupus nephritis
- Nephrotic nephritis, C-reactive protein reverses proteinuria in autoimmune mice, 642
- Neuropathy, chemokines and Th1 cytokines in hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy, 2917
- Neuropsychiatric lupus
 - electroencephalographic assessment of, 841

Neuropsychiatric lupus (cont'd)

- elevated levels of soluble fractalkine in, 1670
- MMP-9 in and brain MRI abnormalities, 673, 674
- New Zealand cohort, association of *PTPN22* variant with RA in, 2222
- NF45 and NF90, SLE, granzyme B in autoimmunity, mouse study, 1684
- NF- κ B
 - Behçet's disease pathogenesis and, 2179
 - inhibition of bone erosion by STAT-6-VT by blockade of, mouse study, 2719
 - NEMO-binding domain peptide, antiinflammatory effects of, mouse study, 951
- NK T cells (NKT cells), V α 14 NKT cells in murine arthritis, 1941
- Nonsteroidal antiinflammatory drugs (NSAIDs)
 - AS treatment, 1634
 - OA, health state preferences, impact of disease severity and gastrointestinal side effects on, 2366
 - OA, radiologic progression of, 3137
 - reduction of radiographic progression of AS with, 1756
 - spontaneous circadian behavior in monoarthritic rats, 3470
- NRAMP1* gene, in JIA, 247
- Nuclear autoantigens, SSc, proteasome-dependent processing of topoisomerase I, 877
- Nur77, overexpression inhibits collagen-induced arthritis, mouse study, 333
- Nurse-like cells, RA, and bone loss, 3819

O

- Obesity
 - functional capacity and inflammation in SLE and, 3651
 - weight loss and reduction of knee-joint load in knee OA, 2026
- OC1N* gene cluster, PsA, common genetic control pathways of inflammation for Crohn's disease and, 3596
- Older adults
 - knee pain, influence of "pain elsewhere" on outcomes in, 2350
 - OA, acetabular dysplasia predicts incident hip OA, 787
 - OA, *COL1A1* polymorphism, hip OA, and genetics in elderly women, 1431
 - OA, weight loss and reduction of knee-joint load in obese adults with, 2026
 - risk factors for functional decline in arthritis, 1274
- Oligodeoxynucleotides, suppressive oligodeoxynucleotides of lupus-like disease, mouse study, 651
- Oncostatin M, acute CD4+ T lymphocyte-dependent IL-1-driven arthritis and, 3749
- Onychodystrophy, psoriasis onset during anti-TNF treatment, 1333, 1334, 2513
- Opioids
 - kappa and delta opioid receptors in fibroblast-like synoviocytes in RA and OA, 1402
 - peripheral μ -opioid receptor expression downregulated in chronic arthritis, 3210
 - peripheral μ -opioid receptors as potential therapy targets, 2955
 - use by orthopedics spine clinic patients, 312
 - use for pain, 6
- Organ transplantation, subchondral femoral head insufficiency fracture after renal transplantation, 1293
- Osteosarcoma, radiographic healing, 2225
- Osteoarthritis (OA)
 - alignment in knee radiography for clinical trials of structure-modifying drugs, 1343, 1411
 - ankle, acoustic properties of early cartilage lesions, 3125
 - asporin polymorphism and etiology of, 3502
 - BMD associated with bone marrow lesions, 2814
 - CD44v6 expression on chondrocytes in rabbits with OA, 810
 - chondrocyte phosphate uptake, IL-8 and phosphate transporter/retrovirus receptor, 144

Osteoarthritis (OA) (cont'd)

chondrocytes, reactivity of OA chondrocytes to IL-1 β , 136
 clinical trials of DMOADs, lessons learned, 3349
 doxycycline orally to slow radiographic progression of, 1956, 2015
 epidermal growth factor-TM7 receptor expression in synovial tissue, 442
 extracellular superoxide dismutase and oxidant damage in, 3479
 frizzled-related protein gene variants and, 1077
 hand, as predictor for future hip or knee OA, 3520
 hand, high-resolution MRI for assessment of, 2355
 hand strength in relation to radiographic features in, 1424
 health state preferences, impact of disease severity and gastrointestinal side effects on, 2366
 hip, acetabular dysplasia predicts incident hip OA, 787
 hip, *COL1A1* polymorphism, hip OA, and genetics in elderly women, 1431
 hip, *COL9A1* gene and, 1437
 hip, correlates of cartilage volume, 1069
 hip, hand OA as predictor for, 3520
 hip, IL-1 gene cluster polymorphisms and pathogenesis of, 674
 hip, no association between locus on chromosome 6 and hip OA, 2040
 hip, NSAIDs and radiologic progression of, 3137
 hip, surgical outcomes following arthroplasty, racial/ethnic differences and, 3143
 human β -defensin in tissue remodeling in cartilage, mouse study, 1736
 IL-7 stimulates cell contact-dependent activation of CD4+ T cells and macrophages, 1700
 inhibition of MMPs in cartilage loss in vitro, and in the guinea pig model, 171
 kappa and delta opioid receptors in fibroblast-like synoviocytes in, 1402
 knee, NSAIDs and radiologic progression of, 3137
 knee, acoustic properties of early cartilage lesions, 3125
 knee, alignment in radiography for clinical trials of structure-modifying drugs, 1343, 1411
 knee, and ankle, matrix metabolism in cartilage lesions, 112
 knee, anteroposterior laxity and OA progression, 2343
 knee, assessment of knee-alignment angle, 1730
 knee, association of knee height, knee pain, and knee OA, 1418
 knee, BMD associated with bone marrow lesions, 2814
 knee, body composition and knee cartilage volume in healthy subjects, 461
 knee, bone loss on knee radiographs, 3536
 knee, cartilage loss on MRI and radiographic progression in, 3152
 knee, chondroitin 4 and 6 sulfate treatment, 779
 knee, correlating disease severity and MRI findings, 3492
 knee, cruciate ligament integrity in, 794
 knee, cruciate ligament laxity and femoral intercondylar notch narrowing in early-stage disease, guinea pig study, 3100
 knee, delayed gadolinium-enhanced MRI of, 3528
 knee, hand OA as predictor for, 3520
 knee, hip abduction moment and protection against progression, 3515
 knee, lateral view radiography to evaluate joint space width, 3542
 knee, MMP-3 as biomarker of disease progression, 3160
 knee, moderate exercise and glycosaminoglycan content in cartilage, 3507
 knee, MRI bone marrow abnormalities and cartilage degradation in knee OA, 2822
 knee, oral doxycycline to slow radiographic progression, 1956, 2015
 knee, PD-0200347 in experimental OA, dog study, 488
 knee, pioglitazone in experimental OA, guinea pig study, 479
 knee, secondary gait changes in, 2835
 knee, serum hyaluronan levels as biomarker of radiographic OA, 105

Osteoarthritis (OA) (cont'd)

knee, stabilization of knee in medical compartment knee OA, 2845
 knee, surgical outcomes following arthroplasty, racial/ethnic differences and, 3143
 knee, weight loss and reduction of knee-joint load in older obese adults, 2026
 knee pain in older adults, influence of "pain elsewhere" on outcomes in, 2350
 knee structure, heritability of longitudinal changes in, 2830
 matrix degradation, IL-1 and TNF α in, 128
 matrix-degrading enzyme expression in OA chondrocytes, 3110
 metalloproteinase disintegrin ADAM15 and degenerative cartilage remodeling, mouse study, 1100
 MMP-3 as biomarker of OA progression, 3160
 molecular markers of lipid peroxidation in OA cartilage, 2799
 NSAIDs and radiologic progression of, 3137
 quantitative MRI assessment of cartilage morphology, 3132
 RA and, age at onset of symptoms, association with radiographic damage in, 2284
 reactivation of glucocorticoids in synovial cells, 1711
 serum sulfate levels and development of, 2808
 surgical outcomes following joint arthroplasty, racial/ethnic differences and, 3143
 type II collagen helical peptide in, 1081
 vitamin D supplementation and bisphosphonates to modulate, 1622, 1623
 weight loss and reduction of knee-joint load in older obese adults, 2026
 Osteoblast-like cells, stimulation of IL-6 receptor shedding by IL-1 β and TNF α , 84
 Osteoblasts, Egr2/Krox20 in dexamethasone-mediated osteocalcin repression, mouse study, 929
 Osteoclastogenesis
 kinetics of, rat study, 3192
 STAT-6-VT inhibition of osteoclastogenesis and bone erosion, 2719
 Osteoclasts
 collagen-induced arthritis, exacerbation in IFN- β -deficient mice, 3739
 formation in by RANKL in spontaneous erosive arthritis, mouse study, 3257
 RA, nurse-like cells and, 3819
 RA, subchondral bone marrow and, 3448
 TNF prevents alendronate-induced osteoclast death, mouse study, 2708
 Osteogenic protein 1
 antisense inhibition of and cartilage integrity, 468
 chondrocyte anabolic activity promoted by, 3910
 Osteonecrosis, subchondral femoral head insufficiency fracture after renal transplantation, 1293
 Osteonectin, specific inhibition of SPARC and decreased expression of type I collagen, 257
 Osteopenia, in childhood-onset SLE, 2051
 Osteopontin gene, SLE, single-nucleotide polymorphisms and susceptibility to, 539
 Osteoporosis
 temporal trends in prevention of glucocorticoid-induced osteoporosis, 2485
 vertebral fractures in SLE patients and low BMD, 2044
 Osteoprotegerin, RA, with RANK/RANKL in, 2960
 OUMS-27 chondrosarcoma cells, ADAMTS-9 induced by IL-1 β and TNF α in inflammatory arthritides in, 1451
 Outcome Measures in Rheumatology Clinical Trials, RAMRIS system, 3860
 Outcomes. *See also* Mortality
 hospital and attending physician volume of admissions and in-hospital mortality, 1628, 1646

Outcomes. *See also* Mortality (*cont'd*)

- knee pain in older adults, influence of "pain elsewhere" on outcomes in, 2350
- knee, radiation synovectomy vs. intraarticular glucocorticoid treatment, 3391
- methodologic issues in superiority trials assessing structural outcomes, 1858
- OA, surgical outcomes following knee or hip arthroplasty, racial/ethnic differences and, 3143
- RA, C-reactive protein as predictor of infliximab treatment outcome, 42
- RA, infliximab plus MTX for poor-prognosis RA, MRI evidence of synovitis and damage, 27
- RA, outcomes of 4 different treatments, BeSt study, 3326, 3381
- SLE, increased lupus activity and obstetric outcomes, 514
- Ovaries, gonadotropin-releasing hormone analog for ovarian protection during cyclophosphamide treatment of SLE, 2761
- Oxidation, in SLE, 2069
- Oxidative damage, OA, extracellular superoxide dismutase and, 3479
- Oxidative stress, free radical production of by rheumatoid synovial T lymphocytes, 2003
- Oxygen radicals, T cell response to oxidatively modified IgG in RA, 80
- Oxymetazoline, Afrin-induced CNS vasospasm and thunderclap headache, 3314

P

- p38 MAPK, APS, involvement of in antiphospholipid antibody-induced up-regulation of tissue factor on HUVECs, 1545
- p40, acute CD4+ T lymphocyte-dependent IL-1-driven arthritis and, 3749
- p53, adaptive immunity in p53 regulation of arthritis, mouse study, 1876
- p200 peptide, maternal antibody specificity and fetal congenital heart block, 3079
- p300, and profibrotic response to TGF β in SSc, 1248
- PADI4* gene, RA and, 3054
- Pain
 - challenges for the rheumatologist, 3685
 - estrogen deprivation arthralgia and aromatase inhibitors, 2594
 - FM, momentary relationship between symptoms and cortisol secretion, 3660
 - FM, pain variability in, 3670
 - knee pain in older adults, influence of "pain elsewhere" on outcomes in, 2350
 - neural activations in depression and chronic pain, 1577
 - OA, association of knee height, knee pain, and knee OA, 1418
 - OA, health state preferences, impact of disease severity and gastrointestinal side effects on, 2366
 - opioid use, 6
 - opioid use by orthopedics spine clinic patients, 312
 - peripheral μ -opioid receptor expression down-regulated in chronic arthritis, 3210
 - peripheral μ -opioid receptors as potential therapy targets, 2955
 - polyarticular arthritis, stress, mood, and symptoms in children with, 1196
 - spontaneous circadian behavior in monoarthritic rats, 3470
- Palmar erythema, APS, dermatologic manifestations of, 1785
- Pannus formation, pristane-induced arthritis, *Cia10* effects on, rat study, 322
- Pathogens. *See names of specific pathogens*
- PD-0200347, in experimental OA, dog study, 488
- PD-1 gene, RA, PD-1 polymorphism and development of, 362
- PDCD1* gene
 - RA, *PDCD1* haplotype associated with, 1058
 - SLE, *PDCD1* polymorphism and renal manifestations in mice, 1665
- Pediatric Rheumatology International Trials Organization (PRINTO), juvenile SLE, criteria for evaluating response to therapy, 2854

Peptides

- AS, HLA-B27-restricted CD8+ T cell response to cartilage-derived peptides in, 892, 2581, 2582
- class II MHC-peptide tetramers for detection of CD4+ T cells, mouse study, 1885
- NEMO-binding domain peptide, antiinflammatory effects of, mouse study, 951
- OA and early RA, type II collagen helical peptide in, 1081
- OA, human β -defensin in tissue remodeling, mouse study, 1736
- Peptidylarginine deiminase type 4 gene, in RA, 3054
- Perforin, SLE, activated CD8+ lymphocytes in SLE pathogenesis, 201
- Periodic syndrome, TRAPS-related TNFRI mutants, 2906
- Periodontal disease, BAFF and, in patients with dry mouth, 2411
- Peripheral blood mononuclear cells
 - RA, *TP53* and apoptosis effects in, 1047
 - SLE, Brn-31 expression in, 1171
- Peroxisome proliferator-activated receptor γ agonists
 - pioglitazone in experimental OA, guinea pig study, 479
 - rosiglitazone-induced IL-1 receptor antagonist in rat synovial fibroblasts, 759
- Peroxynitrite, T cell response to oxidatively modified IgG in RA, 80
- P-glycoprotein, SLE, lymphocyte expression of P-glycoprotein and steroid resistance, 1676
- Phage display expression cloning, antiferritin antibodies and radiographic damage in RA, 3868
- Pharmacogenetics, and rheumatology, 1349
- Pharmacokinetics
 - molecular mechanisms and variability in drug response, 1349
 - of oral glucosamine, equine study, 181
- Phenotyping, detailing ethnicity and phenotypes for pooling association studies, 676
- Phosphate transporter/retrovirus receptor, IL-8 and expression of in OA chondrocytes, 144
- Physical activity. *See* Exercise
- Physician volume, hospital and attending physician volume of admissions and in-hospital mortality, 1628, 1646
- Pinch strength, OA, hand strength in relation to radiographic features in, 1424
- Pioglitazone, in experimental OA, guinea pig study, 479
- Pisetsky, Dr. David S., editor 2000-2005, in appreciation of, 1627
- Pituitary-adrenal axis, intraarticular methylprednisolone therapy and cortisol secretion, 924
- Pituitary hormones, SLE and, 3701
- Plasminogen, deficiency of in different RA models, 2541
- Platelet-derived growth factor receptor antagonist, lupus nephritis, imatinib treatment, mouse study, 3987
- Platelets
 - APS, thrombotic events in, 4011
 - lupus anticoagulant and prolonged bleeding time, 1949
- PM-scleroderma overlap syndrome, anti-Ku autoantibodies, 668
- Pneumonitis, RA, association of CD4+ T cells with interstitial pneumonitis, 73
- Polyarticular-course arthritis
 - daily stress and mood in children with, 1196
 - JIA, infliximab plus MTX in, 548
 - JIA, meloxicam vs. naproxen for, clinical trial, 563
 - JIA, WISP3 polymorphisms and susceptibility to, 3548
 - JRA, leflunomide safety and efficacy in, 554
- Polymorphism. *See also* Genetics; Mutations
 - APS, valine²⁴⁷ β_2 -glycoprotein I and risk of, 212
 - CINCA syndrome, *CIAS1* somatic mosaicism in, 3579
 - Crohn's disease, lack of association with *SLC22A4* polymorphisms, 425
 - haplotype association studies enhanced by examining more polymorphic loci, 674
 - IL-1 β gene promoter polymorphism and levels of IL-1 β protein, 361, 362

Polymorphism. *See also* Genetics; Mutations (*cont'd*)

- JIA, WISP3 polymorphisms and susceptibility to, 3548
molecular mechanisms and variability in drug response, 1349
newly described hereditary cartilage debonding syndrome, 3300
OA, asporin polymorphism and OA etiology in, 3502
OA, *COL1A1* polymorphism, hip OA, and genetics in elderly women, 1431
OA, IL-1 gene cluster polymorphisms and pathogenesis of, 674
PsA, common genetic control pathways of inflammation for Crohn's disease and PsA, 3596
RA and JIA, *PTPN22* as autoimmunity gene, 1694
RA, association of single-nucleotide polymorphisms in *SEC8L1* gene in Japanese, 1371
RA, Fcγ receptor type IIIA polymorphisms and treatment outcomes with TNFα blockade, 2693
RA, *IL1RN* gene and RA susceptibility in Spanish population, 3015
RA, macrophage migration inhibitory factor, correlation with severity, 3020
RA, PD-1 polymorphism and development of, 362
RA, *PDCD1* haplotype associated with, 1058
RA, *PTPN22* C1858T single-nucleotide polymorphism in, 2948
RA, *PTPN22* codon R602W and early onset/disease severity effect, 358
RA, *PTPN22* locus associated with in New Zealand Caucasian cohort, 2222
RA, *PTPN22* polymorphisms in, 219
RA, *PTPN22* variant associated with in Canadian population, 1993
RA, *SLC22A4* gene, no association with RA in Japanese population, 2947
RA, *SLC22A4* gene, no association with RA in UK population, 752
RA, *SLC22A4* polymorphisms, lack of association with, 425, 2947
RA, *TNFR2* not associated with RA susceptibility in Caucasian population, 2579
SLE, high mobility group box chromosomal protein 1 in skin lesions, 3639
SLE, mannose-binding lectin gene polymorphisms and, 3966
SLE, osteopontin single-nucleotide polymorphisms and susceptibility to, 539
SLE, PD-1 polymorphism and development of, 362
SLE, *PDCD1* polymorphism and renal manifestations in mice, 1665
SLE, *PTPN22* polymorphisms in, 219
SLE, *PTPN22* R620W polymorphism in families, 2396
sporadic chondrocalcinosis, *ANKH* sequence variants and, 1110
SSc, X chromosome inactivation in women, 1564, 3679
WG, *PTPN22* 620W allele as risk factor for, 4039
- Polymyositis (PM)
antisynthetase-associated interstitial lung disease, tacrolimus treatment, 2439
consensus guidelines for myopathy trials, 2607
PM-scleroderma overlap syndrome, anti-Ku autoantibodies, 668
seasonal associations with, 2433
- Posterior cruciate ligament, integrity of in knee OA, 794
- Pramipexole, FM treatment with, 2495
- Predictors
inflammatory polyarthritis, baseline C-reactive protein levels and prediction of death from cardiovascular disease in, 2293
OA, acetabular dysplasia predicts incident hip OA, 787
OA, hand OA as predictor for future hip or knee OA, 3520
RA, C-reactive protein as predictor of infliximab treatment outcome, 42
RA, predicting tendon rupture through MRI evidence, 744
- Pregabalin
FM treatment with, 1264
OA, PD0200347 in experimental OA, dog study, 488
- Pregnancy
fetal heart block, anti-SSA/Ro 52-kd antibodies and, 366
SLE, increased lupus activity and obstetric outcomes, 514
Premature ovarian failure, gonadotropin-releasing hormone analog for ovarian protection during cyclophosphamide treatment of SLE, 2761
Preterm birth, SLE, increased lupus activity and obstetric outcomes, 514
Primary anetoderma, APS, dermatologic manifestations of, 1785
- Primate studies
CCR5 antagonist for inhibition of rhesus monkey collagen-induced arthritis, 627
RAGE expression by articular chondrocytes, 2376
Pristane-induced arthritis, *Cia10* effects on severity, pannus formation, and joint damage, rat study, 322
Pristane-induced SLE, granzyme B in autoimmunity, 1684
Procollagen α2 type I messenger RNA, TGFβ2 effects on in embryonic fibroblasts, chicken study, 1804
Prolactin, in SLE, 3701
Prostaglandin E₂ pathway, antirheumatic treatments with, 3439
Prostaglandin J₂, COX-2 gene transcription in human synovial fibroblasts, regulation by 15-deoxy-Δ^{12,14}-prostaglandin J₂, 94
Protease-activated receptor, arthritis severity in mice, 1325
Proteasomes, SSc, proteasome-dependent processing of topoisomerase I, 877
Protective autoantibodies, homeostasis, clinical importance, and therapeutic potential, 2559
- Protein
OA, serum sulfate levels and development of, 2808
regulation of pyrin subcellular localization by 14.3.3 proteins, 1848
SLE, high mobility group box chromosomal protein 1 in SLE skin lesions, 3639
SLE, protein oxidation in, 2069
soluble IL-1 receptor accessory protein in collagen-induced arthritis, 2202
- Protein tyrosine phosphatase gene
RA, *PTPN22* C1858T single-nucleotide polymorphism in, 2948
RA, *PTPN22* codon R602W and early onset/disease severity effect, 358
RA, gratifying replication, 1952
RA, *PTPN22* locus with RA in New Zealand Caucasian cohort, 2222
RA, *PTPN22* variant associated with RA in Canadian population, 1993
RA, R602W and early onset/disease severity effect, 358
RA and JIA, *PTPN22* gene as autoimmunity gene, 1694
RA and SLE, polymorphisms in, 219
RA and SLE, *PTPN22* gene in, 219
SLE, *PTPN22* R620W polymorphism in families, 2396
WG, *PTPN22* 620W allele as risk factor for, 4039
- Proteinuria, SLE, C-reactive protein reverses proteinuria in autoimmune mice, 642
- Proteoglycan
proteoglycan 4 in synovial fluid, inhibition of integrative cartilage repair by, 1091
RA, CXCL8 binding site on endothelial syndecan-3 in synovium, 2331
- Proteoglycan-induced arthritis
Fcγ receptor type III involvement in development of, mouse study, 1612
leukocyte trafficking into ankle joint of mouse model, 3269
- Proteoglycan-induced spondylitis, genetic control of, mouse study, 2452
- Proteomic analysis, of RA autoantibodies, 2645
- Proximal interphalangeal joint, pachydermodactyly, 990, 2953
- Pseudodominant inheritance, hyperimmunoglobulinemia D with periodic fever syndrome, 3606
- Pseudomonas* exotoxin, RA, targeting of synovial macrophages with anti-folate receptor β antibody and truncated *Pseudomonas* exotoxin, 2666
- Pseudovasculitis, APS, dermatologic manifestations of, 1785

- Psoriasis, onset during anti-TNF treatment, 1333, 1334, 2513
- Psoriatic arthritis (PsA)
- adalimumab for treatment, 3279
 - common genetic control pathways of inflammation for Crohn's disease and PsA, 3596
 - infliximab for dermatologic and articular manifestations, 1227
 - OCTN* gene cluster and, 3596
 - POPP, 2954
- Psoriatic onychopachydermo periostitis (POPP)
- adalimumab treatment of, 280
 - clinical image, 2954
- Psychological stress, RA exacerbation and, 16
- Psychosocial factors
- polyarticular arthritis, stress, mood, and symptoms in children with, 1196
 - RA, psychological stress and exacerbation of, 16
- PTPN22* gene
- RA, gratifying replication, 1952
 - RA, *PTPN22* C1858T single-nucleotide polymorphism in, 2948
 - RA, *PTPN22* locus associated with RA in New Zealand Caucasian cohort, 2222
 - RA, *PTPN22* variant associated with RA in Canadian population, 1993
 - RA, R602W and early onset/disease severity effect, 358
 - RA and JIA, as autoimmunity gene, 1694
 - RA and SLE, polymorphisms in, 219
 - SLE, R620W polymorphism in families, 2396
 - WG, 620W allele as risk factor for, 4039
- Pulmonary and activation-regulated chemokines, CCL18 levels in SSc, 2889
- Pulmonary arterial hypertension
- diagnosis in SSc, 3698, 3792
 - prevalence of undiagnosed disease in community rheumatology practices, 2125
- Pulmonary fibrosis, SSc, serum pulmonary and activation-regulated chemokine/CCL18 levels in, 2889
- Purine-rich foods, uric acid levels and diet, NHANES-III, 283
- Purpura, APS, dermatologic manifestations of, 1785
- Pyrin, regulation of pyrin subcellular localization by 14.3.3 proteins, 1848

Q

- Quality of life
- RA, outcomes of 4 different treatments, BeSt study, 3326, 3381
 - SSc, correlation of dyspnea with health-related quality of life in SSc with alveolitis, 592
- Quantitative trait analysis, SSc, transcriptome analysis of nonlesional dermal fibroblasts in, 865

R

- Rabbit studies
- autologous transplantation of basic fibroblast growth factor gene-transduced chondrocytes with adeno-associated virus vector, 164
 - OA, CD44v6 expression on chondrocytes in rabbits with OA, 810
 - OA, oral glucosamine in, 1118, 3680
 - promotion of MTX induction and antiinflammatory effects by sonoporation, 2559
- RABBIT study, RA, infections in patients treated with biologic agents, 3403
- Race, OA, surgical outcomes following knee or hip arthroplasty, racial/ethnic differences and, 3143
- Radiation synovectomy, knee, radiation synovectomy vs. intraarticular glucocorticoid treatment, 3391
- Radiography
- AS, diagnosis and classification of early AS, 1000

Radiography (cont'd)

- AS, measurement of treatment effect on spinal radiographic progression in, 1979
 - AS, NSAIDs for reduction of radiographic progression, 1756
 - JIA, assessment of radiographic change in, 2865
 - OA, acetabular dysplasia predicts incident hip OA, 787
 - OA, alignment in knee radiography for clinical trials of structure-modifying drugs, 1343, 1411
 - OA, assessment of knee-alignment angle, 1730
 - OA, bone loss on knee radiographs, 3536
 - OA, cartilage loss on MRI and radiographic progression in, 3152
 - OA, hand strength in relation to radiographic features in, 1424
 - OA, lateral view radiography to evaluate tibiofemoral joint space width, 3542
 - OA, serum hyaluronan levels as biomarker of radiographic OA, 105
 - osseous sarcoidosis, radiographic healing, 2225
 - RA, age and OA at onset of symptoms, association with radiographic damage in, 2284
 - RA, antiferritin antibodies and radiographic damage in, 3868
 - RA, articular, radiographic, laboratory, and functional status improved from 1985 to 2000, 991, 1009
 - RA, outcomes of 4 different treatments, BeSt study, 3326, 3381
 - RA, presentation and analysis of clinical trial radiographic data, 49
 - RA, sensitivity to change of MRI and radiography, 2300
- RAMRIS system, Outcome Measures in Rheumatology Clinical Trials, 3860
- RANK
- RA, RANK/RANKL/osteoprotegerin system in, 2960
 - RA, RANK/RANKL system in RA inflammation, 2307
- RANKL
- bone-protective effects of anabolic treatment used with RANKL and TNF inhibition, rat studies, 1604
 - RA, RANK/RANKL/osteoprotegerin system in, 2960
 - RA, RANK/RANKL system in RA inflammation, 2307
 - synovial fibroblasts promote osteoclast formation by, mouse study, 3257
- RANTES, adjuvant-induced arthritis, amelioration by Met-RANTES, rat study, 1907
- Rat studies
- adjuvant-induced arthritis, amelioration by Met-RANTES, 1907
 - adjuvant-induced arthritis, chemokine receptor expression in, 3718
 - adjuvant-induced arthritis, electroporation to enhance MTX effect, 637
 - bone morphogenetic protein 2 for tissue engineering in cartilage repair, 155
 - bone-protective effects of anabolic treatment used with RANKL and TNF inhibition, 1604
 - chronic arthritis, peripheral μ -opioid receptor expression down-regulated in, 3210
 - collagen-induced arthritis, combination therapy with M40403 and dexamethasone, 1929
 - collagen-induced arthritis, combination therapy with M40403 and MTX, 3755
 - collagen-induced arthritis, thrombospondin 1 gene therapy for, 339
 - kininogen deficiency to modulate inflammation of arthritis, 2549
 - osteoclastogenesis, kinetics of, 3192
 - pristane-induced arthritis, *Cia10* effects on severity, pannus formation, and joint damage, 322
 - RA, kallistatin gene therapy for, 1319
 - rosiglitazone-induced IL-1Ra in rat synovial fibroblasts, 759
 - spontaneous circadian behavior in monarthritic rats, 3470
- Raynaud's phenomenon, incidence and natural history of, 1259
- Reactive arthritis
- epidermal growth factor-TM7 receptor expression in synovial tissue, 442
 - IL-6 contribution to, mouse study, 2530
 - innate immunity in infection-triggered arthritis, mouse study, 1297

- Reactive arthritis (*cont'd*)
 Toll-like receptors, 2233
- Reactive oxygen species
 extracellular superoxide dismutase and oxidant damage in OA, 3479
 free radical production of by rheumatoid synovial T lymphocytes, 2003
- Reactive systemic AA amyloidosis, infliximab treatment, 2519
- Receptor for advanced glycation end products (RAGE), expression by articular chondrocytes, 2376
- Recurrent fever syndromes
 familial Mediterranean fever, regulation of pyrin subcellular localization by 14.3.3 proteins, 1848
 hyperimmunoglobulinemia D with periodic fever syndrome, pseudodominant inheritance of, 3606
MEFV analysis in western European patients, 3603
- Regulatory T cells, treatment of collagen-induced arthritis with CD25+ regulatory T cells, 2212
- Remission
 JIA, patterns of clinical remission in, 3554
 RA, defining criteria for disease activity states, 2625
 WG, serum proteomic approach to gauging state of remission, 902
- Renal amyloidosis, infliximab treatment, 2519
- Renal flare, SLE, anti-dsDNA antibody levels and, 1129
- Renal transplantation, subchondral femoral head insufficiency fracture after renal transplantation, 1293
- Renin-angiotensin system, angiotensin receptor blockers for amelioration of collagen-induced arthritis, mouse study, 1920, 3678, 4047
- Reticulocytes, SLE, C4d-bearing reticulocytes as disease activity markers, 3087
- Rhesus monkey studies, CCR5 antagonist for inhibition of rhesus monkey collagen-induced arthritis, 627
- Rheumatic disease
 dendritic cells, autoimmunity and disease, 11
 intraarticular methylprednisolone therapy and cortisol secretion, 924
 National Bone and Joint Decade, 707
- Rheumatoid arthritis (RA). *See also* Juvenile rheumatoid arthritis
 abatacept (CTLA-4Ig) treatment, 2229, 2263
 ACR decision tree format for classification, evaluation over 5 years, 2277
 ACR-N index of improvement in RA, con argument, 1642
 ACR-N index of improvement in RA, pro argument, 1637
 age and OA at onset of symptoms, association with radiographic damage in, 2284
 anakinra, nonresponse to after failure of TNF blockade, 364, 365
 angiogenesis and bone destruction in, 1346
 anti-CCP antibodies, regulation in RA, 3813
 anti-CCP antibody-negative RA, HLA-DR3 associated with, 3058
 antiferritin antibodies and radiographic damage in, 3868
 antigen microarray profiling of autoantibodies, 2645
 anti-TNF therapy and apoptosis induction in joint macrophages, 61
 articular, radiographic, laboratory, and functional status improved from 1985 to 2000, 991, 1009
 association of single-nucleotide polymorphisms in *SEC8L1* gene in Japanese, 1371
 atherosclerosis and, 3045
 atherosclerosis, relative contribution of cardiovascular risk factors and RA to, 3413
 BeSt study, 3326, 3381
 biomarkers using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry-based protein chip approach, 3801
 cardiovascular death in, 722
 chemokines and their receptors as future targets, 710
 citrullinated proteins in humoral autoimmunity, 2323
 clinical trials, continuous indices of core data set measures in, 1031
 clinical trials, presentation and analysis of radiographic data, 49
- Rheumatoid arthritis (RA). *See also* Juvenile rheumatoid arthritis (*cont'd*)
 combination MTX-intramuscular gold therapy, 1360
 combination therapy, efficacy of, 2975
 congestive heart failure risk in, 412
 coronary heart disease and sudden death in, 402
 C-reactive protein as predictor of infliximab treatment outcome, 42
 criteria for disease activity status in, 2625
 CTLA-4Ig treatment, 2229
 CXCL8 binding site on endothelial syndecan-3 in synovium, 2331
 CXCL16-CXCR6 pathway, pathogenic role of in, 3004
 CXCL16 recruits memory T cells into rheumatoid joints, 1381
 DERA-encoding HLA alleles and RA severity and susceptibility, 2637
 digital x-ray radiogrammetry as diagnostic tool, 3850
 Disease Activity Score as sole criterion for initiation and evaluation of anti-TNF therapy, 3873
 drug efflux transporters, 670, 671, 672
 epidermal growth factor-TM7 receptor expression in synovial tissue, 442
 etanercept treatment, clinical infection with *Strongyloides stercoralis*, 1336
 familial aggregation of autoimmune diseases in SLE patients, 1138
 fatal tuberculosis in, 1334
 fibroblast activation by necrotic synovial fluid cells via Toll-like receptor 3, 2656
 fibroblast-like synoviocyte invasiveness and joint destruction in, 1999
 fractalkine and T cell-synoviocyte interaction in, 1392
 free radical production by rheumatoid synovial T lymphocytes, 2003
 gene analysis of drug effects in, 2248
 heart failure risk in, 412, 3039
 high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation, long-term followup of health status, 2272
 HLA-DRB1 alleles, new classification in, 1063
 IL-1 receptor antagonist deficiency and, mouse study, 3731
 IL-6 receptor shedding, stimulation of by IL-1 β and TNF α , 84
 IL-7 stimulates cell contact-dependent activation of CD4+ T cells and macrophages, 1700
 IL-10 receptor α chain expression in synovium, animal models, 3315
 IL-15 as therapeutic target in, 2585, 2686
 IL-22 expression in, 1037
IL1RN gene in susceptibility, 3015
 individual joint pathology in, 672, 673
 infections in patients treated with biologic agents, 3403
 inflammation and destruction uncoupled, 995
 infliximab plus MTX, benefit in patients without clinical improvement, 1020, 4044, 4045
 interstitial pneumonitis in, association of CD4+ T cells with, 73
 kallistatin gene therapy and, rat study, 1319
 kappa and delta opioid receptors in fibroblast-like synoviocytes in, 1402
 knee, radiation synovectomy vs. intraarticular glucocorticoid treatment, 3391
 leukocyte trafficking into ankle joint in mouse model, 3269
 membrane type 1-MMP inhibition and reduced invasiveness of synovial fibroblasts, 2010
 migratory inhibitory factor, correlation with RA severity, 3020
 mildness of disease course, 2616
 MTX, folic acid and MTX efficacy, 3030
 MTX metabolism in, 356
 neoantigenic epitopes after posttranslational modification of type II collagen, 3829
 neutrophil recruitment in coculture model of synovium, 3460
 nurse-like cells from RA patients and bone loss, 3819
PADI4 and, 3054
PDCD1 haplotype, association with, 1058

Rheumatoid arthritis (RA). *See also* Juvenile rheumatoid arthritis (cont'd)

- phenotype based on specificity of HLA-DRB1 shared epitope for citrullinated proteins, 3433
 - plasminogen deficiency in different RA models, 2541
 - poor-prognosis, early treatment with infliximab, 27
 - predicting tendon rupture through MRI evidence, 744
 - prednisolone in early RA, 3324, 3360, 3371
 - proinflammatory cytokines and CYP7B expression and activity in fibroblast-like synoviocytes, 770
 - prostaglandin E₂ pathway, antirheumatic treatments with, 3439
 - psychological stress and exacerbation of, 16
 - PTPN22 and, gratifying replication, 1952
 - PTPN22 as autoimmunity gene, 1694
 - PTPN22 C1858T single-nucleotide polymorphism in, 2948
 - PTPN22 codon R602W and early onset/disease severity effect, 358
 - PTPN22 locus, association with in New Zealand Caucasian cohort, 2222
 - PTPN22 polymorphisms in, 219
 - PTPN22 variant, association with in Canadian population, 1993
 - RABBIT study, 3403
 - RANK/RANKL/osteoprotegerin system, animal studies, 2960
 - RANK/RANKL system in inflammation, 2307
 - reactivation of glucocorticoids in synovial cells, 1711
 - reactive systemic AA amyloidosis, infliximab treatment, 2519
 - SLC22A4 gene, no association with RA in Japanese population, 2947
 - SLC22A4 gene, no association with RA in UK population, 752
 - SLC22A4 polymorphisms, lack of association with, 425, 2947
 - Sneddon-Wilkinson disease in RA patient, 3771
 - stromal cell-derived factor 1 chemokine gene variant and radiographic progression, 354
 - subchondral bone marrow and, 3448
 - synovial tissue and fibroblast-like synoviocytes in, 430
 - targeting of synovial macrophages with anti-folate receptor β antibody and truncated *Pseudomonas* exotoxin, 2666
 - targeting Tie2 attenuates collagen-induced arthritis, mouse study, 1585
 - T cell response to oxidatively modified IgG, 80
 - tissue trafficking patterns of effector memory CD4⁺ T cells in, 3839
 - TNF, regulation of myeloid cell function by, 451
 - TNF α -induced modulation of CD28, 2996
 - TNF α production regulated by butyrate, 2697
 - TNF blockers in, 2506
 - TNF inhibition of conversion of dehydroepiandrosterone sulfate to dehydroepiandrosterone, 1721
 - TNFR2 not associated with RA susceptibility in Caucasian population, 2579
 - Toll-like receptor 2 and 4 expression on CD64⁺ monocytes in, 2227
 - Toll-like receptor 3 and 7 in, 2313
 - TP53 and apoptosis effects in, 1047
 - treatment, improvements over time?, 991, 1009
 - treatment strategies, outcomes of 4 different treatments, BeSt study, 3326, 3381
 - tuberculosis risk and anti-TNF treatment, 1334, 1986, 2968
 - type II collagen helical peptide in early RA, 1081
 - ultrasonographic synovitis scoring system for finger joint inflammation, 733
 - ultrasonography to assess, 681
 - vasculitis in, 1620, 1621
 - work capacity, early suppression of disease activity and maintenance of, 36
 - wrist, Outcome Measures in Rheumatology Clinical Trials RAMRIS system, 3860
- Rheumatology
- pharmacogenetics and, 1349
 - status of women in, 694, 697

Ribavirin, systemic vasculitis, PEGylated IFN- α -2b and ribavirin treatment for hepatitis C virus-related systemic vasculitis, 911

Ribosomal P epitope, expression by monocytes in SLE, 847

Rice bodies, tuberculous rice bodies of wrist, 1950

Risedronate, OA, clinical trials of disease-modifying OA drugs, lessons learned, 3349

Risk factors

- APS, valine²⁴⁷ β_2 -glycoprotein I and APS risk, 212
- atherosclerosis, relative contribution of cardiovascular risk factors and RA to, 3413
- Behçet's disease, *TNFRSF1A* R92Q mutation and risk of venous thrombosis, 608, 2582
- for functional decline in older adults with arthritis, 1274
- OA, association of knee height, knee pain, and knee OA, 1418
- OA, variations in innate cytokine activity and risk of OA, 1443
- RA, increased coronary-artery atherosclerosis in, 3045
- RA, risk of heart failure, 412, 3039
- RA, tuberculosis risk and anti-TNF treatment, 1986, 2968
- SLE, cigarette smoking as risk factor for, 1340, 1341
- SLE, hydroxychloroquine and reduction of damage risk in, 1473
- SLE, risk factors for venous thrombosis in LUMINA study patients, 2060
- SLE, thromboembolism in, 2774
- WG, *PTPN22* 620W allele as risk factor for, 4039

Rituximab

- DM treated with, 601
- lupus nephritis, therapeutic B cell depletion therapy, 501, 4080, 4081
- refractory ANCA-associated vasculitis, B lymphocyte depletion for, 262
- SLE treated with, 371
- SS treated with, 2740
- WG treated with, B cells and ANCA-associated vasculitis, 1

RNA

- collagen-induced arthritis, small interfering RNA and joint inflammation in mice, 1314
- TGF β 2, effects on procollagen α 2 type I messenger RNA variants in embryonic fibroblasts, chicken study, 1804
- Rofecoxib, cardiovascular events and, 1968
- Rosiglitazone-induced IL-1Ra in rat synovial fibroblasts, 759
- Rotator cuff disorders, hydroxyapatite crystals and, 3681

S

S-34219, OA, inhibitor of MMPs in cartilage loss, in vitro and guinea pig study, 171

Saliva

- BAFF and periodontal disease in patients with dry mouth, 2411
- FM, momentary relationship between symptoms and cortisol secretion, 3660

Salivary glands

- epithelial cell exosomes, 1517
- SS, acinar damage and MMP-3/TIMP-1 and MMP-9/TIMP-1 imbalance and, 2751
- SS, CXCL13 and CCL21 expression and lymphoid features in, 1773
- SS, Fas and CD40 in salivary epithelial cell death, 573
- SS, gene expression profiling of minor salivary glands, 1534

Sarcoid arthritis, intraarticular etanercept treatment, 987

Sarcoidosis, osseous sarcoidosis, radiographic healing, 2225

Schnitzler syndrome, treatment with anakinra, 2226

Scintigraphy, SpA, intraarticular infliximab in, 1224

Sci-70, SSc, proteasome-dependent processing of topoisomerase I, 877

Scleroderma. *See* Systemic sclerosis

Scoring systems

- JIA, assessment of radiographic change in, 2865
- RA, defining criteria for disease activity states, 2625
- RA, sensitivity to change of MRI and radiography, 2300
- RA, ultrasonographic synovitis scoring system for finger joint inflammation, 733

- SEC8L1* gene, RA, association of single-nucleotide polymorphisms in *SEC8L1* gene in Japanese, 1371
- Secreted protein, acidic and rich in cysteine (SPARC), specific inhibition of SPARC and decreased expression of type I collagen, 257
- Septic arthritis
- anakinra treatment of *Moraxella catarrhalis*-induced septic arthritis of prosthetic knee joint, 1337, 1338
 - due to *Listeria monocytogenes* in etanercept patient, 987
- Serum proteomic profiling, gauge state of remission in WG, 902
- Sevelamer, reduction in serum uric acid with, 290
- Shared epitope
- RA, HLA-DR shared epitope alleles and cigarette smoking, 3675, 3676
 - RA, HLA-DRB1 alleles, new classification in, 1063
 - RA, regulation of anti-CCP antibodies in, 3813
- Sharp/van der Heijde method, RA, sensitivity to change of MRI and radiography, 2300
- Shoulder, hydroxyapatite crystals and rotator cuff disorders, 3681
- Signaling
- C43S TRAPS mutation and TNF α -induced signaling, 1287, 2952
 - IL-17 receptor and streptococcal cell wall-induced arthritis, mouse study, 3239
 - microparticles as regulators of inflammation, 3337
 - SSc, $\alpha\beta5$ -mediated TGF β signaling in, 2897
- Simplified Disease Activity Index (SDAI), RA, defining criteria for disease activity states, 2625
- Single-nucleotide polymorphism
- Crohn's disease, *SLC22A4* polymorphisms, lack of association with, 425
 - hereditary cartilage debonding syndrome, 3300
 - IL-1 β gene promoter polymorphism and levels of IL-1 β protein, 361, 362
 - PsA, common genetic control pathways of inflammation for Crohn's disease and PsA, 3596
 - RA, association of single-nucleotide polymorphisms in *SEC8L1* gene in Japanese, 1371
 - RA, PD-1 polymorphism and development of, 362
 - RA, *PDCDI* haplotype associated with, 1058
 - RA, *PTPN22* C1858T single-nucleotide polymorphism in, 2948
 - RA, *PTPN22* codon R602W and early onset/disease severity effect, 358
 - RA, *PTPN22* locus associated with in New Zealand Caucasian cohort, 2222
 - RA, *PTPN22* variant associated with in Canadian population, 1993
 - RA, *SLC22A4* gene, no association with RA in UK population, 752
 - RA, *SLC22A4* polymorphisms, lack of association with, 425
 - RA, *TNFR2* not associated with RA susceptibility in Caucasian population, 2579
 - RA and JIA, *PTPN22* as autoimmunity gene, 1694
 - SLE, osteopontin single-nucleotide polymorphisms and susceptibility to, 539
 - SLE, *PTPN22* R620W polymorphism in families, 2396
- Sjögren's syndrome (SS)
- acinar damage and MMP-3/TIMP-1 and MMP-9/TIMP-1 imbalance and, 2751
 - antimucarinic antibodies in, 2984
 - BAFF and periodontal disease in patients with dry mouth, 2411
 - chemokine receptors on B cells in primary SS, 2109
 - corrected QT interval in anti-SSA-positive adults with connective tissue disease, 676, 677
 - CXCL13 and CCL21 expression and lymphoid features in, 1773
 - gene expression profiling of minor salivary glands in SS, 1534
 - mortality and causes of death in primary SS, 369
 - rituximab treatment, 2740
 - type I IFN in, 1185
- Skin. *See also* Fibrosis; Systemic sclerosis
- APS, dermatologic manifestations of, 1785
 - cutaneous lupus erythematosus, amplification cycle triggering, 1504
 - cutaneous lupus erythematosus, up-regulation of 52-kd Ro/SSA by TNF α via TNF receptor I, 531
 - generation of novel covalent RNA-protein complexes by ultraviolet B irradiation, 1160
 - specific inhibition of SPARC and decreased expression of type I collagen, 257
 - SSc, IL-21 receptor expression altered in keratinocytes, 856
- Skin ulcers, APS, dermatologic manifestations of, 1785
- SLC11A1* gene, in JIA, 247
- SLC22A4* gene
- lack of association of polymorphisms with RA and Crohn's disease, 425
 - no association with RA in Japanese population, 2947
 - no association with RA in UK population, 752
- Sle2*, *Sle2*-associated component lupus phenotypes, deficiency of type I interferon contribution to, mouse study, 3063
- Small interfering RNA, and joint inflammation in mice with collagen-induced arthritis, 1314
- Smoking
- as risk factor for venous thrombosis in LUMINA study patients, 2060
 - as SLE risk factor, 1340, 1341
 - RA, HLA-DR shared epitope alleles in, 3675, 3676
 - Sneddon-Wilkinson disease, in RA patient, 3771
- Soluble interleukin-1 receptor accessory protein, in collagen-induced arthritis, 2202
- Somatic mosaicism, CINCA syndrome, *CLAS1* somatic mosaicism in, 3579
- Sonography. *See* Ultrasonography
- Sonoporation, antigen-induced arthritis, promotion of MTX induction and antiinflammatory effects by sonoporation, rabbit study, 2559
- Spine
- AS, MRI assessment of spinal inflammation before and after etanercept treatment, 1216
 - opioid use by orthopedics spine clinic patients, 312
 - osteopenia in childhood-onset SLE, 2051
- Splinter hemorrhages, APS, dermatologic manifestations of, 1785
- Spondylarthropathy (SpA)
- axial SpA and AS, diagnosis and classification, 1000
 - etanercept for peripheral joint synovitis in, 3898
 - HLA-B*5703 in HIV infection and, 275
 - HLA-B27, association with in Sardinia and Italy, 3319
 - intraarticular infliximab in, 1224
 - KIR3DL2 expression on NK cells in, 3586
 - prevalence of, 4048, 4049
 - proteoglycan-induced spondylitis, genetic control of, mouse study, 2452
 - TNF α blockade and humoral immunity, 2192
 - Toll-like receptor 2 and 4, down-modulation by TNF blockade in, 2146
- Sporadic chondrocalcinosis, *ANKH* sequence variants and, 1110
- STAT-6-VT, inhibition of osteoclastogenesis and bone erosion, mouse study, 2719
- Stem cells, synovium as superior source of, 2521
- Stem cell transplantation
- RA, ASCT and high-dose chemotherapy for joint damage, 421
 - RA, high-dose chemotherapy and ASCT, long-term followup of health status, 2272
 - seronegative arthritis, sustained remission of, 3322
- Steroid injection, for carpal tunnel syndrome, vs. surgery, 612, 2578
- Steroid resistance, SLE, lymphocyte expression of P-glycoprotein and, 1676
- Stiffness, polyarticular arthritis, stress, mood, and symptoms in children with, 1196

- Still's disease, anakinra for adult-onset Still's disease, 1794, 1960
- Streptococcal cell wall-induced arthritis,
IL-17 receptor and cartilage destruction in, mouse study, 3239
T cell IL-17 overexpression in IL-1-deficient arthritic mice, 975
- Stress
polyarticular arthritis, mood and symptoms in children with, 1196
RA, psychological, 16
- Stromal cell-derived factor 1, RA, radiographic progression and, 354
- Stromal cells, collagen-induced arthritis, exacerbation in IFN- β -deficient mice, 3739
- Stromelysin, MMP-3 as biomarker of OA progression, 3160
- Strongyloides stercoralis*, RA, infection with during etanercept treatment, 1336
- Structural outcomes, methodologic issues in superiority trials, 1858
- Subchondral bone loss, OA, on knee radiographs, 3536
- Subchondral bone marrow, in RA, 3448
- Sulfasalazine, combination therapy, efficacy of in RA, 2975
- Sulfate levels, OA, development of and, 2808
- Superiority trials, methodologic issues, assessing structural outcomes, 1858
- Superoxide dismutase
extracellular, and oxidant damage in OA, 3479
mimetic combination therapy with M40403 and dexamethasone in collagen-induced arthritis, rat study, 1929
MTX synergistic interaction with, rat study, 3755
- Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry, biomarkers for RA by, 3801
- Susceptibility
Behçet's disease, whole-genome screen for in, 1836
JIA, WISP3 polymorphisms and, 3548
OA, asporin polymorphism and etiology in, 3502
OA, hip, *COL9A1* gene in, 1437
OA, variations in innate cytokine activity and risk of, 1443
RA, association of single-nucleotide polymorphisms in *SEC8L1* gene in Japanese, 1371
RA, DERA-encoding HLA alleles and RA severity and, 2637
RA, HLA-DRB1 alleles, new classification in, 1063
RA, IL-1 receptor antagonist deficiency and, 3731
RA, *IL1RN* gene, in Spanish population, 3015
RA, *PADI4* gene and, 3054
RA, *PDCD1* haplotype associated with, 1058
SLE, and autoimmune thyroid disease, susceptibility gene at 5q14.3-15, 3646
SLE, genetic origin of in SWR/NZB hybrids, 659
SLE, osteopontin single-nucleotide polymorphisms in, 539
SLE, *Sle2*-associated component lupus phenotypes, deficiency of type I interferon contribution to, mouse study, 3063
Sweden, tuberculosis risk and anti-TNF-treated RA in, 1986
Symphysis pubis, tophaceous gout of, 4082
Syndecans, RA, CXCL8 binding site on endothelial syndecan-3 in synovium, 2331
Synovectomy, knee, vs. intraarticular glucocorticoid treatment, 3391
Synovial cells
intraarticular glucocorticoid treatment reduces inflammation in, 3880
RA, reactivation of glucocorticoids in, 1711
RA, TNF inhibition of conversion of dehydroepiandrosterone sulfate to dehydroepiandrosterone, 1721
Synovial fibroblasts. *See* Fibroblasts
- Synovial fluid
anterior cruciate ligament injury, cartilage glycosaminoglycan loss in acute phase, gadolinium-enhanced MRI, 120
boundary lubrication following injury, rabbit study, 1746
cartilage integrative repair, inhibition by proteoglycan 4, 1091
coefficient of friction in arthritis, 1632
glucosamine levels, equine study, 181
Synovial fluid (*cont'd*)
RA, fibroblast activation by necrotic cells via Toll-like receptor 3, 2656
Synovial membrane, OA, correlating disease severity and MRI findings, 3492
Synovial tissue
antigen-induced arthritis, promotion of MTX induction and anti-inflammatory effects by sonoporation, rabbit study, 2559
epidermal growth factor-TM7 receptor expression in, 442
free radical production of by rheumatoid synovial T lymphocytes, 2003
RA, activation by necrotic synovial fluid cells via Toll-like receptor 3, 2656
RA, anti-TNF therapy and apoptosis induction in joint macrophages, 61
RA, citrullinated proteins in humoral autoimmunity, 2323
RA, CXCL8 binding site on endothelial syndecan-3 in, 2331
RA, CXCL16 recruits memory T cells into rheumatoid joints, 1381
RA, fibroblast-like synoviocytes in, 430
RA, IL-10 receptor α chain expression in synovium, animal models, 3315
RA, neutrophil recruitment in coculture model of, 3460
RA, pathogenic role of CXCL16-CXCR6 pathway in, 3004
RA, RANK/RANKL system in inflammation, 2307
RA, targeting of synovial macrophages with anti-folate receptor β antibody and truncated *Pseudomonas* exotoxin, 2666
RA, Toll-like receptors 3, 4, and 7/8 and, 2313
source of human mesenchymal cells, 2521
- Synoviocytes
RA, fractalkine and interaction with T cells in, 1392
RA, TNF α production by, regulation by butyrate, 2697
- Synovitis
cartilage degeneration and overexpression of cathepsin K in, 3713
knee, radiation synovectomy vs. intraarticular glucocorticoid treatment, 3391
OA, correlating disease severity and MRI findings, 3492
RA, IL-7 stimulates cell contact-dependent activation of CD4+ T cells and macrophages, 1700
RA, infliximab plus MTX for poor prognosis, 27
RA, synovial tissue and fibroblast-like synoviocyte heterogeneity, 430
RA, ultrasonographic scoring system for, in finger joint inflammation, 733
RA, ultrasonography for assessing in, 681
SpA, etanercept for, in peripheral joints, 3898
- Systemic JIA, IL-6 receptor as treatment, 687
- Systemic lupus erythematosus (SLE)
activated CD8+ lymphocytes in pathogenesis of, 201
anetoderma in, with antiphospholipid antibodies, 2228
anti-DNA antibodies and glomerulonephritis, 2403
anti-DNA antibodies and renal flare in, 1129
anti-Ku autoantibodies and DPB1*, 668
APS nephropathy in antiphospholipid antibody-positive patients with, 988
autoantibody clustering to predict clinical subsets and damage, 4003
autoimmune thyroid disease and susceptibility gene at 5q14.3-15, 3646
BAFF overexpression and accelerated glomerular disease in mice, 2080
BAFF receptors in, 3943
B lymphocyte depletion therapy in refractory childhood SLE, 3168
Brn-3 expression in, 1171
C4d-bearing reticulocytes as disease activity markers, 3087
cancer, international cohort study, 1481
cerebral and corpus callosum atrophy in, 2783
cigarette smoking as risk factor for, 1340, 1341
clofazimine compared with chloroquine for, 3073

Systemic lupus erythematosus (SLE) (cont'd)

- complement receptor 1 (CD35) bound to immune complexes in sera, 2950
- corrected QT interval in anti-SSA-positive adults with connective tissue disease, 676, 677
- costimulatory blockade with adeno-associated virus-mediated gene transfer, mouse study, 3975
- C-reactive protein reverses proteinuria in autoimmune mice, 642
- criteria for evaluating response to therapy in children, 2854
- cross-reactive anti-dsDNA/anti- α -actinin antibodies and induction of renal disease, 522
- cutaneous lupus erythematosus, amplification cycle triggering, 1504
- cutaneous lupus erythematosus, high mobility group box chromosomal protein 1 in, 3639
- cutaneous lupus erythematosus, up-regulation of 52-kd Ro/SSA by TNF α via TNF receptor I, 531
- cyclophosphamide therapy, gonadotropin-releasing hormone analog for ovarian protection during, 2761
- elevated levels of soluble fractalkine in, 1670
- Epstein-Barr virus and, 1148
- familial aggregation of autoimmune diseases in SLE patients, 1138
- genetic origin of in SWR/NZB hybrids, 659
- granzyme B in autoimmunity, mouse study, 1684
- high mobility group box chromosomal protein 1 in skin lesions, 3639
- hospital and attending physician volume of admissions and in-hospital mortality, 1628, 1646
- hydroxychloroquine and reduction of damage risk in, 1473
- IFN α pathway in, activation, 1491
- IL-18R signaling and autoantibody production and end-organ disease in, mouse study, 984
- inhibition by IgM anti-dsDNA antibodies, mouse study, 3629
- lipid peroxidase in, 192
- LUMINA cohort, influence of menopause in study patients, 1655
- LUMINA cohort, risk factors for venous thrombosis in study patients, 2060
- lupus nephritis, anti-CD20 therapy, 371
- lupus nephritis, anti-DNA antibodies and, 2403
- lupus nephritis, cross-reactive anti-dsDNA/anti- α -actinin antibodies and induction of, 522
- lupus nephritis, effect of fractalkine antagonist on, mouse study, 1522
- lupus nephritis, imatinib treatment, mouse study, 3987
- lupus nephritis, single-dose C-reactive protein, mouse study, 378
- lupus nephritis, therapeutic B cell depletion therapy, 501, 4080, 4081
- lymphocyte expression of P-glycoprotein and steroid resistance, 1676
- Lyn expression in B cells, 3955
- mannose-binding lectin gene polymorphisms and, 3966
- maternal HLA class II compatibility in men with, 2768
- menopause, influence in LUMINA study patients, 1655
- murine lupus, reduced sensitivity to CD4+, CD25+ regulatory T cells in, 1180
- neuropsychiatric, brain MRI abnormalities and MMP-9 in patients with, 673, 674
- neuropsychiatric, electroencephalographic assessment of, 841
- neuropsychiatric, elevated levels of soluble fractalkine, 1670
- obesity, contributor to functional capacity and inflammation, 3651
- obstetric outcomes and increased lupus activity, 514
- osteopenia in childhood-onset, 2051
- osteopontin single-nucleotide polymorphisms and susceptibility to, 539
- PD-1 polymorphism and development of, 362
- PDCD1 polymorphism and renal manifestations in mice, 1665
- pituitary hormones and, 3701
- protein oxidation in, 2069
- psychiatric symptoms, electroencephalographic assessment, 841
- PTPN22 polymorphisms in, 219

Systemic lupus erythematosus (SLE) (cont'd)

- PTPN22 R620W polymorphism in families, 2396
- raloxifene for postmenopausal women with, 3997
- ribosomal P epitope expression by monocytes, 847
- Sle2-associated component lupus phenotypes, deficiency of type I interferon contribution to, mouse study, 3063
- suppressive oligodeoxynucleotides in, mouse study, 651
- thromboembolism in, incidence and risk factors, 2774
- tolerance breaking by dendritic cells without disease expression, 225
- venous thrombosis risk factors in LUMINA study patients, 2060
- vertebral fractures in SLE patients and low BMD, 2044
- Yaa gene-linked monocytosis, mouse study, 2790
- Systemic sclerosis (SSc)
 - α v β 5-mediated TGF β signaling in, 2897
 - anti-RNA polymerase III antibody detection by ELISA, 2425
 - autologous bone marrow transplantation in, immune reconstitution following, 1555
 - Barrett's esophagus in, 2882
 - chemokine receptor CCR2 expression by fibroblasts, 3772
 - dyspnea, correlation with health-related quality of life in, with alveolitis, 592
 - eicosanoids in pathogenesis of lung disease in, 3693, 3783
 - fibroblast gene expression profiles in twins, 3305
 - FK-506, effects on normal and SSc fibroblasts, 1237
 - IL-21 receptor expression altered in SSc keratinocytes, 856
 - juvenile localized, extracutaneous manifestations of, 2873
 - malignancy risk in, 2415
 - mechanical bull myopathy in, 3682
 - microfibril-associated glycoprotein 2, increased expression of type I collagen and, mouse study, 1812
 - p300 and profibrotic response to TGF β , 1248
 - PM-scleroderma overlap syndrome, anti-Ku autoantibodies, 668
 - proteasome-dependent processing of topoisomerase I, 877
 - pulmonary arterial hypertension, diagnosis in, 3698, 3792
 - pulmonary arterial hypertension, prevalence in community practices, 2125
 - serum pulmonary and activation-regulated chemokine/CCL18 levels in, 2889
 - specific inhibition of SPARC and decreased expression of type I collagen, 257
 - tissue kallikreins in endothelial cells, 3618
 - transcriptosome analysis of nonlesional dermal fibroblasts in, 865
 - X chromosome inactivation in women, 1564, 3679
- Systemic vasculitis, PEGylated IFN- α -2b and ribavirin for hepatitis C virus-related systemic vasculitis, 911

T

- Tacrolimus, for antisynthetase-associated ILD, 2439
- Tasmanian Older Adult Cohort Study, OA, correlates of hip cartilage volume, 1069
- T cells
 - AS, HLA-B27-restricted CD8+ response to cartilage-derived peptides in, 892, 2581, 2582
 - Behçet's disease, NF- κ B protection of against CD95-induced apoptosis up-regulating antiapoptotic proteins, 2179
 - class II MHC-peptide tetramers for detection of CD4+ T cells, mouse study, 1885
 - collagen-induced arthritis, Nur77 overexpression, mouse study, 333
 - collagen-induced arthritis, treatment with CD25+ regulatory T cells, 2212
 - disruption of T cell/antigen-presenting cell interaction by teriflunomide, 2730
 - IL-17 overexpression in IL-1-deficient arthritic mice, 975
 - RA, association of CD4+ T cells with interstitial pneumonitis in, 73
 - RA, CXCL16 recruits memory T cells into rheumatoid joints, 1381
 - RA, fractalkine and interaction with synovocytes in, 1392
 - RA, IL-7 stimulates cell contact-dependent activation of, 1700

- T cells (*cont'd*)
- RA, pathogenic role of CXCL16-CXCR6 pathway in, 3004
 - RA, RANK/RANKL system in inflammation, 2307
 - RA, T cell response to oxidatively modified IgG, 80
 - RA, tissue trafficking patterns of effector memory CD4+ T cells in, 3839
 - SLE, reduced sensitivity to CD4+, CD25+ regulatory T cells in murine lupus, 1180
 - SSc, ASCT, immune reconstitution following, 1555
 - V α 14 NKT cells in murine arthritis, 1941
 - Temporomandibular arthritis, corticosteroid injection for in children with JIA, 3563
 - Tendon rupture, RA, predicting through MRI evidence, 744
 - Teriflunomide, disruption of T cell/antigen-presenting cell interaction by, 2730
 - Tetramer staining, class II MHC-peptide, for detection of CD4+ T cells, mouse study, 1885
 - Th1 lymphocytes
 - hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy and, 2917
 - lymphotoxin regulation of T cell response and autoimmunity in, 3202
 - Thiopurine methyltransferase, molecular mechanisms and variability in drug response, 1349
 - Third National Health and Nutrition Examination Survey (NHANES-III), uric acid levels and diet, 283
 - Thromboembolism, in SLE, incidence and risk factors, 2774
 - Thrombosis
 - antiphospholipid antibody-mediated, complement activation and, mouse study, 2120
 - APS, dermatologic manifestations of, 1785
 - APS, involvement of p38 MAPK in antiphospholipid antibody-induced up-regulation of tissue factor on HUVECs, 1545
 - APS, platelet deposition on extracellular matrix under flow conditions, 4011
 - Behçet's disease, *TNFRSF1A* R92Q mutation and risk of venous thrombosis, 608, 2582
 - COX-2 inhibitors and, 1968
 - microparticles as regulators of inflammation, 3337
 - SLE, venous risk factors in LUMINA study patients, 2060
 - Thrombospondin, collagen-induced arthritis, thrombospondin 1 gene therapy for, rat study, 339
 - Thyroid disease, SLE, *PTPN22* R620W polymorphism in families, 2396
 - Thyroid-stimulating hormone, in SLE, 3701
 - Tibiofemoral narrowing, OA, lateral view radiography for evaluating in, 3542
 - Tie2, collagen-induced arthritis, mouse study, 1585
 - Tissue factor, APS, involvement of p38 MAPK in antiphospholipid antibody-induced up-regulation of on HUVECs, 1545
 - Tissue inhibitor of metalloproteinases 1 (TIMP-1), SS, acinar damage and MMP-3/TIMP-1 and MMP-9/TIMP-1 imbalance and, 2751
 - Tissue plasminogen activator, APS, polyclonal and monoclonal antibodies against, 4018
 - T lymphocytes, RA, free radical production by in, 2003
 - TNF α blockade
 - bone-protective effects of anabolic treatment used with RANKL and, rat studies, 1604
 - humoral immunity and, 2192
 - prostaglandin E $_2$ biosynthetic pathway and, 3439
 - RA, Fc γ receptor type IIIA polymorphisms and treatment outcomes with, 2693
 - RA, nonresponse to anakinra after failure in, 364, 365
 - in RA and AS, comparative effectiveness, 2506
 - SpA, down-modulation of Toll-like receptor 2 and 4 in, 2146
 - RA, risk of tuberculosis in, 1986, 2968
 - reactivation of latent tuberculosis and, 1766
 - TNF receptor 1, up-regulation of 52-kd Ro/SSA by TNF α via, 531
 - TNFR2*, RA susceptibility in Caucasian population and, 2579
 - TNFR1* gene, TRAPS-related mutants, 2906
 - TNFRSF1A* gene, Behçet's disease, R92Q mutation and risk of venous thrombosis in, 608, 2582
 - Toes
 - POPP, 280, 2954
 - RA, sensitivity to change of MRI and radiography, 2300
 - Tolerance breaking, SLE, by dendritic cells without SLE disease expression, 225
 - Toll-like receptor 2
 - gouty inflammation and, mouse study, 2936
 - RA, expression of on CD64+ monocytes, 2227
 - SpA, down-modulation by TNF blockade in, 2146
 - Toll-like receptor 3
 - RA, expression of in synovium, 2313
 - RA, fibroblast activation by necrotic synovial fluid cells via, 2656
 - Toll-like receptor 4
 - gouty inflammation and, mouse study, 2936
 - RA, expression of on CD64+ monocytes, 2227
 - reactive arthritis and IL-6, mouse study, 2530
 - SpA, down-modulation by TNF blockade in, 2146
 - Toll-like receptor 7, RA, expression of in synovium, 2313
 - Toll-like receptors, reactive arthritis, 2233
 - Tophaceous gout, of symphysis pubis, 4082
 - Topoisomerase I
 - cleavage during necrotic cell death, cathepsins and, 2133
 - SSc, proteasome-dependent processing of, 877
 - Total knee arthroplasty, trends in epidemiology of in US 1990-2000, 3928
 - TP53* gene, RA, *TP53* and apoptosis effects in, 1047
 - Transforming growth factor β (TGF β)
 - SSc, α v β 5-mediated signaling in, 2897
 - SSc, p300 and profibrotic response to, 1248
 - Transforming growth factor β 1 (TGF β 1), fibrosis, specific inhibition of SPARC and decreased expression of type I collagen, 257
 - Transforming growth factor β 2 (TGF β 2), effects on procollagen α 2 type I messenger RNA variants in embryonic fibroblasts, chicken study, 1804
 - Transient receptor potential vanilloid 1, in knee inflammation, mouse study, 3248
 - Transplantation. See Autologous stem cell transplantation (ASCT); Stem cell transplantation
 - Traumatic injury, anterior cruciate ligament, cartilage glycosaminoglycan loss in acute phase, gadolinium-enhanced MRI, 120
 - Tuberculosis
 - in RA, treated with infliximab, 1334
 - in RA, with anti-TNF treatment, 1986, 2968
 - TNF antagonists and reactivation of latent tuberculosis, 1766
 - Tumor necrosis factor (TNF)
 - alendronate-induced osteoclast death prevented by, mouse study, 2708
 - RA, inhibition of conversion of dehydroepiandrosterone sulfate to dehydroepiandrosterone, 1721
 - regulation of myeloid cell function by, 451
 - Tumor necrosis factor α (TNF α)
 - ADAMTS-9 induced by inflammatory arthritides in, 1451
 - Behçet's disease, *TNFRSF1A* R29Q mutation and risk of venous thrombosis in, 608, 2582
 - C43S TRAPS mutation and induced signaling, 1287, 2952
 - collagen-induced arthritis, reversal of immunosuppressive properties of mesenchymal stem cells by, mouse study, 1595
 - OA, in cartilage matrix degradation and, 128
 - RA, proinflammatory cytokines and CYP7B expression and activity in fibroblast-like synoviocytes, 770
 - RA, regulation by butyrate in, 2697
 - RA, stimulation of IL-6 receptor shedding by, 84
 - RA, tuberculosis risk and, 1986, 2968

Tumor necrosis factor α (TNF α) (*cont'd*)
 up-regulation of 52-kd Ro/SSA by TNF α via TNF receptor I, 531
 Tumor necrosis factor receptor-associated periodic syndrome (TRAPS)
 effects of C43S mutation on TNF α -induced signaling, 1287, 2952
 TNF receptor I mutants, 2906
 Tumors, SLE and cancer, international cohort study, 1481
 Turkish population, Behçet's disease, whole-genome screen for susceptibility genes in, 1836
 Twin studies
 hyperimmunoglobulinemia D with periodic fever syndrome, pseudodominant inheritance of, 3606
 SSc, gene expression in, 3305
 Type I interferon (IFN-I), *Sle2*-associated component lupus phenotypes, deficiency of, mouse study, 3063
 Type II mixed cryoglobulinemia, chemokines and Th1 cytokines in hepatitis C virus-associated vasculitis neuropathy and, 2917

U

Ultrasonography
 carpal tunnel syndrome, diagnostic value of in, 304
 OA, acoustic properties of knee and ankle joint cartilage, 3125
 RA assessment with, 681
 RA, synovitis scoring system for finger joint inflammation, 733
 Ultraviolet radiation
 cutaneous lupus erythematosus, amplification cycle triggering, 1504
 generation of novel covalent RNA-protein complexes by ultraviolet B irradiation, 1160
 United Kingdom
 aspirin polymorphism and OA etiology in, 3502
 PsA, common genetic control pathways of inflammation for Crohn's disease and PsA, 3596
 RA, *SLC22A4* gene, no association with RA in, 752
 Urate crystals. *See* Monosodium urate monohydrate
 Urate transport, Dalmation defect, hepatic endocrinopathy of, 2257
 Uric acid
 diet and, 283
 reduction in with sevelamer, 290
 vitamin C supplementation and serum concentration, 1843
 Urinary markers, OA and early RA, type II collagen helical peptide in, 1081
 Uveitis
 acute anterior uveitis, unique genetic region on chromosome 9p and, 269
 AS, anti-TNF therapy in, 2447
 Behçet's disease, infliximab efficacy for treatment-resistant uveitis in, 2478

V

Valdecoxib, cardiovascular events and, 1968
 Valine/leucine polymorphism, APS, valine²⁴⁷ β_2 -glycoprotein I and risk of, 212
 Vasculitis
 ANCA-associated, MTX vs. cyclophosphamide to induce remission, 2461
 angiography-negative in primary CNS, in children, 2159
 anti-endothelial cell antibodies in systemic autoimmune diseases and, 4028
 APS, dermatologic manifestations of, 1785
 chemokines and Th1 cytokines in hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy, 2917
 in RA, 1620, 1621
 refractory ANCA-associated vasculitis, B lymphocyte depletion for, 262
 systemic, PEGylated IFN- α 2b and ribavirin, 911

Vasculitis (*cont'd*)

WG treatment with rituximab, B cells and ANCA, 1
 Vasculitis-associated systemic autoimmune diseases, anti-endothelial cell antibodies in, 4028
 Vasculopathy, juvenile DM, angiostatic ELR-CXC chemokines and vasculopathy in, 3175
 Vasospasm, Afrin-induced in CNS, and thunderclap headache, 3314
 Venous thrombosis
 Behçet's disease, *TNFRSF1A* R92Q mutation and risk of, 608, 2582
 SLE, risk factors for in LUMINA study patients, 2060
 Vertebral fractures, in SLE patients and low BMD, 2044
 Vitamin C, serum uric acid concentration and, 1843
 Vitamin D, OA, supplementation and bisphosphonates, 1622, 1623

W

Wegener's granulomatosis (WG)
 ANCA-associated vasculitis and, rituximab for, 1
 ANCA-associated vasculitis, MTX vs. cyclophosphamide to induce remission, 2461
 damage caused by, and treatment, 2168
 MTX treatment for, 2237
PTPN22 620W allele as risk factor for, 4039
 serum proteomic approach to gauging state of remission, 902
 Weight. *See* Body weight
 Weight loss, reduction of knee-joint load in knee OA in older obese adults and, 2026
 Wnt-1-inducible signaling protein 3, JIA, polymorphisms and susceptibility to, 3548
 Women. *See also* Pregnancy
 in academic rheumatology, 694, 697
 estrogen deprivation arthralgia and aromatase inhibitors, 2594
 maternal antibody specificity and fetal congenital heart block, 3079
 OA, association with knee height, knee pain, and, 1418
 OA, cartilage loss on MRI and radiographic progression in knee OA, 3152
 OA, *COL1A1* polymorphism, and genetics in hip OA in elderly women, 1431
 SLE, gonadotropin-releasing hormone analog for ovarian protection during cyclophosphamide treatment, 2761
 SLE, influence of menopause in LUMINA study patients, 1655
 SLE, maternal HLA class II compatibility in men with SLE, 2768
 SLE, raloxifene for postmenopausal women with, 3997
 SSc, X chromosome inactivation in, 1564, 3679
 Work. *See also* Disability
 RA, early suppression of disease activity and maintenance of work capacity, 36
 Wrist
 carpal tunnel syndrome, diagnostic value of sonography, 304
 carpal tunnel syndrome, surgery vs. steroid injection in, 612, 2578
 RA, age and OA at onset of symptoms, association with radiographic damage in, 2284
 RA, Outcome Measures in Rheumatology Clinical Trials RAMRIS system, 3860
 RA, predicting tendon rupture through MRI evidence, 744
 RA, sensitivity to change of MRI and radiography, 2300
 sarcoid arthritis, intraarticular etanercept treatment, 987
 tuberculous rice bodies of, 1950

X

XCI mosaicism, SSc, X chromosome inactivation in women, 1564, 3679
 Xerostomia, BAFF and periodontal disease in patients with dry mouth, 2411

Z

Zambia, HLA-B*5703 in HIV infection and SpA, 275
 Ziff, Morris, In memoriam, 3323

